

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/15, 15/54, 15/80		A1	(11) International Publication Number: WO 95/12661 (43) International Publication Date: 11 May 1995 (11.05.95)
(21) International Application Number: PCT/US94/12423			(US). DAVIS, Charles, Ray [US/US]; 17727 66th Place W., Lynnwood, WA 98037 (US). HENDRICKSON, Lee, E. [US/US]; 35915 NE 112th Street, Carnation, WA 98014 (US).
(22) International Filing Date: 28 October 1994 (28.10.94)			(74) Common Representative: MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US).
(30) Priority Data: 148,132 2 November 1993 (02.11.93) US			
(60) Parent Application or Grant (63) Related by Continuation US Filed on 148,132 (CON) 2 November 1993 (02.11.93)			(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).
(71) Applicant (<i>for all designated States except US</i>): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): VINCI, Victor, A. [US/US]; 2041 Locke Lane, Charlottesville, VA 22901 (US). CONDER, Michael, J. [GB/US]; 767 Northfield Court, Harrisonburg, VA 22801 (US). McADA, Phyllis, C. [US/US]; 15611 173rd Avenue, N.E., Woodenville, WA 98072 (US). REEVES, Christopher, D. [US/US]; 19403 NE 203rd Place, Woodenville, WA 98072 (US). RAMBOSEK, John [US/US]; 7701 17th Avenue, N.E., Seattle, WA 98115			(Published) <i>With international search report.</i>

(54) Title: DNA ENCODING TRIOL POLYKETIDE SYNTHASE

(57) Abstract

DNA encoding triol polyketide synthase (TPKS) has been isolated, purified and sequenced. Expression vectors comprising TPKS, cells transformed with the expression vectors, and processes employing the transformed cells are provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION
DNA ENCODING TRIOL POLYKETIDE SYNTHASE

CROSS-RELATED TO OTHER APPLICATIONS

5 This is a continuation of U.S.S.N. 08/148,132 filed
November 2, 1993, now pending.

BACKGROUND OF THE INVENTION

10 Hypercholesterolemia is known to be one of the prime risk factors for ischemic cardiovascular diseases such as arteriosclerosis. Cholesterol and other lipids are transported in body fluids by 15 lipoproteins of varying density. The two lipoproteins carrying the majority of cholesterol in the blood are low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The role of LDL is to transport cholesterol to peripheral cells outside the liver. LDL-receptors on a cell plasma membrane bind LDL and allow entry of cholesterol into the cell. HDL may scavenge cholesterol in the tissues for transport to the liver and eventual catabolism. LDL levels are positively correlated with the risk of coronary artery disease while HDL levels are negatively 20 related, and the ratio of LDL-cholesterol to HDL-cholesterol has been reported to be the best predictor of coronary artery disease. Thus substances which effectuate mechanisms for lowering LDL-cholesterol 25 may serve as effective antihypercholesterolemic agents.

25 Mevacor® (lovastatin; mevinolin) and ZOCOR® (simvastatin), now commercially available, are two of a group of very active antihypercholesterolemic agents that function by inhibiting the enzyme HMG-CoA reductase. Lovastatin and related compounds inhibit 30 cholesterol synthesis by inhibiting the rate-limiting step in cellular cholesterol biosynthesis, namely the conversion of hydroxymethyl-glutarylcoenzyme A (HMG-CoA) into mevalonate by HMG-CoA reductase [3.7-9.12]. HMG-CoA reductase inhibitors act through cellular homeostatic mechanisms to increase LDL receptors with a consequent reduction in LDL-cholesterol and a resultant therapeutic antihypercholesterolemic effect. The HMG-CoA reductase inhibitors

- 2 -

within this invention include, but are not limited to compactin (ML-236B), lovastatin, simvastatin, pravastatin, fluvastatin and mevastatin.

Many HMG-CoA reductase inhibitors are synthesized by microorganisms. The general biosynthetic pathway of the HMG-CoA reductase inhibitors of the present invention has been outlined by Moore *et al.*, who showed that the biosynthesis of mevinolin (lovastatin) by Aspergillus terreus ATCC 20542 proceeds from acetate via a polyketide pathway (R. N. Moore *et al.*, Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen, and oxygen atoms by ^{13}C NMR and mass spectrometry. *J. Amer. Chem. Soc.*, 1985, 107: 3694-3701). Endo and his coworkers demonstrated that similar biosynthetic pathways existed in Pencillium citrinum NRRL 8082 and Monascus ruber M-4681 (A. Y. Endo *et al.*, Biosynthesis of ML-236B (compactin) and monacolin K., 1985, *J. Antibiot.*, 38:444-448).

The recent commercial introduction of HMG-CoA reductase inhibitors has provided a need for high yielding processes for their production. Methods of improving process yield include, but are not limited to scaling up the process, improving the culture medium or, simplifying the isolation train. The present invention focuses on a method of increasing process yield wherein the increase in productivity is due to the use of a microorganism that produces increased levels of HMG-CoA reductase inhibitor.

It may be desirable to increase the biosynthesis of HMG-CoA reductase inhibitors at the level of gene expression. Such increases could be achieved by increasing the concentration in an HMG-CoA reductase inhibitor-producing microorganism of one or more of the enzymes or enzymatic activities in the biosynthetic pathway of the HMG-CoA reductase inhibitor. It may be particularly desirable to increase the concentration of a rate-limiting biosynthetic activity.

Triol polyketide synthase (TPKS) is a multifunctional protein with at least four activities as evidenced by the product of the enzymatic activity (Moore, *supra*). TPKS is believed to be the rate-

- 3 -

limiting enzymatic activity(ies) in the biosynthesis of the HMG-CoA reductase inhibitor compounds.

The present invention identifies a DNA encoding triol polyketide synthase (TPKS) from *Aspergillus terreus*. The DNA encoding the TPKS of the present invention has been isolated, purified and sequenced. Complementary DNA (cDNA) and genomic DNA sequences corresponding to TPKS have been prepared. The TPKS cDNA of the present invention may be used to increase the production of HMG-CoA reductase inhibitors by HMG-CoA reductase inhibitor-producing microorganisms. The TPKS cDNA of the present invention may also be used to produce purified TPKS.

SUMMARY OF THE INVENTION

DNA encoding the full-length form of triol polyketide synthase (TPKS) is identified. The DNA is sequenced and cloned into expression vectors. Cells transformed with the expression vectors produce increased levels of TPKS and increased levels of HMG-CoA reductase inhibitors. The DNA is useful to produce recombinant full-length TPKS. The DNA may be used to isolate and identify homologues of TPKS present in organisms that are capable of producing polyketides, particularly microorganisms that are capable of producing HMG-CoA reductase inhibitors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the nucleotide sequence of triol polyketide synthase.

Figure 2 is the predicted amino acid sequence of triol polyketide synthase.

Figure 3 shows pTPKS100.

Figure 4 is a graphic view of the open reading frame of the TPKS protein and the overall placement of the TPKS peptides and PKS activities established by alignments generated by the Intelligenetics GeneWorks program.

- 4 -

Figure 5 shows the alignments of keto acyl synthase, acetyl/malonyl transferase and dehydratase carried out on regions of TPKS, rat fatty acid synthase (FAS) and P. patulum 6MSAS.

5 Figure 6 shows the alignments of enoyl reductase, keto reductase and acyl carrier protein carried out on regions of TPKS.

Figure 7 is a Chou-Fasman secondary structure prediction of pyridine nucleotide binding regions of TPKS and related proteins.

10 Figure 8 shows the S-adenosylmethionine binding regions of a variety of prokaryotic and eukaryotic methyl transferases.

Figure 9 is a Southern blot showing the homology of ketoacylsynthase of the TPKS of A. terreus to M. ruber and P. citrinum.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention relates to a DNA molecule encoding triol polyketide synthase (TPKS) which is isolated from TPKS-producing cells. Cells capable of producing TPKS include, but are not limited to, strains of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus,
20 Paecilomyces sp M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

TPKS, as used herein, refers to enzymatic activities that convert acetate precursors and S-adenosyl methionine to an intermediate in the triol biosynthetic pathway. This intermediate is further modified to produce a triol nonaketide. Polyketide synthases from bacteria and fungi employ common enzymatic functions to synthesize polyketides from two carbon units (for a review, see D.A. Hopwood and D.H. Sherman, 1990, "Comparison to fatty acid biosynthesis", Ann. Rev. Genet. 24: 37-66).

30 Polyketides are an important class of natural products because of their structural diversity and because many have antibiotic or other pharmaceutical activities. Most of the economically important polyketides are produced by fungi or actinomycetes.

- 5 -

Polyketide biosynthesis is similar to that of fatty acid biosynthesis in that it involves the sequential condensation of carboxylate units. Unlike fatty acids, which are built from acetate units, polyketides may be built from acetate, propionate, or butyrate units.

5 Additionally, some or all of the β -keto groups added at each cycle of condensation during polyketide biosynthesis are left unreduced, or are reduced only to hydroxyl or enoyl functionalities. This variation in building units and the variation in modification of the beta-keto groups results in a tremendous variety of products as well as difficulty in

10 comparing biosynthetic genes from different pathways.

Aspergillus terreus is a filamentous soil fungus; different strains of A. terreus produce a variety of polyketides (Springer, J. et al., 1979, terretonin, a toxic compound from Aspergillus terreus, J. Org. Chem., Vol. 44, No. 26, 4852-4854). Lovastatin is a polyketide produced by certain strains of A. terreus (Moore, supra). In addition to lovastatin and related metabolites such as triol or monacolin J, other polyketides found in A. terreus include sulochrin and related structures (Curtis, R. G. et al., 1964, "The biosynthesis of phenols", J. Biochem., 90:43-51) derived from emodin (Fujii, I., et al., 1982, "Partial purification and some properties of emodin-o-methyltransferase from (+)-geodin producing strain of Aspergillus terreus". Chem. Pharm. Bull., 30(6):2283-2286); terreic acid (Sheehan, J. C. et al., 1958, J. Am. Chem. Soc., 80:5536); patulin (D. M. Wilson, 1976, "Adv. Chem. Ser. No. 149") and citrinin (Sankawa, U. et al., 1983, "Biosynthesis of citrinin in Aspergillus terreus", Tetrahedron, 39(21):3583-3591). Presumably each of these products is made by a specific PKS encoded by a specific and distinct PKS gene(s), thus increasing the difficulty in cloning the triol PKS.

The structure and activity of lovastatin was reported by A. Alberts et al., (Proc. Natl. Acad. Sci. U.S.A., 1980, 77:3957-3961). Lovastatin is a reduced molecule consisting of a methylbutyryl group joined by an ester linkage to a nonaketide having a conjugated decene ring system.

- 6 -

Moore *et al.*, (*supra*) described lovastatin biosynthesis. Proton and ¹³C NMR studies of *in vivo* labeled lovastatin showed that all the carbons are derived from acetate except in the methyl groups at positions 6 and 2', which were derived from methionine. The triol molecule is composed of nine acetate units. The side-chain is composed of two acetate units. Esterification of triol and the butyrate side chain occurs enzymatically (Kimura, *supra*). The methyl butyrate side chain is presumably synthesized by a separate PKS. Lovastatin is first synthesized as a highly reduced precursor longer than 9 acetate units which undergoes reoxidation, including oxidative cleavage of a carbon-carbon bond.

Limited information is available for compactin biosynthesis. The most likely pathway would be nearly identical to that of lovastatin biosynthesis in *M. ruber* and *A. terreus*, except that methylation does not occur at the 6 position on the diene ring system.

Polyketide synthases (PKS) and fatty acid synthases (FAS) are classified by functional types. Type II enzymes, typical of bacteria and plants, have a separate polypeptide for each enzymatic activity. Type I enzymes, found in animals, bacteria and fungi, consist of large polypeptides with multiple activities or functional domains. Regions of amino acid sequence similarity have been identified in these genes: domains for ketoacyl synthase, acetyl/malonyl transferase, β -keto reductase, enoyl reductase, dehydratase and acyl carrier protein. The identification of these domains is considered evidence of the resulting enzymatic activity in light of the difficulty in obtaining functional Type I PKS *in vitro* (Sherman, *supra*).

Any of a variety of procedures may be used to molecularly clone the TPKS genomic DNA or complementary DNA (cDNA). These methods include but are not limited to, direct functional expression of the TPKS gene in an appropriate host following the construction of a TPKS-containing genomic DNA or cDNA library in an appropriate expression vector system. The preferred method consists of screening a TPKS-containing cDNA expression library constructed in a bacteriophage or vector with an antibody directed against the purified

- 7 -

TPKS protein. The antibody is obtained by standard methods (Deutscher, M. (ed), 1990, Methods in Enzymology, Vol. 182) by isolating purified TPKS protein from HMG-CoA reductase inhibitor-producing cells, inoculating an appropriate host, such as a rabbit, with the purified protein and, after several boosts, collecting immune sera. Antibody collected from the animal is used to screen the cDNA expression library and cDNA clones expressing TPKS epitopes recognized by the antisera are selected. The positive clones are further purified, labeled and used to probe TPKS-containing genomic or cDNA libraries to identify related TPKS containing DNA. Standard restriction analysis of the related clones can be used to create a restriction map of the region and sequence analysis of the genomic and cDNA clones can be used to define a structural map and the open reading frame of the gene, respectively.

Another method of cloning TPKS involves screening a TPKS-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labelled oligonucleotide probe designed from the amino acid sequence of TPKS. The method may consist of screening an TPKS-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the TPKS subunits. This partial cDNA is obtained by the specific PCR amplification of TPKS DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence of the purified TPKS subunits.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells or cell types, may be useful for isolating TPKS-encoding DNA. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines and genomic DNA libraries.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have TPKS activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate TPKS cDNA may be done by first measuring cell associated TPKS activity using incorporation of radiolabelled

- 8 -

acetate and separation of products by high performance liquid chromatography (HPLC).

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well-known cDNA library construction techniques can be found for example, in Maniatis, T., Fritsch, E.F., Sambrook, J., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982).

It is also readily apparent to those skilled in the art that DNA encoding TPKS may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well-known in the art. Well-known genomic DNA library construction techniques can be found in Maniatis et al., (supra).

In order to clone the TPKS gene, knowledge of the amino acid sequence of TPKS may be necessary. To accomplish this, TPKS protein may be purified and partial amino acid sequence determined by conventional methods. Determination of the complete amino acid sequence is not necessary. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized.

Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the TPKS sequence but will be capable of hybridizing to TPKS DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still hybridize to the TPKS DNA to permit identification and isolation of TPKS encoding DNA.

It is readily apparent to those skilled in the art that DNA encoding TPKS from a particular organism may be used to isolate and purify homologues of TPKS from other organisms. To accomplish this, the first TPKS DNA may be mixed with a sample containing DNA encoding homologues of TPKS under appropriate hybridization

- 9 -

conditions. The hybridized DNA complex may be isolated and the DNA encoding the homologous DNA may be purified therefrom.

5 cDNA clones encoding TPKS may be isolated in a two-stage approach employing polymerase chain reaction (PCR) based technology and cDNA library screening.

10 Amino acid sequence information may be obtained by automated amino acid sequencing using Edman chemistry of both the intact protein and the peptide fragments generated by specific proteolytic cleavage. Following incubation for the prescribed periods, digestion is terminated and resulting peptide fragments are fractionated and detected.

15 TPKS in substantially pure form derived from natural sources according to the purification processes described herein, is found to be encoded by a single mRNA.

20 The cloned TPKS cDNA obtained through the methods described above may be expressed by cloning it into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant TPKS. Techniques for such manipulations are well-known in the art.

25 In order to simplify the following Examples and the Detailed Description, certain terms will be defined.

30 Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic genes in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Expression vectors include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Specifically designed vectors allow the shuttling of DNA between hosts, such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited

- 10 -

number of useful restriction enzyme sites, a potential for high copy number, and active promoters.

An expression vector is a replicable DNA construct in which a DNA sequence encoding a TPKS is operably linked to suitable control sequences capable of effecting the expression TPKS in a suitable host. Control sequences include a transcriptional promoter, an optional operator sequence to control transcription and sequences which control the termination of transcription and translation.

Certain vectors, such as amplification vectors, do not need expression control domains but rather need the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants.

A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency.

DNA encoding TPKS may also be cloned into an expression vector for expression in a host cell. Host cells may be prokaryotic or eukaryotic, including but not limited to bacteria, yeast, mammalian and insect cells and cell lines.

The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they contain the TPKS gene or produce TPKS protein. Identification of TPKS expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-TPKS antibodies, and the presence of host cell-associated TPKS activity.

Expression of TPKS DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to

- 11 -

microinjection into frog oocytes, with micro-injection into frog oocytes being preferred.

PCR is the polymerase chain reaction, which is a technique for copying the complementary strands of a target DNA molecule simultaneously for a series of cycles until the desired amount is obtained.

Plasmids are generally designated by a low case p preceded or followed by capital letters and/or numbers. The starting plasmids used in this invention are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids by conventional procedures. In addition other equivalent plasmids or constructs will be readily apparent to one skilled in the art.

Transformed host cells are cells which have been transformed or transfected with TPKS vectors constructed using recombinant DNA techniques. Expressed TPKS may be deposited in the cell membrane of the host cell or may be intracellular or may be secreted.

It is also well known, that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

It is also well known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally-occurring peptide. Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited

- 12 -

to changes in the affinity of an enzyme for a substrate. Alteration of the amino acid sequence may lead to altered properties that in turn result in the production of modified structures; for example, the elimination of one of the reductase activities may result in the biosynthesis of a less-reduced compound.

The full-length TPKS-encoding DNA in plasmid pLOA was designated pTPKS100. A sample of pTPKS-100 in *E. coli* strain JM109, was deposited under the terms of the Budapest Treaty, on September 15, 1993 in the permanent culture collection of the American Type Culture Collection, at 12301 Parklawn Drive, Rockville, MD., 20852, and has been assigned the Accession number ATCC 69416.

The following examples illustrate the present invention without, however, limiting the same thereto.

15

EXAMPLE 1

Culture Conditions

Three strains of *Aspergillus terreus* were used. The two lovastatin-producing strains included *A. terreus* ATCC 20542. A lovastatin nonproducing strain was also used. A lovastatin-nonproducing strain or a lovastatin-overproducing strain of *A. terreus* may be derived from lovastatin-producing strains of *A. terreus* that are publicly available; an example of a publicly-available strain is *A. terreus* MF-4833, which is deposited with the American Type Culture Collection under Accession No. 20542. One skilled in the art would appreciate that a variety of techniques such as mutagenesis techniques, including but not limited to ultraviolet irradiation, treatment with ethylmethanesulfonate (EMS), exposure to nitrous acid, nitrosoguanidine and psoralen-crosslinking, could be used to generate a strain that does not produce or which overproduces lovastatin. The extent of the mutagenesis may be determined in a variety of ways including auxotrophy, i.e., the requirement of the mutated strain for a specific growth substance beyond the minimum required for normal metabolism and reproduction of the parent strain as well as

- 13 -

measurement of production of lovastatin by individual cultures. An alternative monitoring system involves the use of an intercalating dye such as acriflavine, which prevents any growth of the parent (lovastatin-producing) strain when plated at 10,000 spores per plate but, following mutagenesis, allows growth of about 3-5 colonies per plate.

Alternatively, the extent of mutagenesis may be monitored by visual observation of colonies having morphologies or colors that differ from the unmutagenized parent strain. Mutant strains are reisolated and pooled and subjected to further mutagenesis so that, by repetition of these procedures, mutated strains of *A. terreus* that do not produce or which overproduce lovastatin may be obtained.

Monascus ruber ATCC 20657 and Penicillium citrinum ATCC 20606 were used in hybridization studies.

The strains were maintained on YME + TE medium. The recipe for YME + TE medium is as follows:

0.4% Yeast Extract (w/v);
1.0% Malt Extract (w/v);
0.4% Glucose (w/v);
0.5% Trace Element (TE; v/v); and
2.0% agar (w/v) in 1 liter of water, pH 7.2.

The recipe for Trace Elements (TE) is as follows:

0.1% FeSO₄·7H₂O (w/v);
0.1% MnSO₄·H₂O (w/v);
0.0025% CuCl₂·2H₂O (w/v);
0.0132% CaCl₂·2H₂O (w/v);
0.0056% H₃BO₃ (w/v);
0.0019% (NH₄)₆Mo₇O₂₄·4H₂O (w/v); and
0.02% ZnSO₄·7H₂O (w/v) in 1 liter of water.

EXAMPLE 2

Fermentation Conditions

For the generation of spore stocks, single colonies were generated by growing on YME + TE plates for 8 days at 28°C and 65%

- 14 -

relative humidity. Single colonies were removed, and streaked on YME + TE slants. The slants were incubated for 8 days at 28°C in 65% humidity. Spores were harvested by addition of 2 ml of Spore Suspension Solution (SSS). SSS contains 10% Glycerol (v/v) and 5% Lactose (w/v) in water. Spores were scraped into the SSS with a sterile inoculation loop and counted. The suspension was stored at -20°C.

A two-stage fermentation from spore suspensions was used for the production of lovastatin. A seed culture was started by inoculating 1×10^8 spores into 2 ml/15 ml culture tube of HLC medium.

The recipe for HLC medium is as follows:

15 1.5% KH₂PO₄ (w/v);
 2.0% Cerelose (w/v);
 0.1% Ardamine pH (Champlain Industries) (w/v);
 1.5% Pharmamedia (Traders Protein) (w/v);
 0.2% Lactic acid (v/v); and
 0.4% ammonium citrate (w/v) in 1 liter of water.

The pH of HLC medium was adjusted to pH 7.2 before sterilization.

20 Cultures were shaken at a 30 degree angle at 28°C for approximately 28 hours on a rotary shaker with a 70 mm diameter amplitude at 220 rpm. Two ml of seed culture was used to inoculate 25 ml of GP-9 medium in a 250 ml flask.

The recipe for GP-9 medium is as follows:

25 0.9% Ammonium Citrate (w/v);
 0.12% Ardamine pH (w/v);
 1.2% Cerelose (w/v);
 4.0% Pharmamedia (w/v);
 24.5% Lactose (w/v); and
 0.2% P 2000 (v/v) in water at pH 7.2.

30 Incubation was continued as described for seed cultures without the 30 degree angle. Lovastatin production was monitored after 12 days of fermentation.

A one stage fermentation of A. terreus cultures in CM media was used to generate vegetative mycelia for transformations or

- 15 -

DNA preparations. Fermentations were started by inoculating 1×10^8 conidiospores into 50 ml of CM medium in a 250 ml flask and incubated as described.

5 The recipe for Complete Medium (CM) is as follows:

50 ml of Clutterbuck's salts;
2.0 ml Vogel's Trace elements;
0.5% Tryptone (w/v);
0.5% Yeast extract (w/v); and
1.0% Glucose (w/v) in one liter of water.

10 The recipe for Clutterbuck's salts is as follows:

12.0% Na_2NO_3 (w/v);
1.02% KCl (w/v);
1.04% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ (w/v); and
3.04% KH_2PO_4 (w/v).

15 The recipe for Vogel's trace elements is as follows:

0.004% ZnCl_2 (w/v);
0.02% FeCl_3 (w/v);
0.001% CuCl_2 (w/v);
0.001% $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$;
0.001% $\text{NaB}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$ (w/v); and
0.001% $(\text{NH}_4)_6\text{MO}_7\text{O}_24 \cdot 7\text{H}_2\text{O}$ (w/v).

EXAMPLE 3

25 Construction of Vector, pLO9

pLO9 is a 5.6 kb vector constructed with features useful for both cosmid library construction and fungal transformations. For dominant selection in Aspergillus terreus, pLO9 contains a Streptoalloteichus hindustanus phleomycin resistance gene driven by an A. niger β -tubulin promoter and terminated by a Saccharomyces cerevisiae terminator sequence. For selection in Escherichia coli, the vector contains the ampicillin resistance gene and for lambda packaging, the vector contains a lambda cos site. The construction of pLO9 is described below.

- 16 -

The phleomycin resistance marker originated from S. hindustanus and the termination sequence is from the CYC1 gene in S. cerevisiae. Both sequences were isolated on one DNA fragment from pUT713 (CAYLA, Toulouse Cedex, France) by digesting pUT713 with the restriction enzymes BamH1 and BgIII. The isolated fragment was cloned into BamH1-digested pUC18 to produce vector pLO1. The genomic copy of the β -tubulin gene from A. niger ATCC 1015, was cloned as a 4.3 kb EcoR1 fragment in pUC8 to create p35-C-14.

Several modifications were made to the genomic sequence. An EcoRI site was introduced at the initiator ATG by in vitro mutagenesis. The HindIII site in the promoter was removed by digestion with exonuclease, filling in with Klenow, and religation. Finally, an upstream EcoRI site was changed to a PstI site by digestion with EcoRI, filling in with Klenow and addition of a PstI linker by religation with ligase. The β -tubulin promoter was then subcloned as a PstI to EcoRI fragment in pUC8 to create pC15-1. An XbaI site was introduced at the initiator ATG by digestion with EcoRI, filling in with Klenow, addition of a XbaI linker and religation. The resulting vector was named pTL-113.

The β -tubulin promoter was cloned upstream of the phleomycin gene by cutting pTL113 with PstI and XbaI and cloning the isolated promoter fragment into the PstI and XbaI sites of pLO1 to produce pLO3. The BgIII site was removed with a fill in reaction followed by blunt-end ligation to produce vector pCS12. The PstI to Hind III fragment containing the beta tubulin promoter, phleomycin resistance gene, and the terminator sequence were cloned into a pUC8 vector to generate pLO6. The XbaI site at the ATG was removed by a fill-in reaction and ligation to give pLO7. The PstI to HindIII was moved as a fragment into a pUC18 backbone in which the XmaI site had been filled and replaced with a BgIII linker. The resulting vector was named pLO8. A PstI fragment containing the lambda cos site from pJL21 was inserted into the vector to generate pLO9.

- 17 -

EXAMPLE 4

Isolation of Genomic DNA

Vegetative mycelia were generated in CM media for 48 hr at 220 rpm at 28°C. Mycelia were collected by filtration through cheesecloth and frozen in liquid nitrogen for lyophilization overnight. Lyophilized mycelia were ground with sand using a mortar and pestle and suspended in 5 ml of Breaking Buffer (100 mM NaCl; 50 mM EDTA; 10 mM Tris, pH 8.0; 1% SDS; 50 ug/ml pancreatic RNase; 50 ug/ml Proteinase K). The mix was transferred to a 125 ml flask and an equal volume of Tris-saturated phenol/chloroform (50:50) was added. The flask was shaken for 1 hour at 37°C and 200 rpm. The aqueous layer was removed after centrifugation at 10,000 rpm for 10 minutes. The aqueous layer was extracted twice more with phenol/chloroform and was then extracted once with chloroform. DNA was precipitated from the aqueous layer by addition of 0.1 volume 3 M NaCl and 2.5 volumes of ethanol and then freezing at -70°C for 10 minutes. The precipitated DNA was collected by centrifugation at 10,000 rpm for 15 minutes. The pelleted DNA was dried and resuspended in a solution of 10 mM Tris-HCl, 1 mM EDTA, pH 7.5. DNA concentrations were determined by measuring absorbance at wavelength 260 nM.

EXAMPLE 5

25 Construction of A. terreus Libraries

A. Preparation of Genomic Fragments

30 A. terreus genomic DNA was isolated as described. Large random DNA fragments for insertion into the vectors were isolated by partially digesting 10 µg of DNA with the restriction enzyme Sau3A. The digested DNA was electrophoresed on a 1.0% Agarose gel. For the genomic library, an area containing 9-23 kb sized fragments was cut from the gel. For the cosmid library, another segment of the gel containing 30-60 kb sized fragments was excised. The large

- 18 -

chromosomal DNA fragments contained in the gel slices were isolated by electroelution. The DNA was concentrated by addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes, and centrifugation at 10,000 rpm for 10 minutes to precipitate the DNA.

B. Construction of the *A. terreus* Cosmid Library

The pLO9 cosmid DNA was used to supply the two arms and cos sites required for lambda packaging. Two fragments were isolated from pLO9 for the packaging reaction.

Fragment one was isolated by digesting pLO9 with XbaI, phosphatasing with HK phosphatase (Epicenter Technologies), digesting with BgII, electroeluting on a 1% Agarose gel, concentrating by the addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes and centrifuging at 10,000 rpm for 10 minutes to precipitate the DNA.

Fragment two was isolated by digesting pLO9 with SmaI, phosphatasing with HK phosphatase and then digesting with BgIII. Fragment two was isolated with the procedure described for fragment one. Fragment one, fragment two and isolated *A. terreus* insert DNA were ligated in a 1:1:2 ratio at a concentration of 0.5 µg of each DNA.

C. Packaging into Lambda Phage and Plating

Packaging into lambda phage was accomplished by mixing the ligation mixture with 10 µl of extract A from *E. coli* strain BHB2688 (Amersham) and 15 µl of extract B from *E. coli* strain BHB2690 (Amersham). The packaging mix was incubated at 22°C for 120 minutes. A volume of 500 µl of SM (0.58% NaCl(w/v); 0.20% MgSO₄(w/v); 0.05 M Tris pH 7.5; 0.01% Gelatin(w/v)) and 10 µl of chloroform was then added to the packaging mix.

E. coli strain DH5 was prepared for transfection by growing cells to an optical density of 1.0 at wavelength 600 nm in LB + maltose medium. LB + maltose medium consists of 1.0% Bacto-tryptone (w/v); 0.5% Bacto-yeast extract (w/v); 1.0% NaCl (w/v); pH 7.5; 0.2% Maltose (v/v) is added after autoclaving.

- 19 -

The cells were centrifuged at 4,000 rpm for 10 minutes and resuspended in 10 mM MgSO₄. Fifty microliters of the packaging mix was added to 200 µl of the resuspended DH5 cells and incubated for 30 minutes at 37°C. A 500 µl of aliquot of LB medium was added and the mix was incubated for 30 minutes at 37°C. The cell mix was spread on LB agar plates containing 100 µg/ml ampicillin (Sigma) and incubated at 37°C. A total of 10,000 colonies were generated with this library.

10 D. Construction of the A. terreus Genomic Library

The lambda replacement vector, EMBL3 (Promega), was used for the construction of the genomic library. The vector was purchased as predigested arms ready for ligation with the genomic inserts. The two arms were ligated to the 9-23 kb genomic inserts at a ratio of 1:1:2, packaged into lambda phage, and plated for hybridization with selected probes as described above.

EXAMPLE 6

20 A. Isolation of Cosmid DNA from E. coli

The *A. terreus* cosmid library in *E. coli* was grown on 25 cm x 25 cm plates containing 200 ml LB agar supplemented with 100 µg/ml ampicillin added. Nearly confluent colonies were scraped from plates in 10 ml of cold TS solution (50 mM Tris, pH 8.0 and 10% Sucrose(w/v)). A 2.0 ml aliquot of 10 mg/ml lysozyme made in 0.25 M Tris, pH 8.0 was added; then 8 ml of 0.25 M ethylenediamine tetraacetic acid (EDTA) was added. The mix was inverted several times and incubated on ice for 10 minutes. A 4 ml aliquot of a 10% SDS solution was added slowly while mixing gently with a glass rod. Next, 6.0 ml of 5 M NaCl was added slowly while mixing with a glass rod. The cell lysate was incubated on ice for 1 hour and then centrifuged. The supernatant was saved and then extracted twice with an equal volume of Tris-saturated Phenol/Chloroform (50:50). DNA was precipitated by adding 2 volumes of ethanol, freezing at -70°C for 15 minutes and then

- 20 -

centrifuging at 3,000 rpm for 15 minutes. The precipitated cosmid DNA was dried and resuspended in 9 ml of Tris-EDTA.

Cosmid DNA was prepared for cesium chloride density gradient purification by dissolving 10 gm of CsCl₂ in the DNA suspension and then adding 250 µl of 10 mg/ml ethidium bromide. Cosmid DNA was banded with a 20 hour centrifugation in a Ti865.1 Sorvall rotor at 55,000 rpm. The DNA bands representing cosmid DNA were recovered from the gradient, and ethidium bromide was removed by extraction with water-saturated butanol. Cosmid DNA was precipitated by adding 3 volumes of water and 10 volumes of ethanol, incubating on ice for 30 minutes and then centrifuging. The DNA was resuspended in Tris-EDTA and reprecipitated by the addition of 0.1 volume of 3 M sodium acetate and 2.5 volumes of ethanol. DNA was frozen at -70°C for 10 minutes, centrifuged, and resuspended in Tris-EDTA.

The DNA preparation was electrophoresed through a 0.5% Low Melting Temperature Agarose (BioRad) gel to eliminate contamination by pLO9 DNA. The band containing cosmid DNA with inserts was cut from the gel and heated to 65°C with 2 volumes of Tris-EDTA. The melted agarose was extracted 3 times with Tris-saturated phenol and then once with chloroform. Cosmid library DNA was precipitated by addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes, and centrifuging at 10,000 rpm for 15 minutes. The DNA was dried and resuspended in Tris-EDTA. The concentration of DNA was determined by measuring the optical density at 260 nm.

EXAMPLE 7

Transformation of A. terreus

Cultures were grown by inoculating 1×10^8 conidiospores into 50 ml of CM media in a 250 ml Erlenmeyer flask. Cultures were grown for between 24 and 30 hr at 200 rpm and 28°C. Mycelia were harvested by gravity filtration through Miracloth. Mycelia (4 g) were

- 21 -

transferred to a 500 ml Erlenmeyer flask containing 100 ml KMP. KMP consists of 700 mM KCl, 800 mM Mannitol, and 20 mM KH₂PO₄ pH 6.3. Lysing Enzymes from Trichoderma harzianum (100 mg; Sigma) was added. Flasks were shaken at 100 rpm for 18 hours at 28°C.

Spheroplasts were harvested by gravity filtration through Miraclot. The filtrate was collected in 50 ml conical centrifuge tubes, concentrated by centrifugation and washed by resuspending the spheroplasted cells in 15 ml of KCM solution. KCM consists of 700 mM KCl; 10 mM MOPS adjusted to pH 5.8. The washing was repeated twice. Washed spheroplasts were resuspended at a concentration of 5 x 10⁷/ml in KCMC. KCMC consists of 5% 1 M CaCl₂ and 95% KCM.

For each transformation, a sample of 5 µg of DNA was brought to a volume of 20 µl in Tris-EDTA; then 5 units of heparin in 6.5 µl of KCMC was added. Next, 200 µl aliquot of the spheroplast suspension was added to the DNA-containing solution. Finally, 50 µl of aliquot of a solution containing 5% 1 M CaCl₂ and 95% PCMC (40% PEG 8,000; 10 mM MOPS, pH 5.8; 0.05 M CaCl₂) was added. The mixture was incubated on ice for 30 minutes.

An aliquot (600 µl) of the KCMC solution was added to a 45°C equilibrated solution of MA. MA consists of 5% Clutterbuck's salts(v/v); 0.5% Tryptone (w/v); 0.5% Yeast Extract (w/v); 1.0% Glucose(w/v); 23.4% Mannitol(w/v) and 3% Agar. This suspension was divided among 5 preweighed petri dishes and incubated at 28°C for 4 hours. The weight of agar in each plate was determined by a second weight and an equal amount of Overlay (OL) consisting of: 1% Peptone (w/v); 1% Agar (w/v); with between 100 µg/ml and 150 µg/ml (strain ATCC 20542) of phleomycin was added to each petri dish. Petri dishes were incubated at 28°C and 65% humidity for 7-10 days before transformed colonies were picked.

- 22 -

EXAMPLE 8

Rescue of Cosmid DNA from A. terreus

The transforming cosmid DNA was rescued from an A.
5 terreus transformants by isolating chromosomal DNA and packaging
into lambda phage particles. Isolation of genomic DNA and packaging
into lambda phage were performed as described above.

EXAMPLE 9

Detection of Lovastatin

Fermentation extracts were prepared by adding two
volumes of reagent alcohol to the fermentation flasks and shaking the
flasks were shaken for 15 minutes at 220 rpm and 28°C. The contents
were allowed to settle for 15 minutes and 1 ml of the liquid was
removed. The sample was diluted 1/20 in methanol, filtered and then
analyzed by HPLC. Lovastatin was detected by a Waters HPLC using a
8 mm x 10 cm C18 4 um Waters Novapak column. Mobile phases were
A: Acetonitrile with 0.02% Trifluoroacetic acid and B: Distilled water
with 0.02% Trifluoroacetic acid. Gradients were run at a flow rate of
1.5 ml/min. Initial conditions were 35% A and 65% B and were held
for 1 minute after sample injection. A gradient was formed to 65% A
and 35% B over 3 minutes and held for 3.6 minutes. Lovastatin
ammonium salt was detected at 239 nm.

EXAMPLE 10

Southern Analysis of DNA

Southern analysis was performed by electrophoresing 5 µg
30 of digested DNA on a 1.0% agarose gel in TAE buffer (0.04 M Tris
and 0.002 M EDTA). DNA in the gel was denatured by soaking the gel
in Solution A (1.5 M NaCl and 0.5 M NaOH) for 30 minutes. The gel
was then neutralized in Solution B (1.0 M Tris and 1.5 M NaCl) for 30
minutes. DNA was transferred to nitrocellulose or nylon membranes

- 23 -

by blotting overnight with a 10 X SCC solution. SCC consists of 8.75% NaCl (w/v) and 4.4% sodium citrate (w/v), pH 7.0. DNA was baked onto the nitrocellulose at 80°C under vacuum for 30 minutes.

5 Standard hybridization conditions were as described in Sambrook, J. *et al.*, (Molecular Cloning, 1989 (ed. Chris Nolan) Cold Spring Harbor Press). Membranes were prepared for hybridization by incubating at 42°C in hybridization buffer consisting of: 6x SSC, 5x Denhardt's reagent, 0.5% SDS, 100 µg/ml denatured and fragmented salmon sperm DNA, and 40% formamide. After incubating for two
10 hours, the denatured labeled probe was added and further incubated overnight at 42°C. Unless otherwise stated, the filters were washed twice in 6x SSC and 0.1% SDS at room temperature for 15 minutes followed by two 30 minute washes at 42°C in 0.1X SSC and 0.5% SDS.
15 Filters were exposed to X-ray film for visualization of the signal.

EXAMPLE 11

A. Isolation of Triol Polyketide Synthase from A. terreus

20 Mycelia of A. terreus were grown in GP-9 medium. After 48 hours the mycelia were collected by vacuum filtration, washed with cold water, frozen in liquid nitrogen and lyophilized. All subsequent steps of the purification were performed on ice or at 3°C unless otherwise noted.

25 Lyophilized mycelia (6 g) were homogenized by grinding with 20 gm glass beads (0.2 mm) in a mortar with pestle in 135 ml homogenization buffer consisting of: 20 mM Tris, pH 8; 10% glycerol; 5 mM EDTA; 50 mM NaCl; 5 mM ascorbic acid; 3.8 µg/ml leupeptin; 17.7 µg/ml chymostatin; 2.0 µg/ml pepstatin, 42 µg/ml turkey trypsin inhibitor; 0.2 mM PMSF; and 2.2% (dry wt/v) hydrated polyvinyl
30 polypyrrolidone. The homogenate was centrifuged at 7,650 x g for 10 minutes; and the supernatant applied to an SH-affinity column (Affi-gel 501 organomercurial agarose; Bio-Rad; 1.5 x 8.0 cm) equilibrated in Buffer A. Buffer A consists of 20 mM Tris, pH 8; 50 mM NaCl; 5 mM EDTA; 5 mM ascorbic acid; at 30 ml/hr. The column was washed with

- 24 -

25 ml Buffer A followed by 75 ml Buffer A containing 0.5 M NaCl. After reequilibrating the column with 50 ml Buffer A, bound proteins were eluted with 40 ml Buffer A supplemented with 100 mM dithiothreitol (DTT). The eluted protein fraction was made 4.2 µg/ml leupeptin; 2 µg/ml pepstatin; 18 µg/ml chymostatin; 0.2 mM PMSF and then was pelleted by ultracentrifugation at 180,000 x g for 16 hr. The supernatant was discarded, and the pellet was rinsed with a buffer consisting of 20 mM Tris, pH 8; 5 mM ascorbic acid; 1 mM DTT; 1 mM EDTA. The washed pellet was resuspended in 2 ml of buffer consisting of 40 mM Tris, pH 6.8; 20 mM DTT; 2% SDS, then heated to 90°C for 10 minutes and put on ice.

A 250 µl aliquot of the resuspended pellet was combined with an equal volume of sample buffer (125 mM Tris, pH 6.8; 20% glycerol; 0.005%(w/v) bromphenol blue; 4%(w/v) SDS; 1.5 M beta mercaptoethanol) and heated to 95°C for 10 minutes. The sample was electrophoresed on a preparative 1.5 mm, 4% acrylamide SDS precast gel (Novex) at 145V for 2 hr using Laemmeli electrode buffer system (25 mM Tris; 192 mM glycine; 0.1% SDS). When a prestained 200 kD reference standard was 1.4 cm from the bottom of the gel, the electrophoresis was terminated.

Proteins were visualized as follow. The gel was rinsed for 5 seconds in distilled H₂O, then rinsed for 10 minutes in 0.2 M imidazole with shaking and was then transferred to a solution of 0.3 M zinc acetate for 5 minutes with shaking. The gel was then rinsed in water. The TPKS, which ran with an apparent molecular weight of 235 kD, was localized to a relative mobility position of 0.53 (relative to the bottom of the gel). The TPKS protein was the protein of greatest abundance on the gel; no significant protein banding was seen with lower R_f. The apparent 235 kD protein band was excised from the gel and was then destained in 0.25 M Tris and 0.25 M EDTA pH 9.5 for approximately 5 minutes.

The destained gel slice was crushed between two glass plates and placed in a 50 ml tube containing 5 ml of 20 mM Tris, 5 mM EDTA, 0.1% SDS, pH 8.0. The tube was shaken on a rotary shaker for

- 25 -

48 hours at 37°C. Gel fragments were removed by centrifugation, and the supernatant containing the eluted protein was concentrated to 100 µl with a Centricon 30 microconcentrator (Amicon).

5 **B. Molecular Weight Determination**

The gel-purified protein was resuspended in Laemmli load buffer, heated to 95°C for 5 min. and then electrophoresed on a 4-15% gradient SDS polyacrylamide gel (BioRad Ready-Gel) in Laemmli electrode buffer. After staining, the molecular weight of the protein was determined by comparison to molecular weight standard proteins.

10 **C. Antibody Production**

The TPKS protein was prepared via preparative SDS-PAGE as described, except the protein was not electroeluted from the acrylamide gel matrix. Following destaining, the gel slice was crushed between two glass plates, and first forced through a 18 gauge syringe needle and then through a 25 gauge syringe needle. A 0.5 ml aliquot of the 25 gauge needle eluate was mixed with an equal volume of Freund's complete adjuvant and injected intradermally at five sites of a New Zealand white male rabbit. Boosts were done at 21 and 42 days using protein prepared as described, but mixed with 0.5 ml of Freund's incomplete adjuvant. Ten days after the final boost the rabbit was exsanguinated and the antiserum collected.

15 **D. Affinity Purification of Antibody**

Affinity purified antibody was prepared by immobilizing the TPKS protein to PVDF membrane by transfer from a preparative SDS polyacrylamide gel. The TPKS was visualized and that area of the membrane cut out. After blocking in 5%(w/v) non-fat dry milk in TTBS for 1 hour, the membrane was washed 3 x 5 minutes in TTBS. A 2 ml aliquot of antisera was diluted 1:1 with TTBS supplemented with 1%(w/v) non-fat dry milk and incubated with the immobilized antigen for 5 hours. The membrane was then washed 4x (10 minutes per wash) with TTBS, and the bound antibody was eluted with 2 ml of 0.1 M

- 26 -

glycine, pH 2.8. The eluted antibody was neutralized with 50 µl of 1.0 M Tris, pH 9.5 and concentrated twenty-fold.

5 E. Western Blot Analysis

Purified TPKS protein and partially purified protein preparations of organomercurial eluates were resolved by 4% acrylamide SDS-PAGE (NOVEX, precast 1.0 mm thick gels) and then transferred to nitrocellulose in Towbin transfer buffer (25 mM Tris; 192 mM glycine, pH 8.3; 20% methanol; 0.05% SDS) at 240 mA for 2 hr. All subsequent steps were done at room temperature with shaking.

The nitrocellulose blot was rinsed for 1 minute in TBS (50 mM Tris, pH 7.5; 0.5 M NaCl) and then blocked for 2 hours in TBS supplemented with 0.05% Tween 20 (TTBS) and 5%(w/v) non-fat dry milk. The blot was incubated with the primary antibody (a 1:1000 dilution of rabbit antisera in TTBS containing 1%(w/v) non-fat dry milk) for 16 hr. The blot was washed in TTBS 3 times for 5 min. The blot was incubated with the second antibody (goat anti-rabbit alkaline phosphatase conjugate diluted 1:1000) for 2 hr in TTBS supplemented 1%(w/v) non-fat dry milk. After washing 4 times (10 minutes per wash) in TTBS, color development was achieved with 5-bromo-4-chloro-3-indolyl phosphate (115 µg/ml) and nitroblue tetrazolium (330 µg/ml) in 66 mM Tris, pH 9.5; 0.1 M NaCl; 5 mM MgCl₂.

25 EXAMPLE 12

Isolation of Aspergillus RNA

A. Isolation of Total RNA

30 A. terreus was grown for 48 hours in 25 ml of GP-9 fermentation medium at 28°C and 220 rpm on a rotary shaker. Mycelia were collected by vacuum filtration through Miracloth and cheesecloth and washed with approximately 100 ml distilled water. The mycelia were scraped from the filter into a plastic beaker and frozen with liquid nitrogen. Frozen mycelia were stored at -80 C until needed.

- 27 -

Frozen mycelia were weighed and placed in a mortar chilled with liquid nitrogen. Approximately 2 g of 0.2 mm glass beads were added, and the mix was ground to a fine powder with a pestle. Liquid nitrogen was added as needed to keep the mycelia frozen at all times. Ground mycelia were added to a flask containing approximately 2.5 ml/g Breaking Buffer (50 mM Tris pH 7.4; 150 mM NaCl; 5 mM EDTA; 5% SDS(w/v)) and an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol (50:50:1), and vanadyl ribonucleoside complex (BRL) to a final concentration of approximately 2 mM. The mixture incubated on a rotary shaker at 37°C for 20 minutes and was then centrifuged at 12000 x g for 10 min at 4°C. The aqueous layer was removed and extracted with an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol (50:50:1). Second and third extractions were done with 1 M Tris-saturated phenol:chloroform (50:50) and chloroform, respectively. The final aqueous layer was mixed with an equal volume of 6 M LiCl and left at -20°C for at least 4 hours. The precipitate was pelleted at 12,000 x g for 20 minutes at 4°C and resuspended in 0.6 ml water treated with 0.1% diethyl pyrocarbonate (DEPC). The total RNA was reprecipitated with 0.1 volume of sodium acetate and 2.5 volumes ethanol. The final pellet was dissolved in 0.3 ml water treated with 0.1% DEPC.

B. Isolation of Polyadenylated RNA

Polyadenylated RNA was isolated by heating approximately 500 µg of total RNA in 0.2 to 1.0 ml water to 65°C for 5 minutes, cooling on ice, and adding 10X sample buffer consisting of: 10 mM Tris pH 7.5; 1 mM EDTA; 5 M NaCl in 0.1% DEPC-treated water to a final concentration of 1X. The treated sample was applied to a column of oligod(T) cellulose prepared according to the manufacturer's instructions (Poly(A)Quik™ mRNA purification kit - Stratagene). The column was washed twice with High Salt Buffer (10 mM Tris pH 7.5; 1 mM EDTA; 0.5 M NaCl) and three times with Low Salt Buffer (10 mM Tris pH 7.5; 1 mM EDTA and 0.1 M NaCl). PolyA mRNA was then eluted from the column with four 200 µl aliquots of Elution Buffer (10

- 28 -

mM Tris pH 7.5 and 1 mM EDTA) which had been heated to 65°C. RNA concentration was determined spectrophotometrically using absorbance at 260 nm.

5

EXAMPLE 13

Construction of Lambda gt-11 cDNA Library

A cDNA library was constructed using 4 to 5 µg of polyadenylated RNA that had been purified twice over an oligo(dT) column. The reagents for construction of cDNA, addition of adapters and ligation of lambda gt-11 arms except [³²P]dCTP were provided in the Superscript™ Choice System (BRL) and were used according to the manufacturer's instructions.

First strand synthesis was primed using either 0.05 µg random hexamers plus 0.5 µg oligo(dT)12-18 or 1 µg oligo(dT)12-18 alone. The reaction was carried out in a final volume of 20 µl (final composition: 50 mM Tris, pH 8.3; 75 mM KCl; 3 mM MgCl₂; 10 mM DTT; 500 µM each dATP, dCTP, dGTP, dTTP; primers; mRNA; 10 µCi [³²P]dCTP; 200 U Superscript™ reverse transcriptase/µg mRNA). The reaction mixture was incubated for 1 hr at 37°C and then placed on ice.

Second strand synthesis was carried out in a final volume of 150 µl using 18 µl of the first strand reaction. The final composition of the reaction was: 25 mM Tris pH 7.5; 100 mM KCl; 5 mM MgCl₂; 10 mM (NH₄)₂SO₄; 0.15 mM B-NAD⁺; 250 µM each dATP, dCTP, dGTP, dTTP; 1.2 mM DTT; 65 U/ml DNA Ligase; 250 U/ml DNA polymerase I; and 13 U/ml RNase H. This reaction mixture was incubated at 16°C for 2 hr; then 10 U of T4 DNA polymerase was added, and the incubation was continued at 16°C for an additional 5 minutes. The reaction was put on ice and stopped by adding 10 µl of 0.5 M EDTA. The mix was extracted with 150 µl of Tris-saturated phenol:chloroform:isoamyl alcohol (25:24:1). The aqueous layer was removed, and cDNA was precipitated with 0.5 volume 7.5 M ammonium acetate and 3.5 volumes ethanol. The cDNA pellet was

- 29 -

washed with 70% ethanol. EcoRI (Not1) adapters were ligated to the cDNA in a reaction mix comprised of 66 mM Tris, pH 7.6; 10 mM MgCl₂; 1 mM ATP; 14 mM DTT; 200 µg/ml EcoRI (Not1) adapters; 100 U/ml T4 DNA ligase. The reaction mixture was incubated for 16 hours at 16°C, then heated to 70°C and placed on ice. The adapted cDNA was phosphorylated by adding 30 U of T4 polynucleotide kinase to the reaction mix and incubating for 30 minutes at 37°C. The kinase was inactivated by heating to 70°C for 10 minutes. The completed reaction was diluted with 97 µl of TEN buffer (10 mM Tris, pH 7.5; 0.1 mM EDTA; 25 mM NaCl) and placed over a Sephacryl® DNA sizing column prepared according to the manufacturer's directions (BRL). The DNA was eluted with TEN buffer and fractions were collected. Cerenkov counts were obtained for each fraction and the amount of cDNA/fraction was calculated. The column fractions were pooled in order of elution until 50 ng cDNA was collected. The pool was then precipitated with 5 µl yeast tRNA, 0.5 volumes 7.5 M ammonium acetate and 2 volumes ethanol (-20°C). The resultant pellet was washed with 70% ethanol, dried and ligated to lambda gt-11 arms. The final composition of the ligation reaction was 50 mM Tris pH 7.6; 10 mM MgCl₂; 1 mM ATP; 5% PEG 8000(w/v); 1 mM DTT; 100 µg/ml lambda vector EcoRI arms; 10 µg/ml cDNA; and 200 U/ml T4 DNA ligase. This mixture was incubated for 3 hours at room temperature. The cDNA/lambda gt-11 ligation was packaged into infectious lambda phage particles as described above.

EXAMPLE 14

A. Antibody Screening of Lambda gt-11 Library

E. coli strain Y1090 was used as the host for lambda phage infections and was maintained on LB/ampicillin plates consisting of: 1% tryptone (w/v); 0.5% yeast extract (w/v); 0.5% NaCl (w/v); 1.5% agar (w/v); the pH was adjusted to 7.5 before autoclaving, and 100 µg/ml ampicillin added after autoclaving. Cultures were grown for phage infection by incubating a single colony overnight on a rotary shaker at

- 30 -

37°C in 3 ml LB/maltose broth consisting of: 1% tryptone(w/v); 0.5% yeast extract(w/v); 0.5% NaCl(w/v) and 0.2% maltose(w/v).

B. Pretreatment of Antisera

Antisera were treated with an E. coli lysate prior to screening so as to decrease cross-reaction to E. coli protein. E. coli lysate was prepared from Y1090 cells grown overnight in LB broth at 37°C on a rotary shaker at 220 rpm. Cells were pelleted by centrifugation at 10,000xg at 4°C and resuspended in 3 ml Lysate Buffer (50 mM Tris pH 8.0 and 10 mM EDTA). Cells were frozen in a dry ice/ethanol bath and thawed at room temperature; the freeze/thaw process was repeated. The suspension was sonicated 5 x 10 seconds at output control 4 on a constant duty cycle using a Branson Sonifier 450. Cells were placed on ice for 10 seconds after each pulse. Protein concentration in the lysate was estimated using the Bradford Assay (Bio-Rad) according to the manufacturer's suggestion. Sonicated lysate was stored at -20°C until needed. The antisera was diluted 10-fold with TBST plus 1% dried milk(w/v) and mixed with 1/20 volume E. coli lysate. This solution was incubated at room temperature on a rotary shaker for two hours.

C. Screening of Lambda Gt-11 Phage Plaques

Recombinant phage diluted to 6×10^3 pfu in 100 µl of SM was added to 600 µl of an overnight culture of E. coli Y1090 and absorbed at 37°C for 30 minutes. The cells were then added to 7.5 ml of a 47°C solution of LB Top Agarose/MgSO₄ (0.1% tryptone(w/v); 0.5% yeast extract(w/v); 0.5% NaCl(w/v); 10 mM MgSO₄) and plated on a 140 mm LB agar plate. The plate was incubated at 42°C for approximately 5 hours until tiny plaques were visible. The plate was then overlaid with a 137 mm nitrocellulose filter which had been saturated with a 10 mM solution of IPTG (isopropyl-B-D-thiogalactopyranoside) and air-dried. Incubation of the plate was continued overnight at 37°C. The filter was removed and washed 3 times for 15 minutes each. All washes were carried out at room

- 31 -

temperature on a rotary shaker in TBST. The filters were blocked in TBST plus 5% w/v dried milk (Carnation instant non-fat dried milk) for 30 minutes at room temperature on a rotary shaker. Filters were washed 3 x 15 minutes and then incubated with a 1:1000 dilution of goat anti-rabbit IgG alkaline phosphatase conjugate (Bio-Rad) in TBST plus 1% dried milk(w/v) for 2 hours. The filters were washed 3 x 15 minutes and then developed in AP buffer (100 mM Tris pH 9.5; 100 mM NaCl; 5 mM MgCl₂) to which was added NBT (nitroblue tetrazolium) to a final concentration of 0.33 mg/ml and BCIP (5-bromo-4-chloro-3-indoyl phosphate) to a final concentration of 0.165 mg/ml for 2-5 minutes. The color reaction was stopped by washing the filters with water. Positive plaques were picked to 1 ml SM plus 10 µl chloroform and stored at 4°C until needed.

Positive plaques were further purified until all the plaques on a filter were positive. Purification rounds were done on 100 mm LB/agar plates with phage titer adjusted to approximately 100 pfu/plate. Positive plaques were confirmed by screening with an affinity-purified antibody at a dilution of 1:100.

20

EXAMPLE 15

Preparation of Lambda DNA

Phage were adsorbed to 1.5 ml of an overnight culture of *E. coli* Y1090 at a multiplicity of infection of 0.01 for 30 minutes at 37°C and then added to 300 ml LB media. The cells were incubated at 37°C on a rotary shaker about 6 hours (until the cells lysed). One ml chloroform was added to complete the lysis. Cell debris was pelleted by centrifugation at 10,000 x g for 10 minutes at 4°C. Lysate was stored at 4°C until needed.

30

Lysate was treated with DNase I (final concentration 1 µg/ml) and RNase H (final concentration 5 µg/ml) at 37°C for one hour. Phage were pelleted by centrifugation for 90 minutes at 27,000 rpm in a Sorvall AH-629 rotor; and the tubes were inverted to drain. Phage pellets were resuspended in 200 µl 0.05 M Tris, pH 8 and were

- 32 -

extracted with 200 µl Tris-saturated phenol by vigorous shaking for 20 minutes. The mixture was spun in a microcentrifuge, and the aqueous layer saved. The aqueous layer was extracted with phenol and then extracted twice with 200 µl chloroform. DNA was precipitated with 5 0.1 volume 3 M sodium acetate and 6 volumes ethanol at room temperature. DNA was pelleted in a microcentrifuge, washed with 70% ethanol, dried and resuspended in 100 µl TE pH 8.0 (10 mM Tris; 1 mM EDTA).

10

EXAMPLE 16

Screening of EMBL3 Genomic Library

The EMBL3 genomic library was plated for screening with 15 32P-labeled DNA probes. Approximately 10,000 plaques were plated and transferred to nitrocellulose for hybridizations. Filters were prehybridized for 2 hours and hybridized overnight in hybridization buffer in the presence of a DNA probe labeled with 32P-dCTP (Oligolabeling Kit, Pharmacia). For the selection of EMBL-1, the DNA 20 probe consisted of the EcoRI cDNA insert of lambda gt-11 2-9 which was identified using the antibody to the 235 kD protein. Filters were washed using the protocol employed for Southern hybridizations, and positive plaques were identified after an overnight exposure to film. DNA from positive EMBL-3 phage was prepared as described.

25

EXAMPLE 17

Sequencing Strategy and Analysis

A series of overlapping subclones from the genomic 30 EMBL1 clone, which contained the triol PKS gene, were constructed in M13mp18 and M13mp19. Nested deletions of some of the clones were obtained using the Cyclone I Biosystem (International Biotechnologies, Inc., New Haven, CT). Single stranded DNA was purified by precipitation with 20% polyethylene glycol-2.5 M NaCl followed by phenol extraction and ethanol precipitation. The nucleotide sequence of

- 33 -

both strands of the DNA was determined using the USB Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemicals, Cleveland, OH). The -40 sequencing primer from the kit or custom synthesized oligonucleotides were used to prime the reactions. Regions containing GC compressions were resequenced using dITP in place of dGTP. The sequencing reactions were separated on 6% polyacrylamide denaturing gels. The genomic M13 clones were resequenced using a 373A DNA Sequencer (Applied Biosystems, Inc.) for verification.

Introns were identified by sequence analysis of cDNA. The RNA was prepared from a 16 hr culture grown in GP9 medium, and cDNA was synthesized using AMV reverse transcriptase. Custom synthesized oligonucleotides were used to amplify short overlapping stretches of the cDNA by PCR. The PCR conditions, reagents, and product purification were performed as described for PCR with genomic DNA in the PCR/Sequencing Kit PCR Amplification Module manual (Applied Biosystems, Inc., Foster City, CA).

The PCR were performed using a Perkin Elmer GeneAmp PCR system 9600. The PCR products were sequenced as described in the Taq DyeDeoxy Terminator Cycle Sequencing Kit manual (Applied Biosystems, Inc.), and sequencing reactions were analyzed using the 373A DNA Sequencer. All sequence analyses and manipulations were performed using GeneWorks (IntelliGenetics, Inc., Mt. View, CA) on a Macintosh computer (Apple Computer, Inc., Cupertino, CA).

25

EXAMPLE 18

A.

Construction of pTPKS100

30

The transformation vector pTPKS100 contains the polyketide synthase gene responsible for the synthesis of the nonaketide backbone of the triol structure, the phleomycin resistance gene for selection in A. terreus and the ampicillin resistance gene for selection in E. coli.

The vector was constructed from the pUT715 vector (Cayla, Toulouse Cedex, France) which contains the phleomycin

- 34 -

resistance marker from S. hindustanus and the termination sequence from the Cyc1 gene in S. cerevisiae. The pUT715 vector was digested with BamHI and EcoRV. The β-tubulin gene promoter was inserted in front of the phleomycin marker gene as follows. The β-tubulin promoter was removed from pTL113 by digestion with EcoRI, filling with Klenow fragment, and releasing the fragment from the vector with a BgIII digest. The β-promoter was ligated into the pUT715 vector to form pCLS7. The β-tubulin promoter, phleomycin marker and Cyc1 terminator were removed from PCLS7 by digestion with NdeI and BgIII followed by filling in the sites, and ligating into the SmaI site of the Bluescript vector (Strategene). This vector was named pLOA.

The polyketide synthase gene was inserted into pLOA in a two step process. The promoter and 5'-end of the PKS gene was obtained from EMBL-1 as a KpnI to EcoRI fragment and ligated into pLOA which had been digested with KpnI and EcoRI. This vector was named TPKS A. The 3' end of the PKS gene was then added to the construction by digesting TPKS A with EcoRI and ligating in the 3' EcoRI gene fragment isolated from EMBL-1. The resulting vector was named pTPKS100.

Transformation of a lovastatin-nonproducing strain with pTPKS100 restored lovastatin production. Transformation of ATCC 20542 (a lovastatin-producing strain) increased lovastatin production relative to untransformed cells.

25

EXAMPLE 19

Transformation of A. terreus ATCC 20542

To determine whether increasing the copy number of the PKS gene in a lovastatin-producing strain would result in an increase in the amount of lovastatin produced, a set of experiments were designed and carried out using the A. terreus ATCC 20542. ATCC 20542 was transformed with pTPKS-100. Transformants were checked by PCR to confirm that they contained the phleomycin marker and were true transformants. Following single spore isolation, the confirmed

- 35 -

transformants were fermented and lovastatin production was measured by HPLC. The highest producer of single isolates, strain 3-17-7#7, was 32% greater for the transformant than for the parent.

5

EXAMPLE 20

Characterization of the TPKS Protein Sequence

Splicing of the introns from the DNA sequence and translation of the 9114 nucleotide open reading frame results in a protein of 3038 amino acids with a molecular weight of 269,090 daltons. The final amino acid sequence of the TPKS protein is shown in Figure 2. The features discussed below are presented with their amino acid position noted in the following table.

15

TPKS PROTEIN FEATURES

	Description	Motif	Amino Acid
20	Keto-acyl synthase	Cysteine	181
	Acetyl/Malonyl Transferase	GXSXG	654-658
	Dehydratase	HXXXGXXXXP	985-994
	Methyl Transferase	GXGXG	1446-1450
	Enoyl Reductase	SXGXXS	1932-1937
25	Keto Reductase	LXGXXG	2164-2169
	Acyl Carrier Protein	Serine	2498

Inspection of the TPKS amino acid sequence for active site residues and motifs known to be associated with polyketide synthases and fatty acid synthase (FAS) activities resulted in the identification of candidates for expected functional sites. These sites were identified by carrying out searches for amino acid sequences and amino acid homologies using the Intelligenetics Gene Works program. A graphic view of the open reading frame of the protein and the overall placement of the TPKS peptide sequences obtained by partial sequence analysis of

- 36 -

TPKS peptides and PKS activities established by alignments and is shown in the figures. Except for the presence of a methyl transferase, not present in FAS, the succession of activities on the TPKS protein is the same as that observed for the rat FAS protein. The alignments carried out on regions of the TPKS, the rat FAS, and the 6-methylsalicylic acid synthase (6-MSAS) of Penicillium patulin in order to identify the best candidate for each of the activities are also presented in the figures.

10

EXAMPLE 21

Identification of the Keto Acyl Synthase Region

The most 5' site is the β -keto acyl synthase (KAS), also known as the condensing enzyme. This activity is centered around the active site cysteine to which the acyl chain is attached prior to the entry and condensation of the incoming acyl unit. The region shown in the Keto Acyl Synthase Alignment figure contains 30% homology when compared to both the rat FAS and 6-MSAS sequences. However, the TPKS KAS region is most closely related to the rat FAS sequence, exhibiting 49% homology over this region compared to 41% to 6-MSAS.

EXAMPLE 22

25

Identification of the Acetyl Malonyl Transferase

Proceeding towards the COOH terminus, the next functional site identified is the acetyl/malonyl transferase, which is responsible for accepting the incoming substrate for transfer to either the active thiol of the beta-keto synthase (if a priming acetyl unit) or to the active site thiol of the ACP-pantetheine-SH if a malonyl building block. The identification of the acetyl/malonyl transferase site was found by searching for the GXSXG motif found in many proteins with an active site serine (Wakil, S. J., 1989, Biochemistry, 28: 4523-4530).

- 37 -

The conservation of this motif in the TPKS protein was observed beginning at amino acid 654, as shown in the figures.

5

EXAMPLE 23

10

Identification of the Dehydratase

The next site in common with the FAS protein is the dehydratases. The dehydratase motif consistently found not only in the rat FAS, but the 6-MSAS and the erythromycin SU4 as well consist of a "HXXXGXXXXP" sequence (Donadio, S. and Katz, L., 1992, Gene, 111, 51-60.). The homology outside of this signature sequence is very weak.

15

EXAMPLE 24

Identification of the Enoyl and Keto Reductase

The next two activities identified on the rat FAS protein are the enoyl reductase (ER) and keto reductase (KR). In general, the ER and KR are identified by searching for the GXGXXG/A motif which is proposed to represent the pyridine nucleotide binding site in many proteins (Wierenga, R. K. and Hol, W. G. J., 1983, Nature, 302, 842-844). An identical match to this motif has been identified in the rat FAS for both the KR and ER (Witkowski, V., et al., 1991, Eur. J. Biochem., 198, 571-579). Inspection of the TPKS protein identified three matches to the motif. The first begins at position 321 between the β -keto synthase and acetyl/malonyl transferase functions. However, this is not considered to be a good candidate for either of the reductase activities due to its 5' position in the protein and because it lies in a region which is highly homologous to rat FAS. The GXGXXG motif is seen again at position 1446-1451, however, this is considered to be part of the methyl transferase domain. The third time the motif occurs is at position 2438 which lies 60 amino acids 5' of the ACP active site serine. A similar GXGXXG motif is seen in the rat FAS at 125 amino acids prior to the ACP and in 6-MSAS 129 amino acids 5' of the ACP. Since candidates

for the NAD(P) binding sites of the KR and ER were not observed in the TPKS protein, homology searches were performed between the regions of the rat FAS which contain these sites and similar regions of the TPKS protein.

As shown in the Enoyl Reductase Alignment, the region of the TPKS protein which lies between the dehydratase and the keto reductase and shows the best alignment to the rat FAS enoyl reductase does not bear a strong homology to the GXGXXG motif or to the region in general. A much stronger homology is evident between the ER domain of SU4 of Erythromycin AII and the rat FAS sequence. The Keto Reductase Alignment of the rat FAS and 6-MSAS keto reductase regions with the TPKS shows slightly higher homology, with 6 out of 30 amino acids surrounding the glycine-rich region conserved between all genes and 13 of 30 conserved between TPKS and either FAS or 6-MSAS.

The glycine-rich segment is part of an overall structural motif for pyridine-nucleotide binding domains in many proteins (Wierenga, *ibid.*; Scrutton, N. S., *et al.*, 1990, *Nature*, 343, 38-43; Ma, Q., *et al.*, 1992, 267, 22298-22304; Hanukoglu, I., and Gutfinger, T., 1989, *Eur J. Biochem.*, 180, 479-484). This structural motif consists of a beta sheet-turn-alpha helix where the glycine rich region codes for the strong turn signal in the middle. In addition, downstream acidic or basic amino acids are positioned to bind to the phosphate (NADP) or hydroxyl group (NAD) on the 2' ribose position. This is depicted in a Chou Fasman analysis of the secondary structure of horse alcohol dehydrogenase as a model NADP binding protein. The analysis of the structural characteristics using the Chou Fasman algorithm indicate that this structural motif is conserved in the rat FAS ER and KR domains, (Witkowski, A., 1991, *Eur. J. Biochem.*, 198, 571-579). The structural predictions of the amino acid sequence of the TPKS ER and KR, as well as the 6MSAS KR, show variations of the model. All predicted structures show a β sheet leading into a turn region, even when amino acid homologies are not strong. It has been suggested that deviations from the structural model may reflect differences in substrate

- 39 -

specificity (Ma, Q., supra). It is possible that these structural variations are important in the programming of the PKS, resulting in different levels of reduction of the beta-keto group during successive cycles of the biosynthesis of the triol precursor. Consistent throughout the alignments are the presence of basic amino acids at position 20 to 23 amino acids from the "glycine rich" regions identified by the homology searches. The structural similarities and the presence of these basic amino acids suggest that these regions do indeed represent the keto and enoyl reductases of the TPKS protein.

10

EXAMPLE 25

Identification of the Acyl Carrier Protein

15

The last active site identified by alignment of the rat FAS with the TPKS is the acyl carrier protein (ACP) active site serine which binds the 4'-phosphopantetheine prosthetic group. While only 6 out of 30 amino acids surrounding the active site serine are conserved over TPKS, rat FAS and 6-MSAS, a higher degree of homology (13 of 30 amino acids) is observed between TPKS and either rat FAS or 6-MSAS.

20

EXAMPLE 26

Identification of the Methyl Transferase

25

One activity identified within the reading frame of the TPKS protein which is not present in rat FAS is the methyl transferase responsible for transfer of the methyl group from S-adenosylmethionine (SAM) to the polyketide chain at position 6. A comparison of both eucaryotic and procaryotic methyl transferases responsible for the methylation of RNA, DNA, and protein substrates has identified a sequence motif thought to be part of the SAM-binding domain (Ingrosso, D. *et al.*, 1989, *J. Biol. Chem.*, **264**, 20131-20139; Wu, G. *et al.*, 1992, *J. Gen. Micro.*, **138**, 2101-2112). The binding motif and its alignment with the proposed methyl transferase of the TPKS are shown in the figures.

30

- 40 -

The absence of a methyl group in compactin suggests that the methyl transferase domain may be absent or altered in the compactin PKS.

5

EXAMPLE 27

A. Transformation of Monascus ruber

Cultures of M. ruber strains M4681 AND M82121 are grown, spheroplasted and transformed essentially according to the procedures described above. Petri dishes are incubated at 28°C and 65% humidity for 7-10 days before transformed colonies are picked.

B. Fermentation of Monascus

The transformed cultures are grown aerobically in a medium containing 7% glycerol, 3% glucose, 3% meat extract, 0.8% peptone, 0.2% NaNO₃, and 0.1% MgSO₄•7H₂O at 25 degrees C for 10 days (Kimura et al., 1990. "Biosyn. of Monacolins, Conversion of Monacolin J. To Monacolin K (Mevinolin)", J. of Antibiotics, Vol. XLIII No. 12, 1621-1622). M. ruber M82121 is grown aerobically at 25°C for 11 days in a medium containing 11% glycerol, 1% glucose, 5% soy bean powder, 0.8% peptone, 0.1% NaNO₃, 0.05% Zn(NO₃)₂, and 0.5% olive oil (pH 6.5) (Endo, et al., "Dihydromonacolin L and Monacolin X, New Metabolites Those Inhibit Cholesterol Biosynthesis", J. Antibiot., Vol. XXXVIII No. 3, 321-327). The culture broth is extracted with a solvent such as methanol or dichloromethane, concentrated and analyzed by methods such as HPLC. By comparison with an untransformed host or a M. ruber culture containing pL09 without the TPKS genes, the TPKS100 containing host or a derivative thereof produces increased levels of lovastatin, triol, monacolin, dihydromonacolin L or monacolin X.

- 41 -

EXAMPLE 28

A. Transformation of *Paecilomyces viridis*

P. viridis strain L-63 is grown, spheroplasted and transformed essentially according to the procedures described above. Cells are transformed with pTPKS100 or a derivative thereof. An example of such a derivative is one in which the DNA encoding the methyl transferase activity of the TPKS protein is altered such that an active methyl transferase is not produced. Petri dishes are incubated at 28°C and 65% humidity for 7-10 days before transformed colonies are picked.

B. Fermentation of *Paecilomyces*

P. viridis L-63 is grown aerobically in a medium containing 7% glycerol, 3% glucose, 3% meat extract, 0.8% peptone, 0.2% NaNO₃, and 0.1% MgSO₄•7H₂O at 25°C for 4 to 10 days (Kimura *et al.*, *supra*). The culture broth is extracted with a solvent such as methanol or dichloromethane and concentrated by evaporation if necessary. By comparison with an untransformed host or a *P. viridis* culture containing pLOA without the TPKS genes, the transformed host can be shown to ferment increased levels of ML-236A and compactin.

EXAMPLE 29

A. Transformation of *Penicillium citrinum*

A suitable culture of *P. citrinum* (e.g., Nara, *et al.*, 1993. "Development of a transformation system for the filamentous, ML-236B (compactin) - producing fungus *Penicillium citrinum*". *Curr. Genet.*, **23**, 28-32) is transformed with pTPKS100 or an appropriate derivative thereof using conventional methods.

B. Fermentation of *P. citrinum*

The transformed culture is maintained on yeast-malt extract agar slant (4 g/l dextrose, 10 g/l malt extract, 4 g/l yeast extract, agar

- 42 -

20 g/l, pH 7 prior to sterilization). The slant is washed and used to inoculate to flasks containing KF seed medium (10 g/l CaCl₂, 5 g/l corn steep liquor, 40 g/l tomato paste, 10 g/l oatmeal, 10 g/l cereose, 10 ml trace element per liter, pH 6.8; trace elements consist of 1 g
5 FeSO₄•7H₂O 1 g MnSO₄•4H₂O, 25 mg CuCl₂•2H₂O, 100 mg CaCl₂, 56 mg H₃BO₃, 19 mg (NH₄)₆Mo₇O₂₄•H₂O, 200 mg ZnSO₄•7H₂O in liter of dH₂O). The KF seed flasks are incubated for about 3 days at about 28°C and 220 rpm. Approximately 1.5 ml is used to inoculate 40 ml of LM production medium per 250 ml flask. LM medium contains 10 20 g/l dextrose, 20 ml/l glycerol, 10 g/l ardamine pH, 20 g/l malt extract, 8 mg/l CoCl₂•6H₂O and 0.25% polyglycol P2000, pH 7.0. After 5 to 10 days at 25°C on a shaker, the broth is collected, extracted and concentrated. The transformed culture produces more compactin and dihydrocompactin than does the untransformed parent culture.
15

EXAMPLE 30

Cloning of TPKS cDNA into a Mammalian Expression Vector

20 TPKS cDNA expression cassettes are ligated at appropriate restriction endonuclease sites to the following vectors containing strong, universal mammalian promoters:

25 Cassettes containing the TPKS cDNA in the positive orientation with respect to the promoter are ligated into appropriate restriction sites 3' of the promoter and identified by restriction site mapping and/or sequencing. These cDNA expression vectors are introduced into various host cells by standard methods including but not limited to electroporation, or chemical procedures (cationic liposomes, DEAE dextran, calcium phosphate). Transfected cells and cell culture supernatants can be harvested and analyzed for TPKS expression as described below.

30 Vectors used for mammalian transient expression may be used to establish stable cell lines expressing TPKS.

- 43 -

EXAMPLE 31

Cloning of TPKS cDNA into a Baculovirus Expression Vector for Expression in Insect Cells

Baculovirus vectors, which are derived from the genome of the AcNPV virus, are designed to provide high level expression of cDNA in the Sf9 line of insect cells. Recombinant baculoviruses expressing TPKS cDNA are produced essentially by standard methods (InVitrogen Maxbac Manual). The TPKS cDNA constructs are ligated into the polyhedrin gene in a variety of baculovirus transfer vectors including but not limited to pAC360 and the BlueBac vector (InVitrogen). Recombinant baculoviruses are generated by homologous recombination following co-transfection of the baculovirus transfer vector and linearized AcNPV genomic DNA [Kitts, P.A., Nuc. Acid. Res., 18, 5667 (1990)] into Sf9 cells. Following plaque purification, TPKS expression is measured by the assays described above.

Authentic, enzymatically-active TPKS is found in the cytoplasm of infected cells. Active TPKS is extracted from infected cells under native conditions by hypotonic or detergent lysis.

EXAMPLE 32

Cloning of TPKS cDNA into a yeast expression vector

Recombinant TPKS is produced in the yeast S. cerevisiae following the insertion of the optimal TPKS cDNA cistron into expression vectors designed to direct the intracellular or extracellular expression of heterologous proteins. In the case of intracellular expression, vectors such as EmBLyex4 or the like are ligated to the TPKS cistron [Rinas, U. et al., Biotechnology, 8, 543-545 (1990); Horowitz B. et al., J. Biol. Chem., 265, 4189-4192 (1989)]. For extracellular expression, the TPKS cistron is ligated into yeast expression vectors which fuse a secretion signal (a yeast or mammalian peptide) to the NH₂ terminus of the TPKS protein [Jacobson, M. A.,

- 44 -

Gene, 85, 511-516 (1989); Riet L. and Bellon N., Biochem., 28, 2941-2949 (1989)].

EXAMPLE 33

5

Use of TPKS for in vitro production of HMG-CoA inhibitors

Recombinant proteins, including complex proteins, can be overexpressed in a heterologous cells (e.g., Roberts *et al.*, 1993, "Heterologous expression in E. coli of an intact multienzyme component of the erythromycin-producing polyketide synthase". Eur J. Biochem, 214, 305-311). If the recombinant protein is produced in an inclusion body, renaturation of the desired protein is carried out prior to enzymatic assay (Roberts, 1993).

15

A suitable host cell is transformed with a vector encoding the TPKS gene. The transformed host cell is grown under conditions that permit the expression of TPKS. The expressed TPKS is isolated and partially purified. The recovered active TPKS enzyme can be added to a reaction mixture containing acetyl-CoA or other charged acyl compounds, appropriate cofactors, and buffer. Incubation of the system can result in the formation of HMG-CoA reductase inhibitors.

20

EXAMPLE 34

Cloning of other PKS genes using TPKS gene

25

The cross hybridization of the DNA representing portions of the TPKS gene to genomic DNA isolated from other organisms such as M. ruber or P. citrinum, makes it possible to clone the homologous genes from the parent organisms. To do this, a genomic library of M. ruber or P. citrinum was constructed from genomic DNA according to conventional methods. Using, for example, an EMBL vector, an EMBL genomic library was prepared, plated and screened by hybridization with a ³²P-labeled DNA probe consisting of the PstI fragment from the TPKS gene. The PstI fragment contains the keto synthase sequence of the gene. Positive plaques were selected and subjected to additional

30

- 45 -

screening until a purified cross-reacting plaque was selected. The DNA contained in the positive clone is further characterized by physical methods such as restriction mapping, Southern hybridization and DNA sequencing. The function of the defined gene is characterized by cloning the gene in an appropriate transformation vector and transforming a lovastatin non-producing strain with the vector. In the case of M. ruber, the cross-reacting PKS would be expected to restore production of Monacolin K (lovastatin) while introduction of a functional P. citrinum PKS would result in production of compactin.

10

EXAMPLE 35

Homology of *A. terreus* TPKS to other strains

15

A large segment of the 5' end of the A. terreus TPKS gene containing the keto synthase region was used to look for cross-hybridization of this region to other strains, including M. ruber, P. citrinum and P. brevicompactum. The homology was examined by Southern analyses with two probes. The Southern showed cross-reaction to all three strains.

20

The first probe was the PstI fragment, an 800 bps probe which spans the KAS active site. This probe contains intron I 5' of the active site cysteine in addition to the entire KAS region. This probe was used to detect homology in all three strains. A. terreus displayed the profile of cross-reacting bands expected from the restriction map. M. ruber, another lovastatin-producing organism, and P. citrinum, a compactin-producing organism, showed different but strong hybridizations to the probe.

25

The second probe was a synthetic oligonucleotide probe having the following sequence:
5'GATACGGCATGCAGCTCGTGTGGTTGCCGTTCATCTGGCT
GCA3' (SEQ ID NO:3). Although the hybridization signal to this probe was weaker than the hybridization to the first probe, the results confirm the observations made with the PstI fragment.

- 46 -

When a 3' end cDNA probe was used, cross reaction to all three strains was observed. Single cross-reacting bands in many of the digests indicate that only one gene is being detected in the genomic DNA of each strain. These data suggest that M. ruber and P. citrinum contain a gene with substantial homology to the TPKS gene of A. terreus.

EXAMPLE 36

Use of mutagenized TPKS

The DNA encoding TPKS is mutagenized using standard methods to produce an altered TPKS gene. Host cells are transformed with the altered TPKS to produce altered triol polyketides or altered polyketides with therapeutic use. The altered TPKS protein may be isolated and purified

15

20

25

30

- 47 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: VINCI, VICTOR A.
CONDER, MICHAEL J.
MCADA, PHYLLIS C.
REEVES, CHRISTOPHER D.
DAVIS, CHARLES R.
HENDRICKSON, LEE E.
RAMBOSEK, JOHN

(ii) TITLE OF INVENTION: DNA ENCODING TRIOL POLYKETIDE SYNTHASE

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: CHRISTINE E. CARTY
(B) STREET: P.O. BOX 2000; 126 E. LINCOLN AVENUE
(C) CITY: RAHWAY
(D) STATE: NJ
(E) COUNTRY: USA
(F) ZIP: 07065

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US
(B) FILING DATE: 01-NOV-1993
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: CARTY, CHRISTINE E.
(B) REGISTRATION NUMBER: 36,099
(C) REFERENCE/DOCKET NUMBER: 19076

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 908-594-6734
(B) TELEFAX: 908-594-4720

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11561 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 48 -

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: TPKS cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTGCAGTCAA CGGATCACTT ACCATTGCTG TCGCCAAAAA TATCCGTGAT AATCCCGCTG	60
GCTTCATTGG CAAGAGGCTT GACGTACTTG GGAGCTTGGG TCTGGAAC TG GTTCATAACC	120
ACCTTGGTGA TGAGATGTGC ATCCCTCGTG ACTTCCTTGA ATCCATCGAA TCCGGGAAGA	180
TGAGAGTGAA AGTCCTGATG AGAGCACGAA GATCAGTAAG TCAGGTCCCTC ACAGCGGAAG	240
CAGTTGAAA GAACGGTGG A CTCCTTACCG TGCCCAAGAA CTTGTACATA CAGAGCTCTT	300
TCATCTTGGG AAACTCATCG GCCATAGAGG AGGGAAAGAT GGTGCAGTAC CCAGAGTCGA	360
CTATGAACCG AATGGGCTTA TCATTTGCG AGAACCAAGCT CTCATCCAT GACGGTGCAT	420
TCGCATCAA ATCCCCTTG GCCCTCATGG TCGTCAGTTC CCACCATGTT TTCCGGATTGA	480
ACACCGGCAG ATCAGATCTC CGGCCACTCG AGCACAGGT AAGAAGAAGG CATAGTAGCC	540
CCGCACTGGT AGTGACCAAG GGCGCAAACC ACGAGCCATG TTGCTGCGTG TCATTCCAAG	600
CCAGCGACAG AAGGTGGTGC GGCTGTGTGA GCGCGTCGAC AGTCATGGCT AGGAGACCAG	660
GTGTGGTTGA GGGATAAGAT ATCGAGAGTG ATGTGAGCAA AAGATCCGGG AAAGGTGCG	720
AAGGAAAGGG CGTCTCTCTT ACCAAGAAAG TCTGTTCCCT ATCATGCAAT CACCGTTGC	780
TGTACGGTGG TGATGATGCT GGGATGGTGG TGGGTCCCCA CCGAATAACG CCGGACAGCT	840
GTGAAGCCG AATGACGCCG GCAGGCCAA AGAACCCCTAC CTTCACTTAC TCAATCGCG	900
CTTCCCCCTCC TATCACCAAA TCGGATGTAA ATGGACGGGC CTTAATAGCG ACCGGCCGGG	960
CCGGGAATCC CCAAACGTAG ATAGATAGGC ATAGACCCGA AATCTTGGC CCGGCATACA	1020
TGAGCACAGG AAGTTACAG CGACGGCGCC TTTCTGCCT CAGCTTCAAT CCAAGCTCAC	1080
GAGTTCTGTC GCCTCTATCA GTCGTGCAAT TGTCTACTG CAAACAGCAT GGCTCAATCT	1140
ATGTATCCTA ATGAGCCTAT TGTCGTGGTC GGCAGTGGTT GTCGCTTCCC TGGTGACGCC	1200
AACACACCCCT CCAAGCTCTG GGAGCTACTC CAGCATCCTC GCGATGTGCA GAGTCGAATC	1260
CCCAAAGAAC GATTGACGT CGACACATTT TATCACCCGG ACGGGAAGCA CCACGGCGA	1320
ACAAATGCAC CCTACGCCA TGTTCTCCAA GACGATCTGG GCGCCTTCGA TGCGGCCTTC	1380
TTCAATATCC AGGCTGGAGA GGCGAGAGT ATGGACCCCC AGCACCGGCT GTTGCTGGAG	1440

- 49 -

ACGGTGTACG	AGGCCGTAAC	GAATGCTGGA	ATGCGTATCC	AGGATCTGCA	GGGAACCTTCG	1500
ACTGCTGTTT	ACGTCGGGGT	GATGACGCAC	GACTATGAGA	CTGTCTCAAC	CCGCGACCTG	1560
GAGAGCATCC	CCACCTACTC	GGCGACGGGT	GTCGCGGTCA	GTGTTGCGTC	CAACCGCATC	1620
TCGTATTTTT	TTGACTGGCA	TGGACCAAGT	GTAAGTCACC	CAATATCGTG	TAGCAGTCTA	1680
ATCATGCTCT	AACGGACCGG	GATGGTTGAA	AGATGACGAT	CGATAACGGCA	TGCAGCTCGT	1740
CGTTGGTTGC	CGTTCATCTG	GCGGTGCAAC	AGCTACGGAC	GGGTCAAAGC	TCCATGGCAA	1800
TTGCTGCGGG	TGCGAATCTG	ATTCTGGGGC	CCATGACATT	CGTCCTTGAA	AGCAAATTGA	1860
GCATGCTATC	CCCCTCGGGT	CGATCCCGCA	TGTGGGACGC	CGGAGCTGAC	GGCTATGCCA	1920
GAGCGTGTAG	TGTTCTTGAA	GCTCGTAGAT	GACAGTTCCC	ATCGCTGACC	GTGATCAGGA	1980
AGCTGTTGTC	TCTGTAGTGT	TGAAGACATT	GAGTCAGGCC	TTGCGCGATG	GGGACACGAT	2040
TGAATGTGTC	ATCCGAGAAA	CTGGGGTGAA	TCAAGATGGC	CGAACGACCG	GAATTACGAT	2100
GCCGAACCAT	AGTGCTCAGG	AGGCACTCAT	CAAGGCTACC	TACGCCAGG	CTGGCCTTGA	2160
CATCACCAAG	GCCGAGGACA	GGTGCCAATT	CTTCGAGGCT	CATGGTCAGC	AAAGAGAAC	2220
TGTTCTGTTG	GCCCCCTGCA	GCTGACATT	GTATGATAGG	GAETGGTACT	CCGGCCGGAG	2280
ATCCCCAGGA	GGCGGAGGCC	ATTGCAACAG	CCTTCTTCGG	CCACGAGCAG	GTAGCACGCA	2340
GCGACGGAAA	CGAGAGGGCC	CCTCTGTTCG	TGGGCAGTGC	AAAAACTGTT	GTCGGGCACA	2400
CCGAGGGCAC	GGCCGGTCTG	GCTGGTCTCA	TGAAGGCGTC	GTTCGCTGTC	CGCCATGGGG	2460
TAATCCCCCC	CAACCTGCTG	TTCGACAAAA	TCAGCCCGCG	AGTCGCCCCA	TTCTATAAAA	2520
ACCTGAGGAT	TCCGACAGAA	GCTACCCAT	GGCCAGCTCT	CCCACCCGGA	CAACCGCGCC	2580
GCGCCAGTGT	CAACTCCTTT	GGTAAGCGAG	GATTGCCCGG	AGGAACCCCTC	ACAAGTACTC	2640
GAATTAATGC	TAACTGAACC	GCGCCGATGG	ACAGGATTG	GCGGCACGAA	TGCGCATGCC	2700
ATTATTGAGG	AATACATGGA	GCCAGAGCAA	AACCAGCTGC	GAGTCTCGAA	TAATGAGGAC	2760
TGCCCAACCA	TGACCGGTGT	CCTGAGTTTA	CCCTTAGTCC	TCTCGGCAGA	GTCCCAGCGC	2820
TCCTTAAAGA	TAATGATGGA	GGAGATGCTG	CAATTCTTC	AGTCTCACCC	CGAGATAACAC	2880
TTGCACGACC	TCACCTGGTC	CTTACTGCGC	AAGCGGTCA	TTCTACCCCTT	CCGCCGGGCT	2940
ATTGTCGGCC	ATAGTCATGA	AACCATCCGC	CGGGCTTGG	AGGATGCCAT	CGAGGATGGT	3000
ATTGTGTCGA	GCGACTTCAC	TACGGAGGTC	AGAGGCCAGC	CATCGGTGTT	GGGAATCTTC	3060
ACCGGGCAGG	GGGCGCAGTG	GCCGGGGATG	TTAAAGAAC	TGATAGAGGC	ATCGCCATAT	3120

- 50 -

GTGCGGAACA TAGTGAGGGA GCTGGACGAC TCCCTGCAGA GCTTGCCGGA AAAATACCGG	3180
CCCTCGTGGAA CGCTACTGGAA CCAGTTCATG CTAGAAGGAG AGGCCTCCAA CGTCCAATAT	3240
GCTACTTTCT CCCAGCCATT ATGCTGCCGCG GTGCAAATTG TCCTGGTCCG TCTCCTTGAA	3300
GCCGCGAGAA TACGATTCAC GGCTGTTGTT GGACATAGCT CCGGCGAAAT TGCTTGCGCC	3360
TTTGCTGCCG GGCTCATCAG TGCCTCGTTG GCGATTCGGA TTGCTTACTT ACGTGGAGTC	3420
GTCTCGGCAG GGGGCGCCAG AGGCACACCG GGAGCCATGT TGGCCGCCGG GATGTCCCTT	3480
GAGGAAGCAC AAGAGATCTG CGAGTTGGAT GCCTTGAGG GCCGCATCTG CGTGGCTGCC	3540
AGCAATTCCC CAGACAGTGT AACTTTCTCT GGCGACGCGA ACGCAATTGA TCACCTGAAG	3600
GGCATGTTGG AGGATGAGTC CACTTTGCG AGACTGCTCA AGGTCGATAAC AGCGTACCAAC	3660
TCGCATCATA TGCTTCCATG TGCAGACCCA TATATGCAAG CCCTAGAACAGA GTGTGGTTGT	3720
GCTGTTGCCG ATGCAGGTTG CCCAGCCGGA AGTGTACCCCT GGTATTGTC CGTGGACGCC	3780
GAGAACAGGC AAATGGCAGC AAGAGACGTG ACCGCCAAGT ACTGGAAAGA TAACCTAGTA	3840
TCTCCGGTGC TATTCTCCCA CGCAGTGCAG CGGGCAGTCG TCACGCACAA GGCGCTGGAT	3900
ATCGGGATTG AAGTGGGCTG TCACCCAGCT CTCAAGAGCC CATGCGTCGC CACCATCAAG	3960
GATGTCCTAT CTGGGGTTGA CCTGGCGTAT ACAGGTTGCT TGGAGCGAGG AAAGAATGAT	4020
CTCGATTCAT TCTCTCGAGC ACTGGCATAT CTCTGGAAA GGTTGGTGC CTCCAGTTTC	4080
GATGCGGACG AGTTCATGCG TGCAGTCGCG CCTGATCGGC CCTGTATGAG TGTGTCGAAG	4140
CTCCTACCGG CCTATCCATG GGACCGCTCT CGTCGCTACT GGGTGGAAATC CCGAGCAACT	4200
CGCCACCATC TTCGAGGGCC CAAGCCCCAT CTTCTATTAG GAAAGCTCTC CGAATACAGC	4260
ACTCCGCTAA GCTTCCAGTG GCTGAATTG GTGGCCAC GAGACATTGA ATGGCTTGAT	4320
GGACATGCAT TGCAAGGCCA GACTGTCCTTC CCTGCGGCCG GCTATATCGT CATGGCAATG	4380
GAAGCAGCCT TAATGATTGC TGGCACCCAC GCAAAGCAGG TCAAGTTACT GGAGATCTTG	4440
GATATGAGCA TTGACAAGGC GGTGATATTG GACGACGAAG ACAGCTTGGT TGAGCTAAC	4500
CTGACAGCTG ACGTGTCTCG CAACGCCGGC GAAGCAGGTT CAATGACCAT AAGCTTCAAG	4560
ATCGATTCCCT GTCTATCGAA GGAGGGTAAC CTATCCCTAT CAGCCAAGGG CCAACTGGCC	4620
CTAACGATAG AAGATGTCAA TCCCAGGACG ACTTCCGCTA GCGACCAGCA CCATCTTCCC	4680
CCGCCAGAAG AGGAACATCC TCATATGAAC CGTGTCAACA TCAATGCTTT CTACCACGAG	4740
CTGGGGTTGA TGGGGTACAA CTACAGTAAG GACTTCCGGC GTCTCCATAA CATGCAACGA	4800

- 51 -

GCAGATCTTC GAGCCAGCGG CACCTTAGAC TTCATTCTC TGATGGACGA GGGTAATGGC	4860
TGTCCCTCTCC TGCTGCATCC TGCATCATTG GACGTCGCCT TCCAGACTGT CATCGGCGCA	4920
TACTCCTCCC CAGGTGATCG GCGTCTACGC TGTCTGTATG TACCCACTCA CGTTGATCGC	4980
ATCACACTTG TCCCACCCCT TTGCTGGCA ACGGCTGAGT CCGGATGCGA GAAGGTTGCC	5040
TTCAATACTA TCAATACGTA CGACAAGGGA GACTACTTGA GCGGTGACAT TGTGGTGT	5100
GACGCGGAGC AGACCACCCCT GTTCCAGGTT GAAAATATTA CTTTTAACCC CTTTCACCC	5160
CCGGATGCTT CAACTGACCA TGCGATGTTT GCCCGATGGA GCTGGGTCC GTTGACTCCG	5220
GACTCGCTGC TGGATAACCC GGAGTATTGG GCCACCGCGC AGGACAAGGA GCGGATTCC	5280
ATTATCGAAC GCATCGTCTA CTTCTATATC CGATCGTCC TCAGTCAGCT TACGCTGGAG	5340
GAGCGCCAGC AGGCAGCCTT CCATTTGCAG AAGCAGATCG AGTGGCTCGA ACAAGTCCTG	5400
GCCAGCGCCA AGGAGGGTCG TCACCTATGG TACGACCCCCG GGTGGGAGAA TGATACTGAG	5460
GCCCAGATTG AGCACCTTTG TACTGCTAAC TCCTACCACC CTCATGTTCG CCTGGTTCA	5520
CGAGTCGGCC AACACCTGCT CCCCACCGTA CGATCGAACG GCAACCCATT CGACCTTCTG	5580
GACCACGATG GGCTCCTGAC GGAGTTCTAT ACCAACACAC TCAGCTTCGG ACCCGCACTA	5640
CACTACGCC GGGATTGGT GCGCAGATC GCCCATCGCT ATCAGTCAT GGATATTCTG	5700
GAGATTGGAG CAGGGACCCG CGGGCTTAC AAGTACGTGT TGGCCACGCC CCAGCTGGGG	5760
TTCAACAGCT ACACATACAC CGATATCTCC ACCGGATTCT TCGAGCAAGC GCGGGAGCAA	5820
TTTGCCTTCT TCGAGGACCG GATGGTGT GAAACCCCTCG ATATCCCGC CAGTCCCGCC	5880
GAGCAGGGCT TCGAGCCGCA TGCCTATGAT CTGATCATTG CCTCCAATGT GCTACATGCG	5940
ACACCCGACC TAGAGAAAAC CATGGCTCAC GCCCGCTCTC TGCTCAAGCC TGGAGGCCAG	6000
ATGGTTATTC TGGAGATTAC CCACAAAGAA CACACACGGC TCGGGTTTAT CTTGGTCTG	6060
TTCGCCGACT GGTGGGCTGG GGTGGATGAT GGTGGCTGCA CTGAGCCGTT TGTCTCGTTC	6120
GACCGCTGGG ATGCGATCCT AAAGCGTGTG CGGTTTCCG GTGTGGACAG TCGCACCACG	6180
GATCGGGACG CAAATCTATT CCCGACCTCT GTGTTTAGTA CCCATGCAAT TGACGCCACC	6240
GTGGAGTACT TAGACGCGCC GCTTGCAGC AGCGGCACCG TCAAGGACTC TTACCCCTCCC	6300
TTGGTGGTGG TAGGAGGGCA GACCCCCCAA TCTCAGCGTC TCCCTGAACGA TATAAAAGCG	6360
ATCATGCCTC CTCGTCCGCT CCAGACATAC AAGCGCCTCG TGGATTTGCT AGACGCGGAG	6420
GAGCTGCCGA TGAAGTCCAC GTTGTCAATG CTCACGGAGC TGGACGAGGA ATTATCGCC	6480

- 52 -

GGGCTCACTG AAGAGACCTT CGAGGCACC AAGCTGCTGC TCACGTACGC CAGCAATACG	6540
GTCTGGCTGA CAGAAAATGC CTGGGTCCAA CATCCTCACCC AGGCGAGCAC GATCGGCATG	6600
CTACGCTCCA TCCGCCGGGA GCATCCTGAC TTGGGAGTTC ATGTTCTGGA CGTCGACGCG	6660
GTTGAAACCT TCGATGCAAC CTTCCCTGGTT GAACAGGTGC TTGGCTTGA GGAGCATAACG	6720
GATGAGCTGG CCAGTTCAAC TACATGGACT CAAGAACCCG AGGTCTCCTG GTGTAAAGGC	6780
CGCCCCGTGGA TTCCCTCGTCT GAAGCGCGAT CTGGCTCGCA ATAACCGAAT GAACTCCTCG	6840
CGCCCGTCCC TATACGAGAT GATCGATTG TCGCGGGCTC CCGTGGCATT ACAGACGGCT	6900
CGGGATTCACT CATCCTACTT CTTGGAGTCC GCTGAAACCT GGTTTGTGCC TGAGAGTGTT	6960
CAGCAGATGG AAACAAAGAC GATCTATGTC CACTTAGCT GTCCCCATGC GCTTAGGGTC	7020
GGACAGCTCG GGTTTTCTA TCTTGTGCAG GGTACGTCC AGGAGGGCAA TCGCCAAGTG	7080
CCCGTCGTGG CCTTAGCAGA GCGTAACGCA TCCATTGTGC ACGTTCTGCC CGATTATATA	7140
TATACTGAGG CAGATAACAA TCTGTCTGAG GGTGGTGGCA GCCTTATGGT AACCGTCCTC	7200
GCCGCCGGCGG TGTTGGCGGA GACGGTGATC AGTACCGCCA AGTGCCTGGG GGTAACTGAC	7260
TCAATCCTCG TTCTGAATCC CCCCAGCATA TGTGGCAGA TGTTGCTCCA TGCTGGTGAA	7320
GAGATCGGTC TTCAAGTTCA TCTGCCACC ACTTCTGGCA ACAGGAGTTC GGTTTCTGCT	7380
GGAGACGCCA AGTCCTGGCT AACATTGCAT GCTCGCGACA CGGACTGGCA CCTGCGACGG	7440
GTACTGCCCC GGGGTGTCCA GGCTTTAGTC GACTTATCAG CCGACCAGAG CTGTGAAGGT	7500
TTGACTCAGA GGATGATGAA AGTTCTGATG CCTGGCTGTG CCCATTACCG TGCAGGCAGAC	7560
CTGTTCACAG ACACCGTTTC CACTGAATTG CATAGCGGAT CGCGGCATCA AGCTTCACTG	7620
CCCGCCGCAT ATTGGGAGCA TGTGGTATCC TTAGCCGCC AGGGACTTCC TAGTGTCAAGC	7680
GAGGGGTGGG AGGTGATGCC GTGCACTCAA TTTGCAGCGC ATGCCGACAA GACGGGCCCG	7740
GATCTCTCGA CAGTTATTC CTGGCCCCGG GAGTCGGACG AGGCTACGCT TCCTACCAGG	7800
GTTCGCTCCA TTGACGCTGA GACCCCTTTT GCGGCCGACA AAACATATCT CCTGGTCGGA	7860
CTGACTGGAG ATCTTGGACG ATCACTAGGT CGTTGGATGG TCCAGCATGG GGCTGCCAC	7920
ATTGTACTTA CGAGCAGAAA TCCGCAGGTG AACCCCAAGT GGCTGGCGCA TGTTGAAGAA	7980
CTGGGTGGTC GAGTCACTGT TCTTCCATG TAAGAGGAGT CCTTCCTCT GCAATTCTC	8040
CTTATGATCC CGACTAACGC AGCTGGCTTC AGGGACGTGA CAAGCCAAA CTCAGTGGAA	8100
GCTGGCCTGG CTAAACTCAA GGATCTGCAT CTGCCACCAAG TGGGGGGTAT TGCCTTGGC	8160

- 53 -

CCTCTGGTTC	TGCAGGATGT	GATGCTAAAT	AATATGGAAC	TGCCAATGAT	GGAGATGGTG	8220
CTCAACCCCA	AGGTCGAAGG	CGTCCGCATC	CTGCACGAGA	AGTTCTCCGA	TCCGACCAGT	8280
AGCAACCCCTC	TCGACTTCTT	CGTGATGTTTC	TCCTCGATTG	TGGCCGTCAT	GGGCAACCCG	8340
GGTCAGGCTA	ACTACAGTGC	GGCTAACTGC	TACCTTCAAG	CGCTGGCGCA	GCAGCGAGTT	8400
GCATCCGGAT	TAGCAGTACG	TTTTCACTCC	ATCCTTGCT	AAACACTCCT	ATGGGCCTTT	8460
ACTAAACCGG	GCAGGGCGTCC	ACCATCGACA	TCGGTGCCGT	GTACGGCGTT	GGGTTCGTCA	8520
CTCGGGCGGA	GCTGGAGGAG	GACTTTAATG	CAATTGGT	CATGTTGAT	TCGGTTGAGG	8580
AACATGAACT	GCATACACTG	TTTGCTGAGG	CAGTGGTGGC	CGGTCGACGA	GCCGTGCACC	8640
AGCAAGAGCA	GCAGCGGAAG	TTCGCGACAG	TGCTCGACAT	GGCTGATCTG	GAACTGACAA	8700
CCGGAATTCC	GCCCCCTGGAT	CCAGCCCTCA	AAGATCGGAT	CACCTTCTTC	GACGACCCCG	8760
GCATAGGCAA	CTTAAAAAATT	CCGGAGTACC	GAGGGGCCAA	AGCAGGCGAA	GGGGCAGCCG	8820
GCTCCAAGGG	CTCGGTCAAA	GAACAGCTCT	TGCAGGCGAC	GAACCTGGAC	CAGGTCCGTC	8880
AGATCGTCAT	CGGTAAGTTG	AGCGAATCCG	GGGAATATTG	TCCCCTTCCT	CACTCAGCGG	8940
ACTGGAGATT	AACCGCTTCT	TTTCCTTTGG	CAGATGGACT	CTCCGCGAAG	CTGCAGGTGA	9000
CCCTGCAGAT	CCCCGATGGG	GAAAGCGTGC	ATCCCACCAT	CCCACTAATC	GATCAGGGGG	9060
TGGACTCTCT	GGGCGCGGTC	ACCGTGGAA	CCTGGTTCTC	CAAGCAGCTG	TACCTTGATT	9120
TGCCACTCCT	GAAAGTGCTT	GGGGGTGCTT	CGATCACCGA	TCTCGCTAAT	GAGGCTGCTG	9180
CCCGATTGCC	ACCTAGCTCC	ATTCCCCTCG	TCGCAGCCAC	CGACGGGGGT	GCAGAGAGCA	9240
CTGACAATAC	TTCCGAGAAT	GAAGTTTCGG	GACGCGAGGA	TACTGACCTT	AGTGCCGCCG	9300
CCACCATCAC	TGAGCCCTCG	TCTGCCGACG	AAGACGATAAC	GGAGCCGGGC	GACGAGGACG	9360
TCCCGCGTTC	CCACCATCCA	CTGTCTCTCG	GGCAAGAATA	CTCCTGGAGA	ATCCAGCAGG	9420
GAGCCGAAGA	CCCCACCGTC	TTTAACAACA	CCATTGGTAT	GTTCATGAAG	GGCTCTATTG	9480
ACCTTAAACG	GCTGTACAAG	GCGTTGAGAG	CGGTCTTGCG	CCGCCACGAG	ATCTTCCGCA	9540
CGGGGTTTGC	CAACGTGGAT	GAGAACGGGA	TGGCCCAGCT	GGTGTGGT	CAAACCAAAA	9600
ACAAAGTCCA	GACCATCCAA	GTGTCTGACC	GAGCCGGCGC	CGAAGAGGGC	TACCGACAAAC	9660
TGGTGCAGAC	ACGGTATAAC	CCTGCCGCAG	GAGACACCTT	GCGGCTGGTG	GACTTCTTCT	9720
GGGGCCAGGA	CGACCATCTG	CTGGTTGTGG	CTTACCAACCG	ACTCGTCGGG	GATGGATCTA	9780
CTACAGAGAA	CATCTTCGTC	GAAGCGGGCC	AGCTCTACGA	CGGCACGGTCG	CTAAGTCCAC	9840

- 54 -

ATGTCCCTCA	GTTTGCAGAC	CTGGCGGAC	GGCAACGCGC	AATGCTCGAG	GATGGGAGAA	9900
TGGAGGAGGA	TCTCGCGTAC	TGGAAGAAAA	TGCATTACCG	ACCGTCCTCA	ATTCCAGTGC	9960
TCCCACGTAT	CGGGCCCCTG	GTAGGTAACA	GTAGCAGGTC	CGATACTCCA	AATTTCCAGC	10020
ACTGTGGACC	CTGGCAGCAG	CACGAAGCCG	TGGCGCGACT	TGATCCGATG	GTGGCCTTCC	10080
GCATCAAGGA	GCGCAGTCGC	AAGCACAAAGG	CGACGCCGAT	GCAGTTCTAT	CTGGCGGCGT	10140
ATCAGGTGCT	GTTGGCGCGC	CTCACCGACA	GCACCGATCT	CACCGTGGGC	CTCGCCGACA	10200
CCAACCGTGC	GACTGTGAC	GAGATGGCGG	CCATGGGGTT	CTTCGCCAAC	CTCCTTCCCC	10260
TGCGCTTCCG	GGATTTCCGC	CCCCATATAA	CGTTTGGCGA	GCACCTTATC	GCCACCCGTG	10320
ACCTGGTGC	TGAGGCCTTG	CAGCACGCC	CGGTGCCCTA	CGGCGTCCTC	CTCGATCAAC	10380
TGGGGCTGGA	GGTCCCGGTC	CCGACCAGCA	ATCAACCTGC	GCCTTTGTT	CAGGCCGTCT	10440
TCGATTACAA	GCAGGGCCAG	GCGGAAAGTG	GAACGATTGG	GGGTGCCAAC	ATAACCGAGG	10500
TGATTGCCAC	GCGCGAGCGC	ACCCCTTACG	ATGTCGTGCT	GGAGATGTCG	GATGATCCCA	10560
CCAAGGATCC	GCTGCTCACG	GCCAAGTTAC	AGAGTTCCCG	CTACGAGGCT	CACCACCCCTC	10620
AAGCCTTCCTT	GGAGAGCTAC	ATGTCCTTC	TCTCTATGTT	CTCGATGAAT	CCGGCCCTGA	10680
AGCTGGCATG	ATGGCGAAA	CATAGAACAT	GATAGCCAG	CAGGGACGAT	GTAGATAGAG	10740
CTTTGCTTCT	GCGGGTGGAT	CTATAATATA	GTATATATAA	ATATGGTGAG	CCGAACGAAG	10800
AGGGGGGAAT	GCCACAATTA	TTTACTGTTT	TGCGCCGTAC	ACGAGGAGAA	GACGTCCAGA	10860
ACAACATAAA	TATATCACTC	TAGTGAGACA	CCATATATTC	GGAGAGACTA	AAAAAATATA	10920
CATCTACTCC	AATGTCCTGGG	CCGTCACACA	CAGCTTACGA	AAACGATTAA	TGACCTCCAA	10980
CACGTCGCGC	GGTCGATTGG	GAAACTGATG	CTGCCCAGCA	AACTCCAATA	CCTGCGCCTC	11040
TCGGGGGGAG	AAATGGCGCG	CCACCAGCAT	CTTCGATCCT	GCGAGCGCAA	AATCATCGCG	11100
ACCCCTGCAGA	TGTAATGTCG	GTATCCGAAT	GACCAGTTCC	TCCTGCCACT	CGGTATCTTT	11160
GCTGTCGTG	TCGTCGTCA	GGTTCTTCAT	CATTGTTCC	TCATATACTG	GCTTGCCCTCG	11220
TCTTGATACC	AGGGACAGAT	CAACAGCGCA	ACACTCATCC	GGGGCAACCA	GGGCAGGTGA	11280
CCCATCTGCT	GCTGCCAGAG	GAGCAAGGTC	GTCACCAGGG	CACCTTCGGA	GAAACCGATA	11340
GCACCCACGA	TAGGGATGTG	GGGGTGTGGA	GTCTGCCAGT	CGACAATGGT	GCGGCGGATG	11400
GGGTGCGTGA	CGGGGGCGAG	GCGTTGCCCT	ACGGAGGGTC	CATTATGATT	GTTGTCGCTG	11460
CTGCTTCAA	ACCAGGAGTA	ATATGGCCCT	AGGTCGGCGA	AGACGGGGAG	AATCCCAGGC	11520

- 55 -

CCTGCAGAGG AAGGGAACGG AGCTGTCACG TAGACGAATT C

11561

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 3038 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: TPKS Protein

(xi) SEQUENCE DESCRIPTION: SEQ. ID NO:2:

Met Ala Gln Ser Met Tyr Pro Asn Glu Pro Ile Val Val Val Gly Ser
1 5 10 . . . 15

Leu Leu Gln His Pro Arg Asp Val Gln Ser Arg Ile Pro Lys Glu Arg
35 40 45

Phe Asp Val Asp Thr Phe Tyr His Pro Asp Gly Lys His His Gly Arg
50 55 60

Thr Asn Ala Pro Tyr Ala Tyr Val Leu Gln Asp Asp Leu Gly Ala Phe
65 70 75 80

Asp Ala Ala Phe Phe Asn Ile Gln Ala Gly Glu Ala Glu Ser Met Asp
85 90 95

Pro Gln His Arg Leu Leu Leu Glu Thr Val Tyr Glu Ala Val Thr Asn
100 105 110

Ala Gly Met Arg Ile Gln Asp Leu Gln Gly Thr Ser Thr Ala Val Tyr
115 120 125

Val Gly Val Met Thr His Asp Tyr Glu Thr Val Ser Thr Arg Asp Leu
 130 135 140

Glu Ser Ile Pro Thr Tyr Ser Ala Thr Gly Val Ala Val Ser Val Ala
145 150 155 160

Ser Asn Arg Ile Ser Tyr Phe Phe Asp Trp His Gly Pro Ser Met Thr
165 170 175

Ile Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Val His Leu Ala Val
180 185 190

- 56 -

Gln	Gln	Leu	Arg	Thr	Gly	Gln	Ser	Ser	Met	Ala	Ile	Ala	Ala	Gly	Ala
195						200						205			
Asn	Leu	Ile	Leu	Gly	Pro	Met	Thr	Phe	Val	Leu	Glu	Ser	Lys	Leu	Ser
210						215					220				
Met	Leu	Ser	Pro	Ser	Gly	Arg	Ser	Arg	Met	Trp	Asp	Ala	Gly	Ala	Asp
225						230					235			240	
Gly	Tyr	Ala	Arg	Gly	Glu	Ala	Val	Cys	Ser	Val	Val	Leu	Lys	Thr	Leu
						245			250			255			
Ser	Gln	Ala	Leu	Arg	Asp	Gly	Asp	Thr	Ile	Glu	Cys	Val	Ile	Arg	Glu
						260			265			270			
Thr	Gly	Val	Asn	Gln	Asp	Gly	Arg	Thr	Thr	Gly	Ile	Thr	Met	Pro	Asn
						275			280			285			
His	Ser	Ala	Gln	Glu	Ala	Leu	Ile	Lys	Ala	Thr	Tyr	Ala	Gln	Ala	Gly
						290			295			300			
Leu	Asp	Ile	Thr	Lys	Ala	Glu	Asp	Arg	Cys	Gln	Phe	Phe	Glu	Ala	His
						305			310		315			320	
Gly	Thr	Gly	Thr	Pro	Ala	Gly	Asp	Pro	Gln	Glu	Ala	Glu	Ala	Ile	Ala
						325			330			335			
Thr	Ala	Phe	Phe	Gly	His	Glu	Gln	Val	Ala	Arg	Ser	Asp	Gly	Asn	Glu
						340			345			350			
Arg	Ala	Pro	Leu	Phe	Val	Gly	Ser	Ala	Lys	Thr	Val	Val	Gly	His	Thr
						355			360			365			
Glu	Gly	Thr	Ala	Gly	Leu	Ala	Gly	Leu	Met	Lys	Ala	Ser	Phe	Ala	Val
						370			375			380			
Arg	His	Gly	Val	Ile	Pro	Pro	Asn	Leu	Leu	Phe	Asp	Lys	Ile	Ser	Pro
						385			390		395			400	
Arg	Val	Ala	Pro	Phe	Tyr	Lys	Asn	Leu	Arg	Ile	Pro	Thr	Glu	Ala	Thr
						405			410			415			
Gln	Trp	Pro	Ala	Leu	Pro	Pro	Gly	Gln	Pro	Arg	Arg	Ala	Ser	Val	Asn
						420			425			430			
Ser	Phe	Gly	Phe	Gly	Gly	Thr	Asn	Ala	His	Ile	Ile	Glu	Glu	Tyr	
						435			440			445			
Met	Glu	Pro	Glu	Gln	Asn	Gln	Leu	Arg	Val	Ser	Asn	Asn	Glu	Asp	Cys
						450			455			460			
Pro	Pro	Met	Thr	Gly	Val	Leu	Ser	Leu	Pro	Leu	Val	Leu	Ser	Ala	Lys
						465			470		475			480	
Ser	Gln	Arg	Ser	Leu	Lys	Ile	Met	Met	Glu	Glu	Met	Leu	Gln	Phe	Leu
						485			490			495			

- 57 -

Gln Ser His Pro Glu Ile His Leu His Asp Leu Thr Trp Ser Leu Leu
500 505 510

Arg Lys Arg Ser Val Leu Pro Phe Arg Arg Ala Ile Val Gly His Ser
515 520 525

His Glu Thr Ile Arg Arg Ala Leu Glu Asp Ala Ile Glu Asp Gly Ile
530 535 540

Val Ser Ser Asp Phe Thr Thr Glu Val Arg Gly Gln Pro Ser Val Leu
545 550 555 560

Gly Ile Phe Thr Gly Gln Gly Ala Gln Trp Pro Gly Met Leu Lys Asn
565 570 575

Leu Ile Glu Ala Ser Pro Tyr Val Arg Asn Ile Val Arg Glu Leu Asp
580 585 590

Asp Ser Leu Gln Ser Leu Pro Glu Lys Tyr Arg Pro Ser Trp Thr Leu
595 600 605

Leu Asp Gln Phe Met Leu Glu Gly Glu Ala Ser Asn Val Gln Tyr Ala
610 615 620

Thr Phe Ser Gln Pro Leu Cys Cys Ala Val Gln Ile Val Leu Val Arg
625 630 635 640

Leu Leu Glu Ala Ala Arg Ile Arg Phe Thr Ala Val Val Gly His Ser
645 650 655

Ser Gly Glu Ile Ala Cys Ala Phe Ala Ala Gly Leu Ile Ser Ala Ser
660 665 670

Leu Ala Ile Arg Ile Ala Tyr Leu Arg Gly Val Val Ser Ala Gly Gly
675 680 685

Ala Arg Gly Thr Pro Gly Ala Met Leu Ala Ala Gly Met Ser Phe Glu
690 695 700

Glu Ala Gln Glu Ile Cys Glu Leu Asp Ala Phe Glu Gly Arg Ile Cys
705 710 715 720

Val Ala Ala Ser Asn Ser Pro Asp Ser Val Thr Phe Ser Gly Asp Ala
725 730 735

Asn Ala Ile Asp His Leu Lys Gly Met Leu Glu Asp Glu Ser Thr Phe
740 745 750

Ala Arg Leu Leu Lys Val Asp Thr Ala Tyr His Ser His His Met Leu
755 760 765

Pro Cys Ala Asp Pro Tyr Met Gln Ala Leu Glu Glu Cys Gly Cys Ala
770 775 780

- 58 -

Val	Ala	Asp	Ala	Gly	Ser	Pro	Ala	Gly	Ser	Val	Pro	Trp	Tyr	Ser	Ser		
785															800		
Val	Asp	Ala	Glu	Asn	Arg	Gln	Met	Ala	Ala	Arg	Asp	Val	Thr	Ala	Lys		
															815		
805																	
Tyr	Trp	Lys	Asp	Asn	Leu	Val	Ser	Pro	Val.	Leu	Phe	Ser	His	Ala	Val		
															830		
820																	
825																	
Gln	Arg	Ala	Val	Val	Thr	His	Lys	Ala	Leu	Asp	Ile	Gly	Ile	Glu	Val		
															845		
835																	
Gly	Cys	His	Pro	Ala	Leu	Lys	Ser	Pro	Cys	Val	Ala	Thr	Ile	Lys	Asp		
															860		
850																	
855																	
Val	Leu	Ser	Gly	Val	Asp	Leu	Ala	Tyr	Thr	Gly	Cys	Leu	Glu	Arg	Gly		
															880		
865																	
870																	
Lys	Asn	Asp	Leu	Asp	Ser	Phe	Ser	Arg	Ala	Leu	Ala	Tyr	Leu	Trp	Glu		
															895		
885																	
890																	
Arg	Phe	Gly	Ala	Ser	Ser	Phe	Asp	Ala	Asp	Glu	Phe	Met	Arg	Ala	Val		
															910		
900																	
905																	
Ala	Pro	Asp	Arg	Pro	Cys	Met	Ser	Val	Ser	Lys	Leu	Leu	Pro	Ala	Tyr		
															925		
915																	
920																	
Pro	Trp	Asp	Arg	Ser	Arg	Arg	Tyr	Trp	Val	Glu	Ser	Arg	Ala	Thr	Arg		
															940		
930																	
935																	
His	His	Leu	Arg	Gly	Pro	Lys	Pro	His	Leu	Leu	Leu	Gly	Lys	Leu	Ser		
															960		
945																	
950																	
Glu	Tyr	Ser	Thr	Pro	Leu	Ser	Phe	Gln	Trp	Leu	Asn	Phe	Val	Arg	Pro		
															975		
965																	
970																	
Arg	Asp	Ile	Glu	Trp	Leu	Asp	Gly	His	Ala	Leu	Gln	Gly	Gln	Thr	Val		
															990		
980																	
985																	
Phe	Pro	Ala	Ala	Gly	Tyr	Ile	Val	Met	Ala	Met	Glu	Ala	Ala	Leu	Met		
															1005		
995																	
1000																	
Ile	Ala	Gly	Thr	His	Ala	Lys	Gln	Val	Lys	Leu	Glu	Ile	Leu	Asp			
															1010		
1010																	
1015																	
Met	Ser	Ile	Asp	Lys	Ala	Val	Ile	Phe	Asp	Asp	Glu	Asp	Ser	Leu	Val		
															1025		
1025																	
1030																	
1035																	
Glu	Leu	Asn	Leu	Thr	Ala	Asp	Val	Ser	Arg	Asn	Ala	Gly	Glu	Ala	Gly		
															1045		
1045																	
1050																	
1055																	
Ser	Met	Thr	Ile	Ser	Phe	Lys	Ile	Asp	Ser	Cys	Leu	Ser	Lys	Glu	Gly		
															1060		
1060																	
1065																	
1070																	
Asn	L	u	Ser	L	u	Ser	Ala	Lys	Gly	Gln	Leu	Ala	Leu	Thr	Ile	Glu	Asp
															1075		
1075																	
1080																	
1085																	

- 59 -

Val Asn Pro Arg Thr Thr Ser Ala Ser Asp Gln His His Leu Pro Pro
1090 1095 1100

Pro Glu Glu Glu His Pro His Met Asn Arg Val Asn Ile Asn Ala Phe
1105 1110 1115 1120

Tyr His Glu Leu Gly Leu Met Gly Tyr Asn Tyr Ser Lys Asp Phe Arg
1125 1130 1135

Arg Leu His Asn Met Gln Arg Ala Asp Leu Arg Ala Ser Gly Thr Leu
1140 1145 1150

Asp Phe Ile Pro Leu Met Asp Glu Gly Asn Gly Cys Pro Leu Leu Leu
1155 1160 1165

His Pro Ala Ser Leu Asp Val Ala Phe Gln Thr Val Ile Gly Ala Tyr
1170 1175 1180

Ser Ser Pro Gly Asp Arg Arg Leu Arg Cys Leu Tyr Val Pro Thr His
1185 1190 1195 1200

Val Asp Arg Ile Thr Leu Val Pro Ser Leu Cys Leu Ala Thr Ala Glu
1205 1210 1215

Ser Gly Cys Glu Lys Val Ala Phe Asn Thr Ile Asn Thr Tyr Asp Lys
1220 1225 1230

Gly Asp Tyr Leu Ser Gly Asp Ile Val Val Phe Asp Ala Glu Gln Thr
1235 1240 1245

Thr Leu Phe Gln Val Glu Asn Ile Thr Phe Lys Pro Phe Ser Pro Pro
1250 1255 1260

Asp Ala Ser Thr Asp His Ala Met Phe Ala Arg Trp Ser Trp Gly Pro
1265 1270 1275 1280

Leu Thr Pro Asp Ser Leu Leu Asp Asn Pro Glu Tyr Trp Ala Thr Ala
1285 1290 1295

Gln Asp Lys Glu Ala Ile Pro Ile Ile Glu Arg Ile Val Tyr Phe Tyr
1300 1305 1310

Ile Arg Ser Phe Leu Ser Gln Leu Thr Leu Glu Glu Arg Gln Gln Ala
1315 1320 1325

Ala Phe His Leu Gln Lys Gln Ile Glu Trp Leu Glu Gln Val Leu Ala
1330 1335 1340

Ser Ala Lys Glu Gly Arg His Leu Trp Tyr Asp Pro Gly Trp Glu Asn
1345 1350 1355 1360

Asp Thr Glu Ala Gln Ile Glu His Leu Cys Thr Ala Asn Ser Tyr His
1365 1370 1375

- 60 -

Pro His Val Arg Leu Val Gln Arg Val Gly Gln His Leu Leu Pro Thr			
1380	1385	1390	
Val Arg Ser Asn Gly Asn Pro Phe Asp Leu Leu Asp His Asp Gly Leu			
1395	1400	1405	
Leu Thr Glu Phe Tyr Thr Asn Thr Leu Ser Phe Gly Pro Ala Leu His			
1410	1415	1420	
Tyr Ala Arg Glu Leu Val Ala Gln Ile Ala His Arg Tyr Gln Ser Met			
1425	1430	1435	1440
Asp Ile Leu Glu Ile Gly Ala Gly Thr Gly Gly Ala Thr Lys Tyr Val			
1445	1450	1455	
Leu Ala Thr Pro Gln Leu Gly Phe Asn Ser Tyr Thr Tyr Thr Asp Ile			
1460	1465	1470	
Ser Thr Gly Phe Phe Glu Gln Ala Arg Glu Gln Phe Ala Pro Phe Glu			
1475	1480	1485	
Asp Arg Met Val Phe Glu Pro Leu Asp Ile Arg Arg Ser Pro Ala Glu			
1490	1495	1500	
Gln Gly Phe Glu Pro His Ala Tyr Asp Leu Ile Ile Ala Ser Asn Val			
1505	1510	1515	1520
Leu His Ala Thr Pro Asp Leu Glu Lys Thr Met Ala His Ala Arg Ser			
1525	1530	1535	
Leu Leu Lys Pro Gly Gly Gln Met Val Ile Leu Glu Ile Thr His Lys			
1540	1545	1550	
Glu His Thr Arg Leu Gly Phe Ile Phe Gly Leu Phe Ala Asp Trp Trp			
1555	1560	1565	
Ala Gly Val Asp Asp Gly Arg Cys Thr Glu Pro Phe Val Ser Phe Asp			
1570	1575	1580	
Arg Trp Asp Ala Ile Leu Lys Arg Val Gly Phe Ser Gly Val Asp Ser			
1585	1590	1595	1600
Arg Thr Thr Asp Arg Asp Ala Asn Leu Phe Pro Thr Ser Val Phe Ser			
1605	1610	1615	
Thr His Ala Ile Asp Ala Thr Val Glu Tyr Leu Asp Ala Pro Leu Ala			
1620	1625	1630	
Ser Ser Gly Thr Val Lys Asp Ser Tyr Pro Pro Leu Val Val Val Gly			
1635	1640	1645	
Gly Gln Thr Pro Gln Ser Gln Arg Leu Leu Asn Asp Ile Lys Ala Ile			
1650	1655	1660	
Met Pro Pro Arg Pro Leu Gln Thr Tyr Lys Arg Leu Val Asp Leu Leu			
1665	1670	1675	1680

- 61 -

Asp Ala Glu Glu Leu Pro Met Lys Ser Thr Phe Val Met Leu Thr Glu			
1685	1690	1695	
Leu Asp Glu Glu Leu Phe Ala Gly Leu Thr Glu Glu Thr Phe Glu Ala			
1700	1705	1710	
Thr Lys Leu Leu Leu Thr Tyr Ala Ser Asn Thr Val Trp Leu Thr Glu			
1715	1720	1725	
Asn Ala Trp Val Gln His Pro His Gln Ala Ser Thr Ile Gly Met Leu			
1730	1735	1740	
Arg Ser Ile Arg Arg Glu His Pro Asp Leu Gly Val His Val Leu Asp			
1745	1750	1755	1760
Val Asp Ala Val Glu Thr Phe Asp Ala Thr Phe Leu Val Glu Gln Val			
1765	1770	1775	
Leu Arg Leu Glu Glu His Thr Asp Glu Leu Ala Ser Ser Thr Thr Trp			
1780	1785	1790	
Thr Gln Glu Pro Glu Val Ser Trp Cys Lys Gly Arg Pro Trp Ile Pro			
1795	1800	1805	
Arg Leu Lys Arg Asp Leu Ala Arg Asn Asn Arg Met Asn Ser Ser Arg			
1810	1815	1820	
Arg Pro Ile Tyr Glu Met Ile Asp Ser Ser Arg Ala Pro Val Ala Leu			
1825	1830	1835	1840
Gln Thr Ala Arg Asp Ser Ser Tyr Phe Leu Glu Ser Ala Glu Thr			
1845	1850	1855	
Trp Phe Val Pro Glu Ser Val Gln Gln Met Glu Thr Lys Thr Ile Tyr			
1860	1865	1870	
Val His Phe Ser Cys Pro His Ala Leu Arg Val Gly Gln Leu Gly Phe			
1875	1880	1885	
Phe Tyr Leu Val Gln Gly His Val Gln Glu Gly Asn Arg Glu Val Pro			
1890	1895	1900	
Val Val Ala Leu Ala Glu Arg Asn Ala Ser Ile Val His Val Arg Pro			
1905	1910	1915	1920
Asp Tyr Ile Tyr Thr Glu Ala Asp Asn Asn Leu Ser Glu Gly Gly			
1925	1930	1935	
Ser Leu Met Val Thr Val Leu Ala Ala Ala Val Leu Ala Glu Thr Val			
1940	1945	1950	
Ile Ser Thr Ala Lys Cys Leu Gly Val Thr Asp Ser Ile Leu Val Leu			
1955	1960	1965	

- 62 -

Asn Pro Pro Ser Ile Cys Gly Gln Met Leu Leu His Ala Gly Glu Glu			
1970	1975	1980	
Ile Gly Leu Gln Val His Leu Ala Thr Thr Ser Gly Asn Arg Ser Ser			
1985	1990	1995	2000
Val Ser Ala Gly Asp Ala Lys Ser Trp Leu Thr Leu His Ala Arg Asp			
2005	2010	2015	
Thr Asp Trp His Leu Arg Arg Val Leu Pro Arg Gly Val Gln Ala Leu			
2020	2025	2030	
Val Asp Leu Ser Ala Asp Gln Ser Cys Glu Gly Leu Thr Gln Arg Met			
2035	2040	2045	
Met Lys Val Leu Met Pro Gly Cys Ala His Tyr Arg Ala Ala Asp Leu			
2050	2055	2060	
Phe Thr Asp Thr Val Ser Thr Glu Leu His Ser Gly Ser Arg His Gln			
2065	2070	2075	2080
Ala Ser Leu Pro Ala Ala Tyr Trp Glu His Val Val Ser Leu Ala Arg			
2085	2090	2095	
Gln Gly Leu Pro Ser Val Ser Glu Gly Trp Glu Val Met Pro Cys Thr			
2100	2105	2110	
Gln Phe Ala Ala His Ala Asp Lys Thr Arg Pro Asp Leu Ser Thr Val			
2115	2120	2125	
Ile Ser Trp Pro Arg Glu Ser Asp Glu Ala Thr Leu Pro Thr Arg Val			
2130	2135	2140	
Arg Ser Ile Asp Ala Glu Thr Leu Phe Ala Ala Asp Lys Thr Tyr Leu			
2145	2150	2155	2160
Leu Val Gly Leu Thr Gly Asp Leu Gly Arg Ser Leu Gly Arg Trp Met			
2165	2170	2175	
Val Gln His Gly Ala Cys His Ile Val Leu Thr Ser Arg Asn Pro Gln			
2180	2185	2190	
Val Asn Pro Lys Trp Leu Ala His Val Glu Glu Leu Gly Gly Arg Val			
2195	2200	2205	
Thr Val Leu Ser Met Asp Val Thr Ser Gln Asn Ser Val Glu Ala Gly			
2210	2215	2220	
Leu Ala Lys Leu Lys Asp Leu His Leu Pro Pro Val Gly Gly Ile Ala			
2225	2230	2235	2240
Phe Gly Pro Leu Val Leu Gln Asp Val Met Leu Asn Asn Met Glu Leu			
2245	2250	2255	
Pro Met Met Glu M t Val Leu Asn Pro Lys Val Glu Gly Val Arg Ile			
2260	2265	2270	

- 63 -

Leu His Glu Lys Phe Ser Asp Pro Thr Ser Ser Asn Pro Leu Asp Phe
2275 2280 2285
Phe Val Met Phe Ser Ser Ile Val Ala Val Met Gly Asn Pro Gly Gln
2290 2295 2300
Ala Asn Tyr Ser Ala Ala Asn Cys Tyr Leu Gln Ala Leu Ala Gln Gln
2305 2310 2315 2320
Arg Val Ala Ser Gly Leu Ala Ala Ser Thr Ile Asp Ile Gly Ala Val
2325 2330 2335
Tyr Gly Val Gly Phe Val Thr Arg Ala Glu Leu Glu Glu Asp Phe Asn
2340 2345 2350
Ala Ile Arg Phe Met Phe Asp Ser Val Glu Glu His Glu Leu His Thr
2355 2360 2365
Leu Phe Ala Glu Ala Val Val Ala Gly Arg Arg Ala Val His Gln Gln
2370 2375 2380
Glu Gln Gln Arg Lys Phe Ala Thr Val Leu Asp Met Ala Asp Leu Glu
2385 2390 2395 2400
Leu Thr Thr Gly Ile Pro Pro Leu Asp Pro Ala Leu Lys Asp Arg Ile
2405 2410 2415
Thr Phe Phe Asp Asp Pro Arg Ile Gly Asn Leu Lys Ile Pro Glu Tyr
2420 2425 2430
Arg Gly Ala Lys Ala Gly Glu Gly Ala Ala Gly Ser Lys Gly Ser Val
2435 2440 2445
Lys Glu Gln Leu Leu Gln Ala Thr Asn Leu Asp Gln Val Arg Gln Ile
2450 2455 2460
Val Ile Asp Gly Leu Ser Ala Lys Leu Gln Val Thr Leu Gln Ile Pro
2465 2470 2475 2480
Asp Gly Glu Ser Val His Pro Thr Ile Pro Leu Ile Asp Gln Gly Val
2485 2490 2495
Asp Ser Leu Gly Ala Val Thr Val Gly Thr Trp Phe Ser Lys Gln Leu
2500 2505 2510
Tyr Leu Asp Leu Pro Leu Leu Lys Val Leu Gly Gly Ala Ser Ile Thr
2515 2520 2525
Asp Leu Ala Asn Glu Ala Ala Ala Arg Leu Pro Pro Ser Ser Ile Pro
2530 2535 2540
Leu Val Ala Ala Thr Asp Gly Gly Ala Glu Ser Thr Asp Asn Thr Ser
2545 2550 2555 2560

- 64 -

Glu	Asn	Glu	Val	Ser	Gly	Arg	Glu	Asp	Thr	Asp	Leu	Ser	Ala	Ala	Ala	
															2575	
2565																
Thr	Ile	Thr	Glu	Pro	Ser	Ser	Ala	Asp	Glu	Asp	Asp	Thr	Glu	Pro	Gly	
															2590	
2580																
Asp	Glu	Asp	Val	Pro	Arg	Ser	His	His	Pro.	Leu	Ser	Leu	Gly	Gln	Glu	
															2605	
2595																
Tyr	Ser	Trp	Arg	Ile	Gln	Gln	Gly	Ala	Glu	Asp	Pro	Thr	Val	Phe	Asn	
															2620	
2610																
Asn	Thr	Ile	Gly	Met	Phe	Met	Lys	Gly	Ser	Ile	Asp	Leu	Lys	Arg	Leu	
															2640	
2625																
Tyr	Lys	Ala	Leu	Arg	Ala	Val	Leu	Arg	Arg	His	Glu	Ile	Phe	Arg	Thr	
															2655	
2645																
Gly	Phe	Ala	Asn	Val	Asp	Glu	Asn	Gly	Met	Ala	Gln	Leu	Val	Phe	Gly	
															2670	
2660																
Gln	Thr	Lys	Asn	Lys	Val	Gln	Thr	Ile	Gln	Val	Ser	Asp	Arg	Ala	Gly	
															2685	
2675																
Ala	Glu	Glu	Gly	Tyr	Arg	Gln	Leu	Val	Gln	Thr	Arg	Tyr	Asn	Pro	Ala	
															2700	
2690																
Ala	Gly	Asp	Thr	Leu	Arg	Leu	Val	Asp	Phe	Phe	Trp	Gly	Gln	Asp	Asp	
															2720	
2705																
His	Leu	Leu	Val	Val	Ala	Tyr	His	Arg	Leu	Val	Gly	Asp	Gly	Ser	Thr	
															2735	
2725																
Thr	Glu	Asn	Ile	Phe	Val	Glu	Ala	Gly	Gln	Leu	Tyr	Asp	Gly	Thr	Ser	
															2750	
2740																
Leu	Ser	Pro	His	Val	Pro	Gln	Phe	Ala	Asp	Leu	Ala	Ala	Arg	Gln	Arg	
															2765	
2755																
Ala	Met	Leu	Glu	Asp	Gly	Arg	Met	Glu	Glu	Asp	Leu	Ala	Tyr	Trp	Lys	
															2780	
2770																
Lys	Met	His	Tyr	Arg	Pro	Ser	Ser	Ile	Pro	Val	Leu	Pro	Leu	Met	Arg	
															2800	
2785																
Pro	Leu	Val	Gly	Asn	Ser	Ser	Arg	Ser	Asp	Thr	Pro	Asn	Phe	Gln	His	
															2815	
2805																
Cys	Gly	Pro	Trp	Gln	Gln	His	Glu	Ala	Val	Ala	Arg	Leu	Asp	Pro	Met	
															2830	
2820																
Val	Ala	Phe	Arg	Ile	Lys	Glu	Arg	Ser	Arg	Lys	His	Lys	Ala	Thr	Pro	
															2845	
2835																
Met	Gln	Phe	Tyr	L	u	Ala	Ala	Tyr	Gln	Val	Leu	Leu	Ala	Arg	Leu	Thr
															2860	
2850																

- 65 -

Asp Ser Thr Asp Leu Thr Val Gly Leu Ala Asp Thr Asn Arg Ala Thr			
2865	2870	2875	2880
Val Asp Glu Met Ala Ala Met Gly Phe Phe Ala Asn Leu Leu Pro Leu			
2885	2890	2895	
Arg Phe Arg Asp Phe Arg Pro His Ile Thr Phe Gly Glu His Leu Ile			
2900	2905	2910	
Ala Thr Arg Asp Leu Val Arg Glu Ala Leu Gln His Ala Arg Val Pro			
2915	2920	2925	
Tyr Gly Val Leu Leu Asp Gln Leu Gly Leu Glu Val Pro Val Pro Thr			
2930	2935	2940	
Ser Asn Gln Pro Ala Pro Leu Phe Gln Ala Val Phe Asp Tyr Lys Gln			
2945	2950	2955	2960
Gly Gln Ala Glu Ser Gly Thr Ile Gly Gly Ala Lys Ile Thr Glu Val			
2965	2970	2975	
Ile Ala Thr Arg Glu Arg Thr Pro Tyr Asp Val Val Leu Glu Met Ser			
2980	2985	2990	
Asp Asp Pro Thr Lys Asp Pro Leu Leu Thr Ala Lys Leu Gln Ser Ser			
2995	3000	3005	
Arg Tyr Glu Ala His His Pro Gln Ala Phe Leu Glu Ser Tyr Met Ser			
3010	3015	3020	
Leu Leu Ser Met Phe Ser Met Asn Pro Ala Leu Lys Leu Ala			
3025	3030	3035	

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: probe

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GATACGGCAT GCAGCTCGTC GTTGGTTGCC GTTCATCTGG CTGCA

- 66 -

WHAT IS CLAIMED IS:

1. Purified DNA molecule encoding triol polyketide synthase.

5

2. The purified DNA molecule of Claim 1 wherein the DNA encodes triol polyketide synthase from a microorganism, the microorganism being selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

10

3. The purified DNA molecule of Claim 1 wherein the DNA encodes triol polyketide synthase from Aspergillus terreus.

15

4. The purified DNA molecule of Claim 1 having the sequence

20

CTGCAGTC	AA	CGGATCA	CTT	ACCATTG	GCTG	TGGCA	AAAAA	TATCCGTG	AT	50		
AATCCC	GGCTG	GCTTCATT	GGG	CAAGAGG	CCTT	GACGTACT	TTG	GGAGCTT	GGG	100		
TCTGGAA	CTG	GTT	CATAACC	ACCTTGGT	GTA	TGAGATGT	GTC	ATCCC	TCGTG	150		
ACTTC	CTTGA	ATC	CATCGAA	TCCGGGA	AGGA	TGAGAGTG	AA	AGTC	CTGATG	200		
AGAGCACG	AA	GATCAGTA	AG	TCAGGT	CCTC	ACAGCGG	AAAG	CAGTTG	CAAA	250		
GAACGGT	GGGA	CTC	CTTACCG	TG	CCCAAG	AA	CTTGTAC	ATA	CAGAGCT	CTT	300	
TCATCTT	GCG	AA	AACTCATCG	GCC	CATAGAGG	AGG	GAAGA	AAAT	GGTGCAG	TAC	350	
CCAGAGTC	GA	CT	ATGAACCG	AAT	GGGCTT	TA	TCATTTG	C	GAGCAG	CT	400	
CTCAATCC	AT	GACGGT	GCAT	TCG	CATCAA	AA	ATCCC	GT	TTG	GCCCTCAT	GG	450
TCGTCAG	TT	CCAC	CATG	TT	CGGATT	GA	ACAC	GGCAG	ATC	CAGAT	CTC	500
CGGCCACT	CG	AG	CACAGGT	AA	GAAGAAGG	CATAG	TA	GAGCC	CCG	CA	CTGGT	550
AGTGACCA	AG	GG	GC	AA	AC	GGCC	CATG	TT	GCTG	CGT	G	600
CCAGCGAC	AG	AAG	GTG	GTG	GG	CTG	TGT	GA	GCG	CG	AC	650
AGGAGACC	AG	GTG	GGT	TGA	GG	GATA	AGAT	ATC	GAG	AGT	GAG	700
AAGATCC	GGG	AA	AGG	TG	CG	A	AGG	AA	GG	CGT	CTC	750

25

30

- 67 -

	TCTGTTCCCT ATCATGCAAT CACCGCTTGC TGTACGGTGG TGATGATGCT	800
	GGGATGGTGG TGGGTCCCCA CCGAATAACG CCGGACAGCT GTTGAAGCCG	850
	AATGACGCCG GCAGGCCAAA AGAACCCCTAC CTTCACTTAC TCAATCGGCG	900
	CTTCCCCCTCC TATCACCAAA TCGGATGTAA ATGGACGGGC CTTAATAGCG	950
5	ACCGGCCGGG CCGGAATCC CCAAACGTAG ATAGATAGGC ATAGACCCGA	1000
	AATCTTTGGC CCGGCATACA TGAGCACAGG AAGTTTCACG CGACGGGCC	1050
	TTTCTGCCT CAGCTCAAT CCAAGCTCAC GAGTTCTGTC GCCTCTATCA	1100
	GTCGTGCAAT TGTCTACTG CAAACAGCAT GGCTCAATCT ATGTATCCTA	1150
10	ATGAGCCTAT TGTCTGGTC GGCAGTGGTT GTCTGCTTCCC TGGTGACGCC	1200
	AACACACCCCT CCAAGCTCTG GGAGCTACTC CAGCATCCTC GCGATGTGCA	1250
	GAGTCGAATC CCCAAAGAAC GATTTGACGT CGACACATT TATCACCCGG	1300
	ACGGGAAGCA CCACGGGCGA ACAAAATGCAC CCTACGCCCTA TGTTCTCCAA	1350
	GACGATCTGG GCGCCTTCGA TGCGGCCTTC TTCAATATCC AGGCTGGAGA	1400
15	GGCCGAGAGT ATGGACCCCC AGCACCGGCT GTTGCTGGAG ACAGGTGTACG	1450
	AGGCCGTAAC GAATGCTGGA ATGCGTATCC AGGATCTGCA GGGAACTTCG	1500
	ACTGCTGTTT ACGTCGGGGT GATGACGCAC GACTATGAGA CTGTCTCAAC	1550
	CCCGCACCTG GAGAGCATCC CCACCTACTC GGCGACGGGT GTCGCGGTCA	1600
	GTGTTGCGTC CAACCGCATC TCGTATTTTT TTGACTGGCA TGGACCAAGT	1650
20	GTAAAGTCACC CAATATCGTG TAGCAGTCTA ATCATGCTCT AACGGACCGG	1700
	GATGGTTGAA AGATGACGAT CGATAACGGCA TGCAAGCTCGT CGTTGGTTGC	1750
	CGTTCATCTG GCGGTGCAAC AGCTACGGAC GGGTCAAAGC TCCATGGCAA	1800
	TTGCTGCGGG TGCGAATCTG ATTCTGGGGC CCATGACATT CGTCCTTGAA	1850
	AGCAAATTGA GCATGCTATC CCCCTCGGGT CGATCCCGCA TGTTGGACGC	1900
25	CGGAGCTGAC GGCTATGCCA GAGGCGTGAG TGTTCTTGA GCTCGTAGAT	1950
	GACAGTTCCC ATCGCTGACC GTGATCAGGA AGCTGTTGTC TCTGTAGTGT	2000
	TGAAGACATT GAGTCAGGCC TTGCGCGATG GGGACACGAT TGAATGTGTC	2050
	ATCCGAGAAA CTGGGTGAA TCAAGATGGC CGAACGACCG GAATTACGAT	2100
	GCCGAACCAT AGTGCTCAGG AGGCACTCAT CAAGGCTACC TACGCCAGG	2150
	CTGGCCTTGA CATCACCAAG GCCGAGGACA GGTGCCAATT CTTCGAGGCT	2200
30	CATGGTCAGC AAAGAGAACC TGTTCTGTTG GCGCCCTGCA GCTGACATTC	2250
	GTATGATAGG GACTGGTACT CCGGCCGGAG ATCCCCAGGA GGCGGAGGCC	2300
	ATTGCAACAG CCTTCTTCGG CCACGAGCAG GTAGCACGCA GCGACGGAAA	2350
	CGAGAGGGCC CCTCTGTTCG TGGGCAGTGC GAAAAACTGTT GTCTGGGCACA	2400
	CCGAGGGCAC GGCGGGCTCG GCTGGTCTCA TGAAGGCGTC GTTCGCTGTC	2450
	CGCCATGGGG TAATCCCCCCC CAACCTGCTG TTGACAAAAA TCAGCCCCGG	2500

- 68 -

	AGTCGCCCCA TTCTATAAAA ACCTGAGGAT TCCGACAGAA GCTACCCAT	2550
	GCCCAGCTCT CCCACCCCGA CAACCGCGCC GCGCCAGTGT CAAACTCCTTT	2600
	GGTAAGCGAG GATTGCCCGG AGGAACCCTC ACAAGTACTC GAATTAATGC	2650
	TAACTGAACC GCGCCGATGG ACAGGATTG GCAGCACGAA TGCGCATGCC	2700
5	ATTATTGAGG AATACATGGA GCCAGAGCAA AACCAAGCTGC GAGTCTCGAA	2750
	TAATGAGGAC TGCCCACCCA TGACCGGTGT CCTGAGTTA CCCTTAGTCC	2800
	TCTCGGCAGA GTCCCAGCGC TCCTTAAAGA TAATGATGGA GGAGATGCTG	2850
	CAATTCCCTTC AGTCTCACCC CGAGATAACAC TTGCACGACC TCACCTGGTC	2900
	CTTACTGCGC AAGCGGTCAG TCTTACCCCTT CGCGGGGGCT ATTGTCGGCC	2950
10	ATAGTCATGA AACCATCCGC CGGGCTTTGG AGGATGCCAT CGAGGATGGT	3000
	ATTGTGTCGA GCGACTTCAC TACGGAGGTC AGAGGCCAGC CATCGGTGTT	3050
	GGGAATCTTC ACCGGGCAGG GGGCGCAGTG GCCGGGGATG TTAAAGAAC	3100
	TGATAGAGGC ATCGCCATAT GTCGGAAACA TAGTGAGGGA GCTGGACGAC	3150
	TCCCTGCAGA GCTTGCCCGA AAAATACCGG CCCTCGTGGA CGCTACTGGA	3200
15	CCAGTTCATG CTAGAAGGAG AGGCCTCCAA CGTCAAATAT GCTACTTTCT	3250
	CCCAGCCATT ATGCTGCGCG GTGCAAATTG TCCTGGTCCG TCTCCTTGAA	3300
	GCCGCGAGAA TACGATTACAC GGCTGTTGTT GGACATAGCT CGGGCGAAAT	3350
	TGCTTGCAGC TTTGCTGCCG GGCTCATCAG TGCTCGTTG GCGATTGGAA	3400
	TTGCTTACTT ACGTGGAGTC GTCTCGGCAG GGGCGCCAG AGGCACACCG	3450
20	GGAGCCATGT TGGCCGCGG GATGTCTTT GAGGAAGCAC AAGAGATCTG	3500
	CGAGTTGGAT GCCTTGAGG GCCGCATCTG CGTGGCTGCC AGCAATTCCC	3550
	CAGACAGTGT AACTTCTCT GGCACGCGA ACGCAATTGA TCACCTGAAG	3600
	GGCATGTTGG AGGATGAGTC CACTTTGCG AGACTGCTCA AGGTGATAAC	3650
	AGCGTACACAC TCGCATCATA TGCTTCCATG TCCAGACCCA TATATGCAAG	3700
25	CCCTAGAAGA GTGTGGTGT GCTGTTGCCG ATGCAGGTTTC CCCAGCCGG	3750
	ACTGTACCCCT GGTATTCGTC CGTGGACGCC GAGAACAGGC AAATGGCAGC	3800
	AAGAGACGTG ACCGCCAAGT ACTGGAAAGA TAACTTAGTA TCTCCGGTGC	3850
	TATTCTCCCA CGCAGTGCAG CGGGCAGTCG TCACGCACAA GGCGCTGGAT	3900
	ATCGGGATTG AAGTGGGCTG TCACCCAGCT CTCAAGAGCC CATCGTCCG	3950
30	CACCATCAAG GATGTCTAT CTGGGGTTGA CCTGGCGTAT ACAGGTTGCT	4000
	TGGAGCGAGG AAAGAATGAT CTCGATTCTAT TCTCTCGAGC ACTGGCATAT	4050
	CTCTGGGAAA GGTGGTGTGCTCCAGTTTC GATGCGGACG AGTTCATGCC	4100
	TGCAGTGCAG CCTGATCGGC CCTGTATGAG TGTGTCGAAG CCTCTACCGG	4150
	CCTATCCATG GGACCCCTCT CGTCGCTACT GGGTGAATC CCGAGCAACT	4200
	CGCCACCACATC TTCGAGGGCC CAAGCCCCAT CTTCTATTAG GAAAGCTCTC	4250

- 69 -

	CGAATACAGC ACTCCGCTAA GCTTCCAGTG GCTGAATTGT GTGCGCCCAC	4300
	GAGACATTGA ATGGCTTGAT GGACATGCAT TGCAAGGCCA GACTGTCTTC	4350
	CCTGCGGCCG GCTATATCGT CATGGCAATG GAAGCAGCCT TAATGATTGC	4400
5	TGGCACCCAC GCAAAGCAGG TCAAGTTACT GGAGATCTTG GATATGAGCA	4450
	TTGACAAGGC GGTGATATTG GACGACGAAG ACAGCTTGGT TGAGCTAAC	4500
	CTGACAGCTG ACGTGTCTCG CAACGCCGGC GAAGCAGGTT CAATGACCAT	4550
	AAGCTTCAAG ATCGATTCCCT GTCTATCGAA GGAGGGTAAC CTATCCCTAT	4600
	CAGCCAAGGG CCAACTGGCC CTAACGATAG AAGATGTCAA TCCCAGGACG	4650
10	ACTTCCGCTA GCGACCAGCA CCATCTTCCC CCGCCAGAAG AGGAACATCC	4700
	TCATATGAAC CGTGTCAACA TCAATGCTTT CTACCACGAG CTGGGTTGA	4750
	TGGGGTACAA CTACAGTAAG GACTTCCGGC GTCTCCATAA CATGCAACGA	4800
	GCAGATCTTC GAGCCAGCGG CACCTTAGAC TTCATTCCTC TGATGGACGA	4850
	GGGTAATGGC TGTCCCTCTCC TGCTGCATCC TGCACTCATG GACGTCGCCT	4900
15	TCCAGACTGT CATCGCGCA TACTCCTCCC CAGGTGATCG GCGTCTACGC	4950
	TGTCTGTATG TACCCACTCA CGTTGATCCG ATCACACTTG TCCCACCCCT	5000
	TTGCCTGGCA ACGGCTGAGT CCGGATGCCA GAAGGTTGCC TTCAATACTA	5050
	TCAATACGTA CGACAAGGG AACTACTTGA GCGGTGACAT TGTGGTGT	5100
	GACCGGGAGC AGACCACCCCT GTTCCAGGTT GAAAATATTA CTTTTAAGCC	5150
20	CTTTTCACCC CCGGATGCTT CAACTGACCA TGCGATGTTT GCCCGATGGA	5200
	GCTGGGGTCC GTTGACTCCG GACTCGCTGC TGGATAACCC GGAGTATTGG	5250
	GCCACCGCGC AGGACAAGGA GGCGATTCCCT ATTATCGAAC GCATCGTCTA	5300
	CTTCTATATTC CGATCGTTCC TCAGTCAGCT TACGCTGGAG GAGCGCCAGC	5350
	AGGCAGCCTT CCATTGAG AAGCAGATCG AGTGGCTCGA ACAAGTCCTG	5400
25	GCCAGCGCCA AGGAGGGTCG TCACCTATGG TACGACCCCG GGTGGGAGAA	5450
	TGATACTGAG GCCCAGATTG AGCACCTTG TACTGCTAAC TCCTACCACC	5500
	CTCATGTTCC CCTGGGTCAG CGAGTCGGCC AACACCTGCT CCCCCACCGTA	5550
	CGATCGAACCG GCAACCCATT CGACCTTCTG GACCACGATG GGCTCCTGAC	5600
	GGAGTTCTAT ACCAACACAC TCAGCTTCGG ACCCGCACTA CACTACGCC	5650
30	GGGAATTGGT GGCCAGATC GCCCATCGCT ATCAGTCAT GGATATTCTG	5700
	GAGATGGAG CAGGGACCGG CGCGCTACC AAGTACGTGT TGGCCACGCC	5750
	CCAGCTGGGG TTCAACAGCT ACACATACAC CGATATCTCC ACCGGATTCT	5800
	TCGAGCAAGC GCGGGAGCAA TTTGCCCCCT TCGAGGACCG GATGGTGT	5850
	GAACCCCTCG ATATCCGCCG CAGTCCCGCC GAGCAGGGCT TCGAGGCC	5900
	TGCCTATGAT CTGATCATG CCTCCAATGT GCTACATGCG ACACCCGACC	5950
	TAGAGAAAAC CATGGCTCAC GCCCCCTCTC TGCTCAAGCC TGGAGGCCAG	6000

- 70 -

	ATGGTTATTTC TGGAGATTAC CCACAAAGAA CACACACGGC TCGGGTTTAT	6050
	CTTGGTCTG TTCGCCACT GGTGGGCTGG GGTGGATGAT GGTCGCTGCA	6100
	CTGAGCCGTT TGTCTCGTTC GACCGCTGGG ATGCGATCCT AAAGCGTGTC	6150
	GGGTTTCCG GTGTGGACAG TCGCACCAAG GATCGGGACG CAAATCTATT	6200
5	CCCGACCTCT GTGTTAGTA CCCATGCAAT TGACGCCACC GTGGAGTACT	6250
	TAGACGCGCC GCTTGCCAGC AGCGGCACCG TCAAGGACTC TTACCCCTCCC	6300
	TTGGTGGTGG TAGGAGGGCA GACCCCCCAA TCTCAGCGTC TCCTGAACGA	6350
	TATAAAAGCG ATCATGCCTC CTCGTCCGCT CCAGACATAC AAGCGCCTCG	6400
10	TGGATTGCT AGACCGGGAG GAGCTGCCGA TGAAGTCCAC GTTTGTCATG	6450
	CTCACGGAGC TGGACGAGGA ATTATTCGCC GGGCTCACTG AAGAGACCTT	6500
	CGAGGCAACC AAGCTGCTGC TCACGTACGC CAGCAATACG GTCTGGCTGA	6550
	CAGAAAATGC CTGGTCCAA CATCCTCACC AGGCGAGCAC GATCGGCATG	6600
	CTACGCTCCA TCCGCCGGGA GCATCCTGAC TTGGGAGTTTC ATGTTCTGGA	6650
15	CGTCGACGCG GTTGAACCT TCGATGCAAC CTTCTGGTT GAACAGGTGC	6700
	TTCGGCTTGA GGAGCAATACG GATGAGCTGG CCAGTTCAAC TACATGGACT	6750
	CAAGAACCCG AGGTCTCCTG GTGTAAAGGC CGCCCGTGGA TTCTCGTCT	6800
	GAAGCGCGAT CTGGCTCGCA ATAACCGAAT GAACTCCTCG CGCCGTCCCA	6850
	TATACGAGAT GATGGATTG TCGCGGGCTC CCGTGGCATT ACAGACGGCT	6900
20	CGGGATTCAT CATCCTACTT CTTGGAGTCC GCTGAAACCT GTTTTGTGCC	6950
	TGAGAGTGTGTT CAGCAGATGG AAACAAAGAC GATCTATGTC CACTTTAGCT	7000
	GTCCCCATGC GCTTAGGGTC GGACAGCTCG GGTTTTCTA TCTTGTGCAG	7050
	GGTCACGTCC AGGAGGGCAA TCGCGAAGTG CCCGTCGTGG CCTTAGCAGA	7100
	GCGTAACGCA TCCATTGTGC ACGTTCGTCC CGATTATATA TATACTGAGG	7150
25	CAGATAACAA TCTGTCTGAG GGTGGTGGCA GCCTTATGGT AACCGTCCTC	7200
	GCCGCAGGGGG TGTTGGCGGA GACGGTGATC AGTACCGCCA AGTGCCTGGG	7250
	GGTAACTGAC TCAATCCTCG TTCTGAATCC CCCCAGCATA TGTGGGCAGA	7300
	TGTTGCTCCA TGCTGGTGAA GAGATCGGTC TTCAAGTTCA TCTGGCCACC	7350
	ACTTCTGGCA ACAGGAGTTTC GGTTTCTGCT GGAGACGCCA AGTCCTGGCT	7400
30	AACATTGGCAT GCTCGCGACA CGGACTGGCA CCTGGCACGG GTACTGCC	7450
	GGGGTGTCCA GGCTTAGTC GACTTATCAG CCGACCAGAG CTGTGAAGGT	7500
	TTGACTCAGA GGATGATGAA AGTTCTGATG CCTGGCTGTG CCCATTACCG	7550
	TGCGGCAGAC CTGTTACAG ACACCGTTTC CACTGAATTG CATAGCGGAT	7600
	CGCGGCATCA AGCTTCAGTCCC CGGCGCGCAT ATTGGGAGCA TGTGGTATCC	7650
	TTAGCCCCGCC AGGGACTTCC TAGTGTCAAGC GAGGGGTGGG AGGTGATGCC	7700
	GTGCACTCAA TTTGCAGCGC ATGCCGACAA GACCGGCCCG GATCTCTCGA	7750

- 71 -

	CAGTTATTTC CTGGCCCCGG GAGTCGGACG AGGCTACGCT TCCTACCAGG	7800
	GTTCGCTCCA TTGACGCTGA GACCCTCTT GCGGCCGACA AAACATATCT	7850
	CCTGGTCGGA CTGACTGGAG ATCTTGGACG ATCACTAGGT CGTTGGATGG	7900
5	TCCAGCATGG GGCCCTGCCAC ATTGTACTTA CGACCAGAAA TCCGCAGGTG	7950
	AACCCCAAGT GGCTGGCGCA TGTTGAAGAA CTGGGTGGTC GAGTCACTGT	8000
	TCTTTCCATG TAAGAGGAGT CCTTCCTTCT GCAATTCCCTC CTTATGATCC	8050
	CGACTAACGC AGCTGGCTTC AGGGACGTGA CAAGCCAAA CTCAGTGGAA	8100
	GCTGGCCTGG CTAAACTCAA GGATCTGCAT CTGCCACCAG TGGGGGTAT	8150
10	TGCCTTTGGC CCTCTGGTTC TGCAGGATGT GATGCTAAAT AATATGGAAC	8200
	TGCCAATGAT GGAGATGGTG CTCACCCCCA AGGTGGAAGG CGTCCGCATC	8250
	CTGCACGAGA AGTTCTCCGA TCCGACCAGT AGCAACCCCTC TCGACTTCTT	8300
	CGTGATGTTTC TCCTCGATTG TGGCCGTCAT GGGCAACCCG GGTCAGGCTA	8350
	ACTACAGTGC GGCTAACTGC TACCTTCAAG CGCTGGCGCA GCAGCGAGTT	8400
15	GCATCCGGAT TAGCAGTACG TTTTCACTCC ATCCTTGTGCT AAACACTCCT	8450
	ATGGGCCTTT ACTAAACCGG GCAGGGCGTCC ACCATCGACA TCGGTGCCGT	8500
	GTACGGCGTT GGGTCGTCA CTCGGGCGGA GCTGGAGGAG GACTTTAATG	8550
	CAATTGGTT CATGTTCGAT TCGGTTGAGG AACATGAACT GCATACACTG	8600
	TTTGCTGAGG CAGTGGTGGC CGGTCGACGA GCCGTGCACC AGCAAGAGCA	8650
20	GCAGCGGAAG TTCGGGACAG TGCTCGACAT GGCTGATCTG GAACTGACAA	8700
	CCGGAATTCC GCCCCTGGAT CCAGCCCTCA AAGATCGGAT CACCTTCTTC	8750
	GACGACCCCC GCATAGCAA CTTAAAAATT CCGGAGTACC GAGGGGCCAA	8800
	AGCAGGCGAA GGGGCAGCCG GCTCCAAGGG CTCGGTCAAA GAACAGCTCT	8850
	TGCAGGGCGAC GAACCTGGAC CAGGTCCGTC AGATCGTCAT CGGTAAGTTG	8900
25	AGCGAATCCG GGGAAATATTC TCCCCTTCCT CACTCAGCGG ACTGGAGATT	8950
	AACCGCTTCT TTTCCTTTGG CAGATGGACT CTCCGGGAAG CTGCAGGTGA	9000
	CCCTGCAGAT CCCCGATGGG GAAAGCGTGC ATCCCAACCAT CCCACTAATC	9050
	GATCAGGGGG TGGACTCTCT GGGCGCGGTC ACCGTGGAA CCTGGTTCTC	9100
	CAAGCAGCTG TACCTTGATT TGCCACTCCT GAAAGTGCCTT GGGGGTGCCTT	9150
	CGATCACCGA TCTCGCTAAT GAGGCTGCTG CGCGATTGCC ACCTAGCTCC	9200
30	ATTCCCCCTCG TCGCAGCCAC CGACGGGGGT GCAGAGAGCA CTGACAATAC	9250
	TTCCGAGAAT GAAGTTTCGG GACGGGAGGA TACTGACCTT AGTGCCGCCG	9300
	CCACCATCAC TGAGCCCTCG TCTGCCGACG AAGACGATAAC GGAGCCGGC	9350
	GACGAGGACG TCCCGCGTTC CCACCATCCA CTGTCCTCTCG GGCAAGAATA	9400
	CTCCTGGAGA ATCCAGCAGG GAGCCGAAGA CCCCACCGTC TTTAACAAACA	9450
	CCATTGGTAT GTTCATGAAG GGCTCTATTG ACCTTAAACG GCTGTACAAG	9500

- 72 -

	GGCGTTGAGAG CGGTCTTGC CGGCCACGAG ATCTTCCGCA CGGGGTTTG CAAACGTGGAT GAGAACGGGA TGGCCCAGCT GGTGTTTGGT CAAACCAAAA ACAAAGTCCA GACCATCCAA GTGTCTGACC GAGCCGGCGC CGAAGAGGGC TACCGACAAC TCGTGCAGAC ACGGTATAAC CCTGCCGCAG GAGACACCTT	9550
5	CGGGCTGGTG GACTTCTTCT GGGGCCAGGA CGACCACATCTG CTGGTTGTGG CTTACCACCG ACTCGTCGGG GATGGATCTA CTACAGAGAA CATCTTCGTC GAAGCGGGCC AGCTCTACGA CGGCACGTCG CTAAGTCCAC ATGTCCCTCA GTTTGC GGAC CTGGCGGCAC GGCAACGCGC AATGCTCGAG GATGGGAGAA	9750
	TGGAGGAGGA TCTCGCGTAC TGGAAGAAAA TGCATTACCG ACCGTCCCTCA ATTCCAGTGC TCCCACGTAT GCGGCCCCCTG GTAGGTAACA GTAGCAGGTC	9900
10	CGATACTCCA AATTTCAGC ACTGTGGACC CTGGCAGCAG CACGAAGCCG TGGCGCGACT TGATCCGATG GTGGCCTTC GCATCAAGGA GCGCAGTCCG AACACACAAGG CGACGCCGAT GCAGTTCTAT CTGGCGCGT ATCAGGTGCT GTTGGCGCGC CTCACCGACA GCACCGATCT CACCGTGGGC CTCGCCGACA	9950
	CCAACCGTGC GACTGTGAC GAGATGGCGG CCATGGGTT CTTGCCAAC CTCCCTCCCC TGCGCTTCCG GGATTTCCGC CCCCATATAA CGTTTGGCGA GCACCTTATC GCCACCCGTG ACCTGGTGCG TGAGGCCTTG CAGCACGCC GCGTGCCTA CGGCCTCCCTC CTCGATCAAC TGGGGCTGGA GGTCCCGGTC	10000
15	CCGACCAGCA ATCAACCTGC GCCTTTGTTC CAGGCCGTCT TCGATTACAA GCAGGGCCAG GCGGAAAGTG GAACGATTGG GGTCGCCAAG ATAACCGAGG TGATTGCCAC GCGCGAGCGC ACCCCTTACG ATGTCGTGCT GGAGATGTG GATGATCCCA CCAAGGATCC GCTGCTCAGG GCCAAGTTAC AGAGTTCCCC CTACGAGGCT CACCACCCCTC AAGCCTTCTT GGAGAGCTAC ATGTCCCTTC	10050
	TCTCTATGTT CTCGATGAAT CCCGCCCTGA AGCTGGCATG ATGGCGAAA CATAGAACAT GATAGCGCAG CAGGGACGAT GTAGATAGAG CTTTGCTTCT	10100
20	GGCGGTGGAT CTATAATATA GTATATATAA ATATGGTGAG CGAACGAAAG AGGGGGGAAT GCCACAATTAA TTTACTGTTT TGCCCGTAC ACGAGGAGAA GACGTCCAGA ACAACATAAA TATATCACTC TAGTGAGACA CCATATATTC GGAGAGACTA TAAAAATATA CATCTACTCC AATGTCGTGGG CCGTCACACA	10150
	CAGCTTACGA AAACGATTAA TGACCTCCAA CACGTGCGC GGTCGATTGG GAAACTGATG CTGCCAGCA AACTCCAATA CCTGCCCTC TCGGGGGGAG AAATGGCGCG CCACCAAGCAT CTTCGATCCT GCGAGCGCAA AATCATCGCG ACCCCTGCAGA TGTAATGTG GTATCCGAAT GACCAGTTCC TCCTGCCACT	10200
25	CGGTATCTT GCTGTCGTTG TCGTCGTAC GGTTCTTCAT CATTGTTCC TCATATACTG GCTTGCCCTCG TCTTGATACC AGGGACAGAT CAACAGCGCA	10250
		10300
		10350
		10400
		10450
30		10500
		10550
		10600
		10650
		10700
		10750
		10800
		10850
		10900
		10950
		11000
		11050
		11100
		11150
		11200
		11250

- 73 -

ACACTCATCC	GGGGCAACCA	GGGCAGGTGA	CCCATCTGCT	GCTGCCAGAG	11300
GAGCAAGGTC	GTCACCAGGG	CACCTTCGGA	GAAACCGATA	GCACCCACGA	11350
TAGGGATGTG	GGGGTGTGTA	GTCTGCCAGT	CGACAATGGT	GCGGCGGATG	11400
GGGTCGTGGA	CGGCGGCGAG	GCGTCGCTC	ACGGAGGGTC	CATTATGATT	11450
5	GTIGTCGCTG	CTGCTTCAA	ACCAAGGAGTA	ATATGGCCCT	AGGTGGCGGA
GTIGTCGCTG	CTGCTTCAA	ACCAAGGAGTA	ATATGGCCCT	AGGTGGCGGA	11500
AGACGGGGAG	AATCCCAGGC	CCTGCAGAGG	AAGGAAACGG	AGCTGTCACG	11550
TAGACGAATT C	(SEQ ID NO:1)				11561

10 5. The purified DNA molecule of Claim 1 having the sequence shown in Figure 1.

15 6. An expression vector for the expression of cloned genes in a host cell, the expression vector containing the DNA molecule of Claim 1.

20 7. The expression vector of Claim 6 wherein the host cell is a fungal cell.

25 8. The expression vector of Claim 6 which is designated pTPKS100 (ATCC 69416).

9. The expression vector of Claim 6, wherein the DNA molecule has the sequence of Figure 1.

25 10. A host cell containing the purified DNA molecule of Claim 1.

30 11. Purified triol polyketide synthase encoded by the DNA of Claim 1.

12. The triol polyketide synthase of Claim 11 having an amino acid sequence of

MAQSMYPNEP	IVVVGSGCRF	PGDANTPSKL	WELLQHPRDV	QSRIPKERFD	50
VDTFYHPDGK	HHGRTNAPYA	YVLQDDLGAF	DAAFFNIQAG	EAESMDPQHR	100

- 74 -

	LLLETVYEAV TNAGMRIQDL QGTSTAVYVG VMTHDYETVS TRDLESIPTY	150
	SATGVAVSVA SNRISYFFDW HGPSMTIDTA CSSSLVAVHL AVQQLRTGQS	200
	SMAIAAGANL ILGPMTFVLE SKLSMLSPSG RSRMWDAGAD GYARGEAVCS	250
	VVLKTLSQL AL RDGDTIECVI RETGVNQDGR TTGITMPNHS AQEALIKATY	300
5	AQAGLDITKA EDRCQFFEAH GTGTPAGDPQ EAEAIATAFF GHEQVARSDG	350
	NERAPLFVGS AKTVVGHTEG TAGLAGLMKA SFAVRHGVIP PNLLFDKISP	400
	RVAPFYKNLR IPTEATQWPA LPPGQPRRAS VNSFGFGGTN AHAIIEEYME	450
	PEQNQLRVSN NEDCPPMTGV LSLPLVLSAK SQRSLKIMME EMLQFLQSHP	500
	EIHLHDLTWS LLRKRSVLPF RRAIVGHSHE TIRRALEDAI EDGIVSSDFT	550
10	TEVRGQPSVL GIFTGQGAQW PGMLKNLIEA SPYVRNIVRE LDDDSLQSLPE	600
	KYRPSWTLLD QFMLEGASN VQYATFSQPL CCAVQIVLVR LLEAARIRFT	650
	AVVGHSSGEI ACAFAAGLIS ASLAIRIAYL RGVVSAGGAR GTPGAMLAAG	700
	MSFEEAQEIC ELDAGEGRIC VAASNPDSV TFSGDANAID HLKGMLEDES	750
	TFARLLKVDT AYHSHHMLPC ADPYMQALEE CGCAVADAGS PAGSVPWYSS	800
15	VDAENRQMAA RDVTAKYWKD NLVSPVLFSH AVQRAVVTHK ALDIGIEVGC	850
	HPALKSPCVA TIKDVLSGVD LAYTGCLERG KNDLDSFSRA LAYLWERFGA	900
	SSFDADEFMR AVAPDRPCMS VSKLLPAYPW DRSSRYWVES RATRHHLRGP	950
	KPHLLLGKLS EYSTPLSFOW LNFVRPRDIE WLDGHALQGQ TVFPAAHYIV	1000
	MAMEAALMIA GTHAKQVKLL EILDMSIDKA VIFDDEDSLV EINLTADVSR	1050
20	NAGEAGSMTI SFKIDSCLSK EGNLSSLAKG QLALTIEDVN PRTTSASDQH	1100
	HLPPPEEEHP HMNRVNINAF YHELGLMGYN YSKDFRRLHN MQRADLRASG	1150
	TLDIFIPLMDE GNGCPLLHP ASLDVAFQTV IGAYSSPGDR RLRCLYVPTH	1200
	VDRITLVPSL CLATAESGCE KVAFNTINTY DKGDYLSGDI VVFDAEQTTL	1250
	FQVENITFKP FSPPDASTDH AMFARWSWGP LTPDSLLDNP EYWATAQDK	1300
25	AIPPIERIVY FYIRSFLSQL TLEERQQAAF HLQKQIEWLE QVLASAKEGR	1350
	HLWYDPGWEN DTEAQIEHLC TANSYYPHVR LVQRVGQHLL PTVRSGNPNF	1400
	DLLHDGGLT EFYTNTLSFG PALHYARELV AQIAHRYQSM DILEIGAGTG	1450
	GATKYVLATP QLGFNSYTYT DISTGFFEQA REQFAPFEDR MVFEPLDIRR	1500
	SPAEGQFEPH AYDLIIASNV LHATPDLEKT MAHARSLLKP GGQMVILEIT	1550
30	HKEHTRLGFI FGLFADWWAG VDDGRCTEPF VSFDRWDAIL KRVGFSGVDS	1600
	RTTDRDANLF PTSVFSTHAI DATVEYLDAP LASSGTVKDS YPPLVVVGGQ	1650
	TPQSQRLLND IKAIMPPRPL QTYKRLVDLL DAEELPMKST FMLTELDEE	1700
	LFAGLTEETF EATKLLLTYA SNTVWLTEA WVQHPHQAST IGMLRSIRRE	1750
	HPDLGVHVLD VDAVETFDAT FLVEQVLRLE EHTDELASST TWTQEPEVSW	1800
	CKGRPWIPLR KRDLARNRNM NSSRRPIYEM IDSSRAPVAL QTARDSSSYF	1850

- 75 -

	LESAETWFVP ESVQQMETKT IYVHFSCPH A LRVGQLGFFY LVQGHVQEGN	1900
	REVPVALAE RNASIVHVRP DYIYTEADNN LSEGGGSILMV TVLAAAVLAE	1950
	TVISTAKCLG VTDSILVLNP PSICGQMLH AGEEIGLQVH LATTSGNRSS	2000
	VSAGDAKSWL TLHARDTDWH LRRVLPRGVQ ALVDLSADQS CEGLTQRMMK	2050
5	VLMPGCAHYR AADLFTDTVS TELHSGSRHQ ASLPAAYWEH VVSLARQGLP	2100
	SVSEGWEVMP CTQFAAHADK TRPDLSVTIS WPRESDEATL PTRVRSIDAE	2150
	TLFAAADKTYL LVGLTGDLLGR SLGRWMVQHG ACHIVLTSRN PQVNPWKLAH	2200
	VEELGGRVTV LSMDVTSQNS VEAGLAKLKD LHLPPVGGIA FGPLVLQDVM	2250
10	LNNMELPMME MVLPNPKVEGV RILHEKFSDP TSSNPLDFV MFSSIVAVMG	2300
	NPGQANYSA A NCYLQALAQQ RVASGLAAST IDIGAVYVG FVTRAELEED	2350
	FNAIRFMFDS VEEHELHTLF AEAVVAGRRA VHQQEQQRKF ATVLDMADE	2400
	LTGIPPLDP ALKDRITFFD DPRIGNLKIP EYRGAKAGEG AAGSKGSVKE	2450
	QLLQATNLDQ VRQIVIDGLS AKLQVTLQIP DGEHSVHPTIP LIDQGVDSL	2500
15	AVTVGTWFSK QLYLDLPLLK VLGGASITDL ANEAAARLPP SSIPLVAATD	2550
	GGAESTDNTS ENEVSGREDT DLSAAATITE PSSADEDDTE PGDEDVPRSH	2600
	HPLSLGQEYS WRIQQGAEDP TVFNNTIGMF MKGSIDLKRL YKALRAVLRR	2650
	HEIFRTGFAN VDENGMQLV FGQTKNKVQT IQVSDRAGAE EGYRQLVQTR	2700
	YNPAAGDTLR LVDFFWGQDD HLLVVAYHRL VGDGSTTENI FVEAGQLYDG	2750
20	TSLSPHVPQF ADLAARQRAM LEDGRMEEDL AYWKKMHYRP SSIPVLPLMR	2800
	PLVGNSSRSD TPNFQHCGPW QQHEAVARLD PMVAFRIKER SRKHKATPMQ	2850
	FYLAAYQVLL ARLTDSTDLT VGLADTNRAT VDEMAAMGFF ANLLPLRFRD	2900
	FRPHITFGEH LIATRDLVRE ALQHARVPYG VLLDQLGLEV PVPTSNQPAP	2950
	LFQAVFDYKQ GQAESGTIGG AKITEVIATR ERTPYDVVLE MSDDPTKDPL	3000
25	LTAKLQSSRY EAHHPQAFLE SYMSLLSMFS MNPALKLA (SEQ ID NO:2)	3038

13. The triol polyketide synthase of Claim 11 having the amino acid sequence of Figure 2.

30 14. An antibody which is immunologically reactive with the triol polyketide synthase of Claim 10.

15. A process for producing HMG-CoA reductase inhibitors, comprising:

- (a) transforming a cell with the DNA molecule of Claim 1;

- 76 -

- (b) cultivating the transformed cell under conditions that permit the expression of the DNA molecule; and
- (c) recovering the HMG-CoA reductase inhibitor.

5

16. The process of Claim 16 wherein the HMG-CoA reductase inhibitors are selected from the group consisting of lovastatin, simvastatin, pravastatin, triol and compactin.

10

17. The process of Claim 16 wherein the culture is selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp. M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

15

18. A method of isolating DNA encoding polyketide synthase, comprising:

20

- (a) hybridizing the DNA of Claim 1 to a sample, the sample containing DNA encoding polyketide synthase, to form a complex; and
- (b) purifying the complex.

25

19. The method of Claim 19 wherein the sample is derived from a microorganism, the microorganism being selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

30

20. Purified nucleic acid encoding functional triol polyketide synthase which is capable of hybridizing with nucleic acid encoding triol polyketide synthase under low stringency conditions

- 77 -

comprising incubating or washing with about 0.15 M sodium chloride and about 0.015 M sodium citrate at about 20°- 55°C or its equivalent.

5

10

15

20

25

30

CTGCAGTCAA CGGATCACTT ACCATTGCTG TCGCCAAAAA TATCCGTGAT AATCCCGCTG	60
GCTTCATTGG CAAGAGGCTT GACGTTACTTG GGAGCCTTGGG TCTGGAACTG GTTCATAACC	120
ACCTTGTGTA TGAGATGTGC ATCCCTCGTG ACTTCCCTTGA ATCCATCGAA TCCGGGAAGA	180
TGAGAGTGAA AGTCCTGTGATG AGAGCACGAA GATCAGTAAG TCAGGTCCTC ACAGGGAAAG	240
CAGTTGCCAA GAACGGTGGAA CTCCTTACCG GCCATAGAGG AGGGAAAGAAT GGTGCAGTAC CCAGAGTCGA	300
TCATCTTGGG AAACCTCATCG TCATTTGGG AGAACCCAGCT CTCAAATCCAT GACGGTGCAT	360
CTATGAAACCG AATGGGCTTA TCATTTGGG AGAACCCAGCT CTCAAATCCAT GACGGTGCAT	420
TCGCATCAAA ATCCCCTTTG GCCCTCATGG TCGTCAGTTC CCACCATGTT TTGGATGTA	480
ACACCGGCAG ATCAGATCTC CGGCCCACTCG AGCACAGGTA AAGAACAGG CATACTAGCC	540
CCGCACTTGGT AGTCACCAAG GGGCAAAACC ACGAGCCATG TTGCTGCGTG TCATTCCAAG	600
CCAGGGACAG AAGGTGGTGC GGCTGTGTGA GGGCGTCGAC AGTCATGGCT AGGAGACCAAG	660
GTGTGGTGA CGGATAAGAT ATCGAGAGTG ATGTGACCAA AAGATCCGGG AAAGGTGGCC	720

SUBSTITUTE SHEET (RULE 26)

FIG. 1A

2 / 30

AAGGAAAGGG CGTCTCTCTT ACCAACAAAG TCTGTTCCCT ATCATGCAAT CACCGCTTGC	780
TGTACCGGTGC TGATGATGCT GGGATGGTGG TGGGTCCCCA CCGAATAACG CCGGACAGCT	840
GTTGAAGCCG AATGACGCCG GCAGGCCAA AGAACCCCTAC CTTCACTTAC <u>TCAATCGGGCG</u>	900
CTTCCCTCC TATCACCAA TCGGATGTAA ATGCACGGGC <u>CTTAATAGGC</u> ACCGGCCGG	960
CGGGAATCC CAAACGTAG ATAGATAGGC ATAGACCCGA AATCTTGGC CCGGCATACA	1020
TGAGCACAGG AAGTTTACCG CGACGGGCC TTTCCTGCCT CAGCTTCAAT CCAAGCTTCAC	1080
GAGTTCTGTC GCCTCTATCA GTCCGTGCAAT TGTCCCTACTG CAAACAGCAT <u>GGCTCAATCT</u>	1140
ATGTATCCTA ATGAGCCTAT TGTCTGGTC GGCAGTGGTT GTCGCTTCCC TGGTGACGCC	1200
AACACACCCT CCAAGCTCTG GGAGCTACTC CAGCATCCCTC GCGATGTGCA GAGTCGAATC	1260
CCCAAAGAAC GATTGACGT CGACACATT TATCACCGG ACGGGAAGCA CCACGGCCGA	1320
ACAAATGCAC CCTACGCCCTA TGTCTCCAA GACGATCTGG GCGCCTTCGA TGGGGCCTTC	1380
TTCAATATCC AGGCTGGAGA GGGCGAGACT ATGGACCCCC AGCACCGGCT GTTGCTGGAG	1440

SUBSTITUTE SHEET (RULE 26)

FIG. 1B

ACGGCTGTACG AGGCCGTAAC GAATGCTGGAA ATGCGTATCC AGGATCTGCA GGGAAACTTCG 1500
ACTGCTCTT ACGTCGGGT GATGACGGCAC GACTATGAGA CTGTCCTAAC CCGCGACCTG 1560
GAGAGCATCC CCACCTACTC GGGGACGGGT GTCCGGGTCA GTGTTGCCGTC CAACCGCATC 1620
TCGTATTTT TTGACTGGCA TGGACCCAAGT GTAAGTCACC CAATATCGTG TAGCAGTCTA 1680
ATCATGCTCT AACGGACCGG GATGGTTGAA AGATGACGGAT CGATAACGGCA TGCAGCTCGT 1740
CGTTGGTTGC CGTTCATCTG GCGGTGCAAC AGCTACGGAC GGCTCAAGGC TCCATGGCAA 1800
TTCGCTGGGG TCGGAATCTG ATTCTGGGGC CCATGACATT CGTCCTTGAA AGCAAATTGA 1860
GCATGCTATC CCCCTCGGGT CGATCCGGCA TGTGGACCC CGGAGCTGAC GGCTATGCCA 1920
GAGGGGTGAG TGTTCCTTGA GCTCGTAGAT GACAGTTCCC ATCGCTGACC GTGATCAGGA 1980
AGCTGTTTGC TCTGTAGTGT TGAAGACATT GAGTCAAAGCC TTGCGGGATG GGGACACCGAT 2040

SUBSTITUTE SHEET (RULE 26)

FIG. 1C

4 / 30

TGAATGTC ATCCGAGAA CTGGGTGAA TCAAGATGCC CGAACGACCG <u>GAATTACGAT</u>	2100
GCCGAACC <u>AT</u> AGTGCCTCAGG AGCCACTCAT CAAGGCTTACCC TACGCCAGG CTGGCCCTTGA	2160
CATCACCAAG GCCGAGGACA GGTGCCAATT CTTCGAGGCT CATGGTCAGC AAAGAGAACCC	2220
TGTTCTGTG GGGCCCTGCA GCTGACATTC GTATGATAGG GACTGGTACT CGGGCCGGAG	2280
ATCCCAGGA GGGGAGGCC ATTGAAACAG CCTTCTTCGG CCACGAGCAG GTAGCACGCCA	2340
GCGACGGAA CGAGGGGCC CCTCTGTTCG TGGCAGTGC GAAAATCTT GTCCGGCACA	2400
CCGAGGGCAC GGCCGGCTG CCTGGTCTCA TGAAGGGCTC GTTCGGCTGTC CGCCATGGGG	2460
TAATCCCCC CAACCTGCTG TTGACAAAA TCAGCCCCG AGTCGGCCCA TTCTATAAAA	2520
ACCTGAGGAT TCCGACAGAA GCTACCCAAAT GGCCAGCTCT CCCACCCGGA CAACCGGCC	2580
GCGCCAGTGT CAACTCCCTT GGTAAAGCGAG GATTGCCCGG AGGAACCTC ACAAGTACTC	2640

FIG. 1D

SUBSTITUTE SHEET (RULE 26)

GAATTAAATGC TAACTGAACC GCGCCGATGG ACAGGATTTCG GCGGCCACGAA TGCGCATGCC	2700
ATTATGAGG AATACATGGA GCCAGAGCAA AACCCAGCTGC GAGTCTCGAA TAATGAGGAC	2760
TGCCAACCCA TGACCCGGGT CCTGAGTTA CCCTTAGTCC TCTCGGGAA GTCCCCAGCGC	2820
TCCTAAAGA TAATGATGGA GGAGATGCTG CAATTCCCTTC AGTCTCACCC CGAGATAACAC	2880
TTGCACCGACC TCACCTGGTC CTTACTGGCC AACCCGGTCAG TTCTACCCCTT CGGGCGGGCT	2940
ATTGTCTGGCC ATAGTCATCA AACCATCCGC CGGGCTTGG AGGATGCCAT CGAGGATGGT	3000
ATTGTCTCGA GCGACTTCAC TACGGAGGTC AGAGGCCAGC CATCGGTGTT GGGAAATCTTC	3060
ACCGGGCAGG GGGCGGCAGTG GCCGGGGATG TAAAGAATC TGATAGAGGC ATCGCCATAT	3120

FIG. 1E

GTGGGAACA TAGTGAGGA GCTGGACGAC TCCCTGCAGA GCTTGGCGGA AAAATAACGG 3180
CCCTCTGGGA CGCTTAATCGA CCAGTTCATG CTAGAAGGAG AGGCCTCCAA CGTCCAATAT 3240
GCTACTTTCT CCCAGCCATT ATGCTGGCG GTGCAAATTG TCCTGGTCCG TCTCCTTGAA 3300
GCCGGAGAA TACGATTCAC GGCTGTTGTT GGACATAGCT CCCGGAAAT TGCTTGGGCC 3360
TTTGCTGCCG GGCTCATCAG TGCCTCGTGC GCGATTGGGA TTGCTTACTT ACGTGGAGTC 3420
GTCTCGGCAG GGGGGCCAG AGGCACACCG GGAGCCATGT TGGCCGCCGG GATGTCCTTT 3480
GAGGAAGCAC AACAGATCTG CGAGTTGGAT GCCTTGGAGG GCCGGCATCTG CCTGGCTGCC 3540
ACCAATTCCC CAGACAGTGT AACTTTCTCT GCGGACCGA ACGCAATTGA TCACCTGAAG 3600
GGCATGTTGG AGGATGACTC CACTTTGG AGACTGCTCA AGGTGATAAC AGCGTACCCAC 3660

6/30
FIG. 1F

7 / 30

TCGCATATA	TGCTTCCATG	TGCAGACCCA	TATATGCAAG	CCCTAGAAAGA	GTGTGGTTGTTGT	3720
GCTGTTGCCG	ATGCAGGTTTC	CCCAGCCCGA	AGTGTACCCCT	GGTATTTCGTC	CGTGACGCC	3780
GAGAACGGC	AAATGGCAGC	AAGAGACCTG	ACCGCCAAGT	ACTGGAAAGA	TAACCTTAGTA	3840
TCTCCGGTGC	TATTCTCCCA	CGCAGTGCAG	CGGGCAGTCG	TCACGGCACAA	GGCCGCTGGAT	3900
ATCGGGATTC	AAGTGGCTG	TCACCCAGCT	CTCAAGAGGCC	CATGGGTGCC	CACCATCAAG	3960
GATGTCCTAT	CTGGGGTTGA	CCTGGGTAT	ACAGGGTGC	TGGAGGCCAGG	AAAGAAATGAT	4020
CTCGATTCAT	TCTCTCGAGC	ACTGGCATAT	CTCTGGAAA	GTTTGGTGC	CTCCAGTTTC	4080
GATGGGACG	AGTTCATGG	TGCAGTGGC	CCTGATGCC	CCTGTATGAG	TGTGTGCGAAG	4140
CTCCCTACCGG	CCTATCCATG	GGACCGCTCT	CGTCGCTACT	GGGTGGAATC	CCGAGGAACT	4200

FIG. 1G

SUBSTITUTE SHEET (RULE 26)

CGCCACCATC TTGAGGGCC CAAGCCCCAT CTTCTATTAG GAAAGCTCTC CGAATAACAGC	4260
ACTCCGCTAA GCTTCCAGTG GCTGAATT TT GTGCCAAC GAGACATTGA ATGGCTTGAT	4320
GGACATGCAT TGCAAGGCCA GACTGTCTTC CCTGGCCCG GCTATATCGT CATGCCAATG	4380
GAAGCCAGCCT TAATGATTGC TGGCACCCAC GCAAAGCAGG TCAAGTTACT GGAGATCTTG	4440
GATATGAGCA TTGACAAGGC GGTGATATT GACGACGAAG ACAGCTTGGT TGAGCTAAC	4500
CTGACAGCTG ACGTGTCTCG CAACGCCGGC GAAGCAGGTT CAATGACCAT AAGCTTCAAG	4560
ATCGATTCCCT GTCTATCGAA GGAGGGTAAC CTATCCCTAT CAGCCAAGGG CCAACTGGCC	4620
CTAACCGATAG AAGATGTCAA TCCCAGGACG ACTTCCGCTA GCGACCCAGCA CCATCTTCCC	4680
CCCCCAGAAG AGGAACATCC TCATATGAAC CGTGTCAACA TCAATGCTTT CTACCAACGAG	4740
CTGGGGTTGA TGGGTACAA CTACAGTAAG GACTTCCGGC GTCTCCATAA CATGCAACGA	4800

FIG. 1H

GCAGATCTC GAGCCAGGG CACCTTAGAC TTCATTCTC TGATGGACGA GGCGTAATGGC 4860
TGCTGCATCC TGCATCATTC GACGTCGCCCT TCCAGACTGT CATCGGGCGCA 4920
TACTCCCTCC CAGGTGATCG CGCTCTACGGC TGTCTGTATG TACCCACTCA CGTTTGATCGC 4980
ATCACACTTG TCCCATTCCCT TTGCTGGCA ACGGCTGACT CCGGATGCCA GAAGGGTGGCC 5040
TTCAAACTA TCAATACGTA CGACAAGGA GACTACTTGA GCGGTGACAT TCTGGTCTTT 5100
GACGGGAGC AGACCAACCT GTTCCAGGT GAAAATATA CTTTAACCC CTTTTCACCC 5160
CCGGATGCTT CAACTGACCA TGGGATGTT GCCCGATGGA GCTGGGTCC GTTGACTCCG 5220
GACTGGCTGC TGGATAACCC GGAGTATTCG GCCACCGGGC AGGACAAAGGA GCGGATTCCCT 5280

9/30

FIG. 11

SUBSTITUTE SHEET (RULE 26)

10 / 30

ATTATCGAAC GCATCGTCTA CTTCTATATC CGATCGTTCC TCAGTCAGCT TACGCTGGAG 5340
GAGGCCAGC AGGCAGCCTT CCATTGCGAG AAGCAGATCG AGTGGCTCGA ACAAGTCCTG 5400
GCCAGGCCA ACGAGGCTCG TCACCTATCG TACGACCCCG GGTGGGAGAA TGATACTGAG 5460
GCCAGCAGATTG AGCACCCTTG TACTGCTAAC .TCCTTACCAAC CTCATGTTCG CCTGGTTCAG 5520
CGAGTCGGCC AACACCTGCT CCCAACCGTA CGATCGAACG GCAACCCATT CGACCTTCTG 5580
GACCACGATG GGCTCCTGAC GGAGTTCTAT ACCAACACAC TCAGCTTCGG ACCCGCACTA 5640
CACTACGCC CGGAAATTGCTT GGCCAGATIC GCCCATCGCT ATCAGTCATAAT GGATATTCTG 5700
GAGATTGGAG CAGGGACCGG CGGGCTTACCA AAGTACGTTG TGGCCACGCC CCAGCTGGGG 5760
TTCAACAGCT ACACATACAC CGATATCTC ACCGGATTCT TCGAGCAAGC GGGGGAGCAA 5820
TTTGCCTTCTT TCGAGGACCG GATGCTGTT GAACCCCTCG ATATCCGCCG CAGTCCCGCC 5880

SUBSTITUTE SHEET (RULE 26)

FIG. 1J

11 / 30

GAGCAGGGCT TCGAGCCGA TGCCTATGAT CTGATCATG CCTCCAATGT GCTACATGCG	5940
ACACCCGACC TAGAGAAC CATGGCTCAC GCCCGCTCAC TGCTCAAGCC TCGAGGCCAG	6000
ATGGTTATTTC TGGAGATTAC CCACAAAGAA CACACACGGC TCGGGTTAT CTTTGGTCTG	6060
TTCCGGCACT GGTGGCTGG GGTGGATGAT GGTCGCTGCA CTGAGCCGTT TGTCTCTGTC	6120
GACCGCTGGG ATGCGATCCT AAAGCGTGTG GGGTTTTCG GTGTTGGACAG TCGCACCCAG	6180
<u>GATCGGGACG CAAATCTATT CCCGACCTCTT</u> GTGTTAGTA CCCATGCAAT TGACGCCACC	6240
GTGGACTACT TAGACGGCCC GCTGCCAGC AGGGGACCG TCAAGGACTC TTACCCCTCCC	6300
TTGGTGGTAGGAGGGCA GACCCCCAA TCTCAGGGTC TCCTGAACGA TATAAAAGCG	6360
ATCATGCCCTC CTCGTCCGCT CCAGACATAC AAGGGCCTCG TGATTTGCT AGACGGGAG	6420
GAGCTGCCGA TGAAGTCCAC GTTGTCACTG CTCACGGAGC TGGACGGAGA ATTATTGCC	6480

FIG. 1K

12/30

GGCCTCACTG AAGACGACCTT CGAGGCCAACC AAGCTGTGC TCACCGTACGC CAGCAAATACG	6540
GTCCTGGCTGA CAGAAATGCG CTGGCTCCAA CATCCTCACCC AGGGGACCC GATCGGGCATG	6600
CTACGCTCCA TCCGCCGGGA GCATCCTGAC TTGGGAGTTC ATGTTCTGGA CGTCGACGGCG	6660
GTGAAACCT TCGATGCAAC CTTCCCTGGTT GAACAGGTGC TTrCGGCTTGA GGAGCAATACG	6720
GATGAGGCTGG CCAGTTAAC TACATGGACT CAAGAACCCG AGGTCTCCTG GTGTAAAGGC	6780
CGCCCGTGGAA TTCCTCGTCT GAAGGGCGAT CTGGCTCCCA ATAACCGAAT GAACTCCTCG	6840
CGCCGTCCTA TATACGAGAT GATCGATTG TCCGGGGCTC CGGTGGCATT ACAGACGGCT	6900
CGGCATTCAT CATCTACTT CTTGGAGTCC GCTGAAACCT GGTTTGTGCC TGAGACTGTT	6960
CAGCAGATGG AAACAAAGAC GATCTATGTC CACTTTAGCT GtCCCCATGTC GCTTAGGGTC	7020

FIG. 1L

SUBSTITUTE SHEET (RULE 26)

13 / 30

GGACAGCTCG	GGTTTTCTA	TCTTGTGCAG	GGTCACGTC	AGGAGGCCAA	TCGGGAAGTG	7080
CCCGTCGTGG	CCTTAGCAGA	CCGTAACGCA	TCCATTGTGC	ACGTTCTGCC	CGATTATATA	7140
TATACTGAGG	CAGATAACAA	TCTGTCTGAG	GGTGGTGGCA	GCCTTATGGT	AACCGTCCCT	7200
GGCGGGCGG	TGTTGGCGGA	GACGGTGATC	AGTACCGCCA	AGTGCCTGGG	GGTAACGTGAC	7260
TCAATCCTCG	TTCTGAATCC	CCCCAGCATA	TGTGGCGAGA	TGTGGCTCCA	TGCTGGTGAA	7320
GAGATGGTC	TTCAAGTTCA	TCTGCCAAC	ACTTCTGGCA	ACAGGAGTTTC	GGTTTCTGCT	7380
GGAGACGCCA	AGTCCTGGCT	AACATTGCAT	GCTCGCGACA	CGGAAGTGGCA	CCTGGCACGG	7440
GTACTGCC	GGGGTGTCCA	GGCTTTAGTC	GACTTATCAG	CCGACCAGAG	CTGTGAAGGT	7500
TTGACTCAGA	GGATGATGAA	AGTTCTGATG	CCTGGCTGTG	CCCATTAACCG	TGCGGGCAGAC	7560

FIG. 1M

CTGTTCACAG ACACCGTTTC CACTGAATTG CATAGCGGAT CGGGCATCA AGCTTCACTG 7620
CCGGCCAT ATTGGGAGCA TGTGCTATCC TTAGCCCCGC AGGGACTTCC TAGTGTCAGC 7680
GAGGGGTGGG AGGTGATGCC GTGCACTCAA TTTGCAGGCC ATGCCGACAA GACGGGCCCG 7740
GATCTCTCGA CAGTTATTTC CTGGCCCCGG GACTCGGACG AGGCTACCGT TCCTTACCAAG 7800
GTTCGCTCCA TTGACGCTGA GACCCTCTT GCGGCCGACA AAACATATCT CCTGCTGGGA 7860
CTGACTGGAG ATCTTGGACG ATCACTAGGT CGTTGGATGG TCCAGGATGG GGCCCTGCCAC 7920
ATTGTACTTA CGAGCAGAAA TCCGCAGGTG AACCCCAGT GGCTGGGCA TGTGAAAGAA 7980
CTGGGTGGTC GAGTCACTGT TCTTTCATG TAAGAGGAGT CCTTCCTTCT GCAATTCCCTC 8040
CTTATGATCC CGACTAACGC AGCTGGCTTC AGGGACGTGA CAAGCCAAA CTCAGTGGAA 8100
GCTGGCCTGG CTAAACTCAA GGATCTGCAT CTGCCACCAAG TGGGGGTAT TGCCTTGGC 8160

14/30

FIG. 1N

SUBSTITUTE SHEET (RULE 26)

15/30

CCTCTGGTTC	TGCAGGGATGT	GATGCTAAAT	AATATGGAAC	TGCCAATGAT	GGAGATGGTG	8220
CTCAACCCA	AGGTCTGAAGG	CGTC CGC ATC	CTGCACGAGA	AGTTCTCCGA	TCCGACCACT	8280
AGCAAACCCCTC	TCGACTTCTT	CGT GAT GTTC	TCCTCGATTG	TGCCGT CAT	GGCAACCCG	8340
GCTCAGGCTA	ACTACAGTGC	GGCTAACTGC	TACCTTCAAG	CGCTGGCGCA	GCAGCGAGTT	8400
GCATCCGGAT	TAGCAGTACG	TTT TCACTCC	ATCCTT TGCT	AAACACTCCT	ATGGGCCTTT	8460
ACTAAACCGG	GCAGGGGTCC	ACCATTGACA	TCGGTGCCGT	GTACGGCGTT	GGTTTCGTCA	8520
CTCGGGGGA	GCTGGAGGAG	GA CTTAATG	CAATT CGGT	CATGTT CGAT	T CGGT TGAGG	8580
AACATGAACT	GCATACACTG	TTTGCTGAGG	CAGTGGT GGC	CGGT CGACGA	GCCGT GCACC	8640
AGCAAGGAGCA	GCAGGGGAAG	TTC CGGACAG	TGCTCGACAT	GGCTGATCTG	GA ACTGACAA	8700

SUBSTITUTE SHEET (RULE 26)

FIG. 10

CCGGAAATTCC	CCCCCTGGAT	CCAGCCCCCTCA	AAGATCGGAT	CACCTTCTTC	GACGACCCCC	8760
GCATAGCAA	CTTAAAATT	CCGGAGTACC	GAGGGCCAA	AGCAGGGCAA	GGGGCAGCCG	8820
GCTCCAAGGG	CTCGTCAA	GAACAGCTCT	TGCAGGCCAC	GAACCTGGAC	CAGGTC CGTC	8880
AGATCGTCAT	CGGTAAAGTTG	AGCCAATCCG	GGGAATAATTC	TCCCCTTCCT	CACTCAGCGG	8940
ACTGGAGATT	AACCGCTCT	TTCCTTGG	CAGATGGACT	CTCCGGAAAG	CTGCAGGTGA	9000
CCCTGCAGAT	CCCCGATGGG	AAAGCGTGC	ATCCCACCAT	CCCACTAATC	GATCAGGGGG	9060
TGGACTCTCT	GGGGCGGTC	ACCCGTGGAA	CCTGGTTCTC	CAAGCAGCTG	TACCTTGATT	9120
<u>TGCCACTCCT</u>	<u>GAAAGTGGCTT</u>	<u>GGGGGTGGCTT</u>	<u>CGATCACCGA</u>	<u>TCTCGCTTAAT</u>	<u>GAGGCTGCTG</u>	<u>9180</u>
CGCGATTGCC	ACCTAGCTCC	ATTCCCTCG	TCCGAGCCAC	CGACGGGGT	GCAGAGAGCA	9240
CTGACAATAC	TTCCGAGAAT	GAAGTTTCCG	GACGGCGAGGA	TACTGACCTT	AGTGGCCGGCG	9300

SUBSTITUTE SHEET (RULE 26)**FIG. 1P**

CCACCATCAC	TGAGGCCCTCG	TCTGCCGACG	AAGACCGATAC	GGAGCCCCGC	GACGGAGGACG	9360
TCCCGCGTTC	CCACCATCCA	CTGTCTCTCG	GGCAAGATA	CTCCTGGAGA	ATCCAGCAGG	9420
GAGCCGAAGA	CCCACCGTC	TTAACAAACA	CCATTGGTAT	GTTCATGAAG	GGCTCTTATTG	9480
ACCTTAACG	GCTGTACAAG	GCGTTGAGAG	CGGTCTTCGG	CCGCCACGAG	ATCTTCCGCA	9540
CGGGGTTTGC	CAACGTTGGAT	GAGAACGGGA	TGGCCCAGCT	GGTGTTCGGT	CAAACCAAAA	9600
ACAAAGTCCA	GACCATCCA	GTGTCTGACC	GAGCCGGGC	CGAAGAGGGC	TACCGACAAAC	9660
TGGTGAGAC	ACGGTATAAC	CCTGCCGAG	GAGACACCTT	GGGGCTGGTG	GAECTTCTTCT	9720
GGGCCAGGA	CGACCATCTG	CTGCTTGTGG	CTTACCAACCG	ACTCGTCCGG	GATGGATCTA	9780
CTACAGAGAA	CATCTTCCGTC	GAAGGGGGCC	AGCTCTACGA	GGGCACCTCG	CTAAAGTCCAC	9840

FIG. 1Q

ATGTCCTCA GTTGGGAC CTGGGCAC GGCAACGGC AATGCTGGAG GATGGAGAA 9900
TGGAGGAGGA TCTCGGTAC TGGAAAGAAA TGCATTACCG ACCGTCCTCA ATTCCAGTGC 9960
TCCCACGTGAT GGGCCCTTG GTAGGTAACA GTAGCAGGTC CGATACTCCA AATTTCAGGC 10020
ACTGTGGACC CTGGCAGGAG CACGAAGCCG TGCGGGACT TGATCCGATG GTGGCCCTTCC 10080
GCATCAAGGA GCGCACTCGC AAGCACAAAGG CGACGCCGAT GCAGTTCTAT CTGGCGCGT 10140
ATCAGGTGCT GTTGGGGGC CTCACCGACA GCACCGATCT CACCGTGGC CTCGCCGACA 10200
CCAACCGTGC GACTGTGAC GAGATGGGG CCATGGGTT CTTGGCCAAC CTCCTTCCCC 10260
TGGCTTCCG GGATTTCCGC CCCATATAA CGTTTGGCGA GCACCTTATC GCCACCCGTG 10320
ACCTGCTGG TGAGGCCCTTG CAGCACGGCC GGCTGCCCTA CGCGTCCCTC CTCGATCAAC 10380

FIG. 1R

19/30

TGGGGCTGGA GGTCGGGTG CCGACCCAGCA ATCAAACCTGCC GCCCTTTGTTC CAGGCCGGTCT 10440
TCGATTACAA GCAGGCCAG GCGGAAAGTG GAACGATTGG GGGTGCCAAG ATAACCGAGG 10500

TGATTGCCAC GCGCGAGGGC ACCCCCTTACG ATGTCGTGCT GGAGATGTCG GATGATCCCA 10560
CCAAGGATCC GCTGCTCACG GCCAAAGTTAC AGAGCTTCCCG CTACCGAGCT CACCACCCCTC 10620
AAGGCCTTCTT GGAGAGCTAC ATGTCGCCCTTC TCTCTATGTT CTGGATGAAT CCCGGCCCTGA 10680
AGCTGGCATG ATGGCCAAA CATAGAACAT GATAAGCCAG CAGGGACGGAT GTAGATAGAG 10740

CTTGCTTCTT GCGGGTGGAT CTATAATATA GTATATAAA ATATGGTGAG CCGAACGAAG 10800
AGGGGGAAT GCCACAATTAA TTACTGTT TGCGCCGTAC ACCGAGGACAA GACGTCAGA 10860
ACAACATAAA TATATCACTC TAGTGAGACA CCATATATTTC GGAGAGACTA TAAAAATATA 10920
CATCTACTCC AATGTCCTGGG CGGTACACAA CAGCTTACGA AACGATTAA TGACCTCCAA 10980

SUBSTITUTE SHEET (RULE 26)

FIG. 1S

20 / 30

CACGTCGGC GGTGATTGG GAAACTGATG CTGCCAGCA AACTCCAATA CCTGCCCTC	11040
TCGGGGAG AAATGGCG CCACCAGCAT CTCGATCCT GCGAGCCAA AATCATCGGC	11100
ACCCCTGCAGA TGTAAATGTCG GTATCCGAAT GACCACTTCC TCCTGCCACT CGGTATCTTT	11160
GCTTCTCGTTG TCGTCTCAT GGTCTTCAT CATTCTCAT TCATATACTG GCTTGCCTCG	11220
TCTTGATACC AGGGACAGAT CAACAGCGCA ACACCTCATCC GGGGCAACCA GGGCAGGTGA	11280
CCCCATCTGCT GCTGCCAGAG GAGCAAGGTC GTCAACCAGG CACCTTCGGA GAAACCGATA	11340
GCACCCACGA TAGGGATGTC GGGGTGTGA GTCTGCCAGT CGACAATGGT GGGGGGATG	11400
GGGTCTGGA CGGGGGAG GCGTTCGCTC ACCGAGGGTC CATTATGATT GTTGTGCTG	11460
CTGCTTTCAA ACCAGGAGTA ATATGGCCCT AGGTCTGGCA AGACGGGGAG AATCCCAGGC	11520
CCTGCAGAGG AAGGGAACGG AGCTGTCAAG TAGACGAATT C	11561

SUBSTITUTE SHEET (RULE 26)

FIG. 1T

21 / 30

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
MAQSMYPNEP	I VVVGSGCRF	PGDANTPSKL	WELLQHPRDV	QSRIPKERFD	50
VDTFYHPDGK	HHGRTNAPYA	YVLQDDLGAF	DAAFFNIQAG	EAESMDPQHR	100
LLLETVYEAV	TNAGMRIQDL	QGTSTAVYVG	VMIHDYETVS	TRDLESIPTY	150
SATGVAVSVA	SNRISYFFDW	HGPSMTTDTA	CSSLVAVHL	AVQQLRTGQS	200
SMAIAAGANL	ILGPMTFVLE	SKLSMLSPSG	RSRMWDAGAD	GYARGEAVCS	250
WLKTLSQAL	RDGDTTECVI	RETGVNQDGR	<u>TIGTTMPKHS</u>	AQEALIKATY	300
AQAGLDITKA	EDRCQFFEAH	GTGTPAGDPQ	EAEAIATAFF	GHEQVAPGGG	350
NERAPLFVGS	AKTVVGHTEG	TAGLAGLMKA	SFAVRHGVIP	PNLLFIKISP	400
RVAPFYKNLR	IPTEATQWPA	LPPGQPRRAS	VNSFGFGGIN	AHAIIIEYME	450
PEQNQLRVSN	NEDCPPMTGV	LSLPLVLSAK	SQRSLKIMME	EMLQFLQSHP	500
EIHLHDETWS	LLRKRSVLPF	RRAIVGHSHE	TEAAALEDAI	EDGIVSSDIT	550
TEVRGQPSVL	GIFTGQGAQW	PGMLKNLIEA	SPVYRNIVRE	LDDSLQLSPE	600
KYRPSWTLLD	QFMLEGASN	VQYATFSQPL	CCAVQIVLVR	LLEAARIRFT	650
AVVGHSSGEI	ACAFAGLIS	ASLAIRIAYL	RGVVSAGGAR	GTPGAMLAAG	700
MSFEEAQEIC	ELDAFEGRIC	VAASNPDSE	TFSGDANAID	HLKGMLEDES	750
TFARLLKVDT	AYHSHHMLPC	ADPYMQALEE	CGCAVADAGS	PAGSVPWYSS	800
VDAENRQMAA	RDVTAKYWKD	NLVSPVLFSH	AVQRAVVIHK	ALDIGIEVGC	850
HPALKSPCVA	TIKDVLSGVD	LAYTGCLERG	KNDLDSFSRA	LAYLWERFGA	900
SSFDADEFMR	AVAPDRPQMS	VSKLLPAYPW	DRSRRYWVES	RATRHHLPGP	950

FIG.2A

SUBSTITUTE SHEET (RULE 26)

22 / 30

10	20	30	40	50
1234567890	1234567890	1234567890	1234567890	1234567890
KPHLLLGKLS	EYSTPLSFQW	LNFVRPRDIE	<u>WLDGHALQQQ</u>	TVFPAAGYTV
				1000
MAMEAALMIA	GTHAKQVKLL	ETLDMSIDKA	VIFDDEDSLV	ELNLTADVS
				1050
NAGEAGSMTI	SFKIDSCLSK	EGNLSLSAKG	QLALTIEDVN	PRTTSASDQH
				1100
HLPPPPEEHP	HMNRVNINAF	YHELGLMGYN	YSKDFRRLHN	MQRADLRASG
				1150
TLDFIGPLMDE	GNGCPLLHP	ASLDVAFQTV	IGAYSSPGDR	RLRCLYVPTH
				1200
VDRITLVPSL	CLATAESGCE	KVAFNTNTY	DKGDYLSGDI	VVFDAEQTL
				1250
FQVENTTFKP	FSPPDASTDH	AMFARWSWGP	TPDSLLDNP	EYWATAQDKE
				1300
AIIPIIERIVY	FYIRSFLSQL	TLEERQQAAF	HLQKQIEWLE	QVLASAKEGR
				1350
HLWYDPGWEN	DTEAQIEHLC	TANSYHPHVR	LVQRVGQHLL	PTVRSGNPF
				1400
DLLDHGGLT	EFTNTLSFG	PALHYARELV	AQIAHRYQSM	<u>DILEIGAGTG</u>
				1450
<u>GATKYVLATP</u>	QLGFNSYT	DISTGFFEQA	REQFAPFEDR	MVFEPLDIR
				1500
SPAEGQFEPH	AYDLIIASWV	LHATPDLEKT	MAHARSLLKP	GGQMVILETT
				1550
HKEHTRLGF	I FGLFADWWAG	VDDGRCTEPF	VSFDRWDAIL	KRGFSGVDS
				1600
<u>RTTDRDANLF</u>	PTSVFSTHAI	DATVEYLDAP	LASSGTVKDS	YPPLVVGGQ
				1650
TPQSQRLLND	IKAIMPPRPL	QTYKRLVDLL	DAEELPMKST	FVMLTELDEE
				1700
LFAGLTEETF	EATKLLLTYA	SNTVWLTEA	WVQHPHQAST	IGMLRSIRRE
				1750
HPDLGVHVLD	VDAVETFDAT	FLVEQVLRLE	EHTDELASST	TWTQEPEVSW
				1800
CKGRPWI	MRDLARNRNM	NSSRRPIYEM	IDSSRAPVAL	QTARDSSSYF
				1850
LESAETWFVP	ESVQQMETKT	IYVHFSCPHA	LRVGQLGFFY	LVQGHVQEGN
				1900
REVPVVALAE	RNASIVHVRP	DYTYTEADNN	<u>LSEGGGSLMV</u>	TVLAAAVLAE
				1950

FIG.2B

SUBSTITUTE SHEET (RULE 26)

23 / 30

10	20	30	40	50
1234567890	1234567890	1234567890	1234567890	1234567890
TVISTAMCLG	VIDSILVLNP	PSICCGQMLLH	ACEEIGLQVH	LATTSGNRSS
				2000
VSAGDAKSAL	TLHARDTDWH	LRRVLPRGVQ	ALVDLSADQS	CEGLTQRMMK
				2050
VIMPGCAHYR	AADLFTDTVS	TELHSCSRHQ	ASLPAAYWEH	WVSLARQGLP
				2100
SVSEGWEVMP	CTQFAAHADK	TRPDLSVTIS	WPRESDEATL	PTRVRSIDAE
				2150
TLFAADKTYL	<u>LVGLTGDLGR</u>	SLGRWWVQHG	ACHIVLTSRN	PQVNPWKLAH
				2200
VEELGGRVTV	LSMDVTSQNS	VEAGLAKLKD	LHLPPVGGIA	FGPLVLQQVM
				2250
LNNMELPMME	MVLNPKVEGV	RILHEKFSDP	TSSNPLDFV	MFSSIVAVMG
				2300
NPGQANYSA	NCYLQALAQQ	RVASGLAAST	IDIGAVYVG	FVTRAELIED
				2350
FNAIRFMFDS	VEEHELHTLF	AEAVVAGRRA	VHQQEQQRKF	ATVLDMADE
				2400
LTGIPPLDP	ALKDRITFFD	DPRIGNLKIP	EYRGAKAGEG	AAGSKGSVKE
				2450
QLLQATNLDQ	VRQIVIDGLS	AKLQVTLQIP	DGESVHPTIP	LIDQGVDSLG
				2500
AVTVGTWFSK	QLYLDLPLLK	<u>VLGGASITDL</u>	ANEAAARLPP	SSIPLVAATD
				2550
GGAESTDNTS	ENEVSGREDT	DLSAAATTTE	PSSADEDDTE	PGDEDVPRSH
				2600
HPLSLGQEYS	WRIQQGAEDP	TVFNNTIGMF	MKGSDLKRL	YKALRAVLRR
				2650
HEIFRTGFAN	VDENGMAQLV	FGQTKNKVQT	IQVSDRAGAE	EGYRQLVQTR
				2700
YNPAAGDTLR	LVDFFWGQDD	HLLVVAYHRL	VGDGSTTENI	FVEAGQLYDG
				2750
TSLSPHVPQF	ADLAARQRAM	LEDGRMEEDL	AYWKKMHYRP	SSIPVLPLMR
				2800
PLVGNSSRSD	TRNFQHCGPW	QQHEAVARLD	RMVAFRIKER	SRKHKATPMQ
				2850
FYLAAYQVLL	ARLTSTDLT	VGLADINRAT	VDEMAAMGFF	ANLLPLRFRD
				2900
FRPHITFGEH	LIATRDLVRE	ALQHARVPYG	VLLDQLGLEV	PVPTSNQPAP
				2950
LFOAVFDYKQ	GQAESGTIGG	AKITEVIATR	ERTPYDVVLE	MSDDPTKDPL
				3000
LTAKLQSSRY	EAHHPQAFL	SYMSLLSMFS	MNPALKLA	
				3038

24/30




ASPERGILLUS TERREUS DNA:

FIG.3

SUBSTITUTE SHEET (RULE 26)

25/30



26/30

KETO ACYLSYNTHASE ALIGNMENT

FAS_RATF (130-229) YSMNGCQRAM MANRLSFFFD FKGPSIALDT ACSSSSLALQ NAYQAIRSQE
 TRIOL PKS (150-249) YSATGVAVSV ASNRISYFFD WHGPSMTIDT ACSSSSLVAVH LAVQQLRTGQ

MSAS_PENPA (173-272) WMCIGTAYCG VPNRISYHLN LMGPSTAVDA ACASSLVAIH HCVQAIRLG

Consensus G NR.S..... GPS...D. AC.SSL.A... Q.R.G.

ACETYL/MALONYL TRANSFERASE ALIGNMENT

MSAS_PENPA (621-671) SDRVQILTYW MQIGLSALQ SNCITPQAVI GHSVGEIAAS WAGALSPE
 FAS_RATF (553-603) F—V—SL—TA IQIALIDLTT SMLKPDGII GHSLGEVAGC YADGCCSORE
 TRIOL PKS (626-676) F—SQPLCICA VQIVLVRILLE AARIIFTAVW GHSSGEIACA FAGLIASAL

Consensus L... QI.L..LL. GHS.GE.A... G.S...

DEHYDRATASE ALIGNMENT

MSAS_PENPA (943-982) YTTRLDNDIK PFPGSPLHG TEIVPAAGLI NFLKG.TGGQ
 FAS_RATF (863-902) NIDASSESSD HYLVQHCIDS RVLFPCTGYL YLVWK-TLAR S
 TRIOL PKS (970-1010) WLNFVRPRDI EWLDGHALQG QTVFPAAGYI WAMEAALMI A

Consensus H...G P..G..

FIG. 5

SUBSTITUTE SHEET (RULE 26)

27/30

ENOYL REDUCTASE ALIGNMENT

TRIOL PKS (1903-1950)	VPWVLAERN ASIVHVRPDY IYTEDANNL S EGGGSLMVT V LAAVLA E
FAS_RATF (1642-1691)	VPWVTTAY SLWVGRIOH GETVLJHSGS GGVGQAAISI ALSLGCCRFT
SU4_ER	VPIAYTTAHY ALHDLAGLRA GQSVLHAAA GGVGMAAVAL ARRAG-LAEV

Consensus

VP..... G.G.....

KETO REDUCTASE ALIGNMENT

TRIOL PKS (2141-2196)	PTRVRSIDAE TLFIAADKTYL LVGLTGDLGR SLGRIMWQHG ACHIVLTSRN
MSAS_PENPA (1398-1451)	LP-ASEG-PR LLPRPEGTYL ITGGLCVLGL EVADFLEVKG ARRLLIISRR
FAS_RATF (1864-1921)	PTLISAI-SK TFCPEHKSYI ITGGGGFGL ELARWLVLRG AQRLVLTSR S

Consensus

Y. .G..G..G. V..G.A....L.SR.

ACYL CARRIER PROTEIN ALIGNMENT

TRIOL PKS (2461-2548)	VRQIVIDGLS AKLOVTLQIP DGESWMPPTIP LIQGVDSLG AVTVGTFWSK
FAS_RATF (2114-2201)	GDGEAQRDLY KAVAHILGIR DLAGINLDSS LADLGLDSL M GVEVRQILER
MSAS_PENPA (1697-1758)	KAYLDEKIR QCVAKVLYMT A-EDVDSKAA LADLGVDSSW TVTLLRQLQ-

Consensus

L..... L.D.G.DS... V.....

FIG. 6

SUBSTITUTE SHEET (RULE 26)

28/30

ALCOHOL DEHYDROGENASE S T C A V F G L G G V G L S V I M G C K A A
β [REDACTED] T T T T T [REDACTED]
R α [REDACTED] R 14aa [REDACTED] K
K [REDACTED] 22aa [REDACTED]

RAT FAS-ER T V L I H S G S G V G Q A A I S I A L S L
 β [] T T T T [] α β 1400 R 2300 K

MSAS-KR
 T Y L I T G C V L G L E V A D F L V E K
 [] T T [] [] []
 β α 14aa R 20aa R

FIG. 7

SUBSTITUTE SHEET (RULE 26)

29/30

Potential SAM Binding Region In Methyl Transferase	
Consensus	$\Delta \triangle D/E \Delta G X G X G X \Delta X X X \Delta \triangle \triangle \wedge / P$
TPKS (1444)	I L E I G A G T G G A T K Y V L P

 Δ = hydrophobic A.A.


X = any A.A.

 \wedge = charged A.A.

FIG. 8

SUBSTITUTE SHEET (RULE 26)

30/30



F I G . 9
SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12423

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12N 1/15, 15/54, 15/80

US CL :435/254.11, 320.1; 536/23.2, 23.74, 24.32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/254.11, 320.1; 536/23.2, 23.74, 24.32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, CA, INPADOC, JICST-E search terms: polyketide synthase, DNA, nucleic acid, RNA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----	EP, A1, 0,556,699 (DAHIYA) 25 August 1993, page 4, lines 15-50, and page 6, Table 1.	10, 20 ----- 1-9, 18, 19
Y	EUROPEAN JOURNAL OF BIOCHEMISTRY, Volume 192, issued September 1990, Beck et al, "The multifunctional 6-methylsalicylic acid synthase gene of <i>Penicillium patulum</i> ", pages 487-498, see entire document.	1-10, 18-20
Y	EUROPEAN JOURNAL OF BIOCHEMISTRY, Volume 204, issued February 1992, Bevitt et al, "6-Deoxyerythronolide-B synthase 2 from <i>Saccharopolyspora erythraea</i> ", pages 39-49, see entire document.	1-10, 18-20

 Further documents are listed in the continuation of Box C.


See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
05 DECEMBER 1994Date of mailing of the international search report
09 FEB 1995Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

STEPHEN WALSH



Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12423

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MOLECULAR & GENERAL GENETICS, Volume 235, Number 2-3, issued November 1992, Mayorga et al, "The developmentally regulated <i>Aspergillus nidulans</i> wA gene encodes a polypeptide homologous to polyketide and fatty acid synthases", pages 205-212, see entire document.	1-10,18-20
Y	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, Volume 107, issued 1985, Moore et al, "Biosynthesis of the Hypocholesterolemic Agent Mevinolin by <i>Aspergillus terreus</i> . Determination of the Origin of Carbon, Hydrogen, and Oxygen Atoms by ¹³ C NMR and Mass Spectrometry", pages 3694-3701, see paragraph bridging pages 3694-3695.	1-10,18-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

